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ABSTRACT
LC-MS FOR PROTEIN BIOMARKER DISCOVERY IN PANCREATIC
ADENOCARCINOMA
Angela Y. Wehr
Ian A. Blair, PhD
Pancreatic cancer is a devastating disease with one of the lowest survival
rates of all cancers, partly due to the difficulty of detection in its early stages.
Recent developments in liquid chromatography – mass spectrometry (LC-MS)
technology have made it possible to profile proteins associated with disease
in a comprehensive manner.

This work sought to apply current LC-MS

methodology to the problem of pancreatic cancer.
A comprehensive list of proteins secreted by the tumor microenvironment
was compiled in the first aim. Culture of human pancreatic cell lines, both
cancerous and stromal, was used to simulate the tumor microenvironment in
vitro and produce a proteome rich in potential biomarkers.

The proteins

identified in this analysis demonstrated the complex signals pancreatic tumor
cells use to communicate with their environment and might encompass
therapeutic targets and biomarkers.
To measure the levels of these proteins in human serum, a relative
quantitative LC-MS method was developed in the second aim.
v

Traditional

bioanalytical techniques were incorporated to enhance the utility of the
method.

Multiple reaction monitoring (MRM)/MS provided sensitivity and

specificity to the method and stable isotope dilution (SID) provided correction
for losses during sample preparation and analysis that enabled precise
quantitation.

The

multiplexed

method

efficiently

determined

the

concentration of over 70 proteins in a single analysis.
In the third aim, the relative quantitative method was used to compare a
panel of putative protein biomarkers in human pancreatic cancer and control
serum.

This analysis identified 15 differential proteins with the ability to

discriminate pancreatic cancer subjects from their age-matched controls with
sensitivity and specificity superior to any other reported pancreatic cancer
biomarkers.

Future validation of this panel could change the way we

diagnose pancreatic cancer.
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1 Chapter 1 – General Introduction
1.1

Pancreatic cancer

Pancreatic cancer is the 4th leading cause of cancer death in the United
States even though it accounts for only 3% of new cancer diagnoses1. One
reason for the high mortality rate is the late stage of progression at
presentation due to the asymptomatic nature of early disease. Early stage
pancreatic cancer can be treated with surgical resection which can improve
the 5-year survival rate to 15-40%2, but few treatment options exist for the
majority of patients that present with locally advanced or metastatic
disease3.

Currently there are no screening measures for the detection of

pancreatic cancer4. The advent of such a diagnostic tool could dramatically
impact the way we treat this devastating disease.
Over 95% of pancreatic malignancies originate in the exocrine pancreatic
ducts and are adenocarcinoma by histology2. These cancers are thought to
evolve from pancreatic intraepithelial neoplasms (PanINs) that develop
through three stages5.
changes.

Each stage is associated with different genetic

Oncogenic mutation in K-ras is common in stage 1, followed by

p16 inactivation in stage 2, and finally p53 and Smad4 are inactivated in
stage 35,6.

The role of K-ras mutation in the development of PanIN and

pancreatic ductal adenocarcinoma (PDAC) is supported by the finding in
mouse models of pancreatic cancer7.
1

Pancreatic adenocarcinoma is characterized by a highly desmoplastic region,
with only a low percentage of cancer cells (<40%)6. The rest of the tumor is
composed of stromal cells, such as pancreatic stellate cells (PSCs), and
extracellular matrix (ECM)8. Pancreatic desmoplasia is a well-described but
poorly understood process that occurs in response to organ damage or tumor
development. The pancreatic desmoplastic response contributes significantly
to the morbidity of pancreatic cancer, limiting the rate of resection9.
Since their initial description in 199810,11, PSCs have become increasingly
recognized as important players in pancreatic fibrosis as seen in pancreatitis
and PDAC. An excessive stromal response is a defining feature of PDAC and
mounting evidence supports PSCs as a major contributor to the ECM proteins
observed with this stromal response8,12.
Under normal conditions, PSCs reside in the exocrine pancreas in a quiescent
state, characterized by the expression of desmin, vimentin, and glial fibrillary
acidic protein (GFAP) and the ability to store vitamin A8. PSCs become
activated in vivo in response to pancreatic injury10,11. Upon activation, PSCs
proliferate, lose the ability to store vitamin A, and express α-smooth muscle
actin (α-SMA) and collagen I11,12. It has been reported that activated PSCs
produce autocrine factors such as platelet derived growth factor (PDGF),
transforming growth factor (TGF)-β, cytokines, and cyclooxygenase-2 to
perpetuate the activated phenotype13-17.

2

Pancreatic cancer cells (PCCs) are known to secrete a number of proteins
that enable them to interact with and modify their environment. PCCs may
enhance cell motility and extracellular matrix remodeling through the
secretion of myosin, vimentin, and matrix metalloproteinases, and evade the
immune response via CD59 glycoprotein and complement decay accelerating
factor18. PCCs may also induce the activation of PSCs via paracrine signaling
in vivo, a phenomenon shown to occur in vitro.
PDGF,

activators

of

PSCs,

are

commonly

For example, TGF- and

upregulated

in

pancreatic

adenocarcinoma19,20 and PSC activation can be achieved in culture following
the application of conditioned media supernatant taken from PCCs in
culture12,21.
It is clear that the pancreatic tumor microenvironment is a complex tissue
composed of a variety of cell types, each shedding an array of proteins into
the extracellular matrix.

This secretome provides a unique signature and

also a unique opportunity to detect pancreatic cancer in biological tissues or
fluids.

1.2

Biomarkers

Biomarkers have been defined by the National Cancer Institute as “cellular,
biochemical, and molecular (including genetic and epigenetic) characteristics
by which normal and/or abnormal processes can be recognized and/or
monitored”22. Disease biomarkers may take the form of cell types, genetic
markers, lipids, proteins, or small molecules such as hormones, and may be
3

detected in tissue or biological fluids. For clinical utility as a diagnostic tool,
a biomarker must possess sufficient sensitivity and specificity to discriminate
between afflicted and unafflicted individuals. Sensitivity refers to the ability
of the biomarker to detect the disease and is a measure of the rate of falsenegatives.

Specificity refers to the ability of the biomarker to discriminate

the disease state from other causes of a positive result and thus is a measure
of the false-positive rate.

It has been estimated that for clinical utility, a

screening biomarker should possess sensitivity and specificity rates of at
least 90%23.

1.2.1 Previous studies
Unfortunately, despite years of research, pancreatic cancer biomarkers have
yet to be found that meet such stringent criteria24,25. Endoscopic procedures
for the sampling of pancreatic juice have been described, but are expensive,
carry significant risk of complications, and have shown only limited success
26,27

.

Proteomic analysis of pancreatic cyst fluid has identified potential

biomarkers, but again relies on invasive testing that is not feasible for
general screening28. A method to detect a biomarker or panel of biomarkers
in the serum would provide a minimally invasive technique that could be
readily applied to the general population.
The carbohydrate CA19-9 is the only pancreatic cancer biomarker currently
in use and lacks sufficient sensitivity and specificity for screening24,25 and as
such is currently only used to monitor response to therapy29-31.
4

Genetic markers such as K-ras have been studied and detected in the blood
of patients with advanced disease.

However, it can be difficult to detect

against a background of normal DNA32,33.

DNA methylation profiling of

leukocytes has been conducted as a cancer biomarker in bladder34, breast35,
lung36, and pancreatic cancer37, although the reasons for why there could be
differences in leukocyte methylation are not clear.
Proteins have been a popular subject of biomarker research.

Many serum

markers of pancreatic cancer have been reported, such as MIC-1, PAM4,
OPN, HSP27, TPS, TSGF, CAM17.1, PF4, CEACAM1, annexin A8, Claudin 18,
lactose binding protein, and plectin -1, yet all lack the necessary levels of
sensitivity and specificity26,38-42.

1.2.2 Development
It has been suggested that the development of biomarkers be conducted in
phases similar to drug development in the pharmaceutical industry43. Just as
new drug trials start in model organisms for toxicity studies, move into small
human studies in Phase I, and ultimately grow into larger and more
significant trials the further and more successful the drug is in the process,
biomarker studies should also expand as the marker gains significance.
Biomarker studies can be broken down into 5 phases: preclinical exploratory
studies aimed at the discovery of candidates, clinical assay development and
validation in a training set of samples, retrospective longitudinal studies to
detect disease immediately prior to diagnosis, prospective screening studies
5

for diagnosis, and cancer control studies to determine whether screening
reduced cancer burden43.
Historically, early biomarker discovery studies can be broken down into two
methods: the hypothesis driven targeted approach and the pattern based
discovery approach.

The hypothesis driven approach sought to an

understanding of the cell and molecular biology of the disease to identify
molecules hypothesized to vary in a disease state.

While well founded

scientifically, these studies were lengthy and produced few results.

The

pattern recognition approach, based largely on surface-enhanced laser
desorption ionization (SELDI)/MS, operated on the theory that the identity of
the biomarkers was irrelevant and their relationship to the disease could
remain unknown as long as a successfully predictive pattern was found. This
approach, which was lacking in bioanalytical rigor and did not consider the
potential for inter-individual differences in ionization efficiency led to
numerous studies that could not be validated including a highly-cited study of
ovarian cancer44, which had serious methodological flaws45-47.

Since those

early studies, a new approach that employs more rigorous systems has
emerged.

MS-based proteomic approaches that survey the proteome are

first used to identify differential proteins in a sample set. The identity of the
proteins can then be verified by immunological or other methods. Once the
identity of the candidate protein is confirmed, targeted methods capable of
quantitating the protein are used in biological samples to validate the
biomarker in the second phase of development.
6

The discovery approach used in my studies have relied on the simulation of
the tumor microenvironment based on the culture of human cell lines. Since
the ultimate goal is to identify proteins secreted by pancreatic cancer and
stromal cells in vivo, it is important to select cell lines that exhibit expression
and mutations similar to those seen in vivo.

As discussed above, during

pancreatic cancer development, activating mutations in K-ras commonly
occur early on, while inactivating mutations in tumor suppressors, such as
p16, p53, and Smad4, follow as PanIN progresses. A number of cancerous
and normal pancreatic cell lines that share a variety of these mutations,
listed in Table 1, are commonly used and commercially available.

Table 1. Pancreatic Cell Line Characteristics
Cell Line

Site of origin

CAPAN-1
CAPAN-2
ASPC-1
BXPC-3
MiaPaCa-2
HPDE6E6E7

Liver Metastasis
Primary Tumor
Ascites
Primary Tumor
Primary Tumor
Pancreatic Duct

Tumor
grade
1
1
2/3
2/3
3
N/A

K-ras

p16

p53

Smad4

Mut
Mut
Mut
WT
Mut
WT

Mut
Mut
Mut
Mut
Mut
WT

Mut
WT
Mut
Mut
Mut
Mut

Mut
ND
WT
Mut
WT
WT

The methods used to validate candidate biomarkers have evolved as well.
Discovery studies generated vast lists of candidate biomarker proteins
awaiting quantitation in human samples for validation48-55. Enzyme-linked
immunosorbent assay (ELISA) is the most common method used for the
quantitation of proteins in serum due to its high sensitivity and specificity.
However, ELISA becomes expensive and labor intensive when applied to a
7

large number of proteins and samples, which is why most biomarker
validation studies are limited to a few proteins56-59.
proteins provides

a

more robust and

LC-MS analysis of

high-throughput alternative

to

immunological methods since it does not require the generation of specific
antibodies for each protein.

Also, since many methods utilize MS for the

identification of biomarkers in the discovery phase, it is a logical progression
to use the same methodology for their quantitation during validation.

1.3

LC-MS for protein analysis

1.3.1 Qualitative analysis
MS-based proteomic profiling is a technique used to survey a spectrum of
proteins in a sample.

Both top-down and bottom-up strategies have been

used effectively60-62.

Top-down strategies rely on high-resolution mass

spectrometers to analyze and fragment intact proteins.

Bottom-up, also

called shotgun, proteomics uses the mass spectrum of the products of tryptic
peptide fragmentation to determine the peptide sequence. These sequences
are then searched against protein databases to determine their identity. It is
this method that was used for the research presented in this dissertation.
The tryptic digests produced by shotgun analysis are complex in the array of
peptides that are formed and the concentration range at which each peptide
is present.

Sample complexity can be reduced by separation using

conventional reversed phase (RP) chromatography with elution online to the
mass spectrometer.

However, to further reduce the sample complexity
8

during

MS

analysis,

multidimensional

(MudPIT) has been developed63.

protein

identification

technology

Such methods depend on orthogonal

separation techniques to fractionate the samples prior to LC-MS analysis.
This work has relied on the use of strong cation (SCX) exchange as the first
dimension of separation, followed by RP chromatography as the second
dimension64.
Discovery MS is achieved through data dependent analysis. In the first stage
of this analysis intact peptides are scanned to produce a mass spectrum.
Instrument software analyzes this spectrum in real-time to identify the most
intense ions.

The most intense precursor ions are then selected for

fragmentation. After acquiring product ion spectra for each of the selected
precursor ions, the process is repeated beginning with a scan of intact
peptides. The time it takes to complete the process of precursor selection
and fragmentation is termed cycle time.

Care must be taken to select an

appropriate cycle time. By selecting more precursors for fragmentation, the
proteome can be searched in greater depth, though this increases the cycle
time and reduces the number cycles that can be completed during a
chromatographic run.

An excessively long cycle time will result in the

omission of significant peptides that elute while other analytes are
undergoing fragmentation.
Once precursor and product ion spectra have been obtained, raw MS/MS files
are batch searched against a reference sequence database using search
9

software such as SEQUEST or Mascot.

The search output files are then

analyzed and validated by PeptideProphet, an automated method to assign
peptides to MS/MS spectra.

1.3.2 Relative quantitation analysis
In the search for biomarkers, proteomic analysis is used not only to identify
the proteins present in a system, but to assess differences in the proteome
that are the result of disease status or response to therapy. To quantitate
relative proteome changes in the model both label-free and isotope/mass tag
labeling approaches have been used. Label-free methods use either external
protein standards or spectral counts, the number of times an analyte was
detected, to approximate the abundance of the analyte in each sample55,65.
Isotope labeling strategies, such as isotope-coded affinity tags (ICAT)66,
iTRAQ™67, and stable isotope labeling by amino acids in cell culture (SILAC)68
rely on the use of stable isotope or isobaric tag labeling of one or more sets
of samples. The differentially labeled samples are then pooled and analyzed
simultaneously;

after

co-eluting

from

the

LC

column,

they

ionize

simultaneously, and are discriminated by the mass spectrometer based on
their mass-to-charge (m/z) ratio.

The ratio of the differentially labeled

analytes can then be used to approximate their relative abundance.

The

ICAT and iTRAQ™ methods rely on chemical modification of the proteins or
peptides; a small molecule tag reacts with a functional moiety of the analyte.
These analyses are based on the assumption that both protease digestion
10

and subsequent chemical reaction of the protease-derived peptides with the
relevant reagent is consistent for all samples, a presumption that may be
false and hence is a potential pitfall of these methods.

However, these

analyses are useful for samples that cannot be cultured for metabolic labeling
such as primary cell lines and human tissues or fluid.
SILAC is a metabolic labeling system amenable to cell culture models. This
methodology uses heavy labeled essential amino acids, such as leucine and
lysine (13C6,

15

N2 L-Lysine dihydrochloride and

13

C6,

15

N L-Leucine), in the

culture of cells. All of the proteins produced by these cells are thus labeled
with stable (or heavy) isotopes and can then be compared with those
produced by unlabeled cells.

SILAC requires the use of cells that can be

passaged many times to guarantee a high percentage of labeling and care
must be taken to ensure any contamination by unlabeled protein is low.
However, labeling efficiency can easily be measured to rule out this problem.

1.3.3 Targeted quantitative analysis – Multiple Reaction Monitoring
MRM is an experiment conducted on tandem mass spectrometers and is
commonly used for bioanalytical analyses69-71. During an MRM experiment on
a triple quadrupole mass spectrometer, the precursor m/z of the analyte is
selected in the first quadrupole.
collision

induced

dissociation

The precursor ion is then fragmented via
(CID)

in

the

second

quadrupole.

A

characteristic product ion is then selected in the third quadrupole and
ultimately recorded by the detector. The goal during MRM/MS development
11

is to select a transition, a pair of precursor and product ions, that is specific
to the analyte of interest. The specificity of this process, the transition from
precursor to product, is what makes it the tool of choice to analyze low
abundance molecules within a complex matrix, such as serum or plasma.
With developments in MS technology, this system has rapidly become even
faster and more sensitive, making the detection of low abundance proteins in
serum feasible72,73.

Within the course of the research presented in this

dissertation, a method to quantitate potential biomarker proteins in human
serum using LC-MRM/MS technology has been developed.
While intact proteins are difficult to analyze by traditional LC columns,
peptides that result from tryptic digestion can be readily separated by RP
chromatography. Tryptic peptides have an additional advantage during LCMS analysis; when subjected to electrospray ionization (ESI) they readily
form multiply charged ions due to the presence of lysine and arginine in
every peptide.

Multiply charged precursor ions generally produce product

ions with a lower charge state than the precursor, some of which possess a
higher m/z ratio than the precursor ion. This effect improves the sensitivity
of MRM/MS analysis by reducing the background as fewer serum matrix ions
are capable of multiple charging. The targeted approach reported here uses
the response of tryptic peptides to estimate the abundance of their
respective proteins present in the serum.
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Human serum is rich in proteins, however this too poses a challenge for
analysis as the proteins in human serum span over 10 orders of magnitude in
concentration74.

Low abundance proteins that are typically of interest in

biomarker analyses comprise less than 1 percent of the serum proteins by
weight75. Immunoaffinity methods have been used to resolve this problem.
Stable isotope standards and capture by anti-peptide antibodies (SISCAPA)
uses antibodies raised against the protein of interest to extract the analyte
prior to MS analysis76. While this method has been effective, like ELISA, it
requires the development of specific antibodies for each protein.

An

alternative approach is to use antibodies raised against the most highly
abundant proteins (HAP) in serum to deplete the serum of these interfering
proteins77-79.
While digestion and depletion aid in enhancing the sensitivity and specificity
of the method, they are also a potential source of variability in the analysis.
A stable isotope labeled internal standard is commonly used in bioanalytical
methods to track analyte losses during sample preparation or analysis72,80.
Similarly, a stable isotope labeled proteome (SILAP) standard can be used to
normalize proteomic profiling and correct for protein losses during extraction
and analysis50,73,81.
The SILAP method is based on SILAC methodology, using heavy isotopicallylabeled essential amino acids, such as leucine and lysine (13C6,
dihydrochloride and

13

C6,

15

15

N2 L-lysine

N L-leucine), to produce fully labeled, correctly
13

folded, fully functional human proteins in cell culture.

These proteins can

then be harvested and used as an internal standard during protein
preparation and LC-MS analysis (Figure 1).

Stable Isotope LAbeled Protein standard
Condition 1

Condition 2

Heavy labeled
cells*
* 13C, 15N
Lysine & Leucine

Individual
Samples

Internal
Standard

Condition 1 Analysis
IS

Analytes

IS

Ion Count

Ion Count

Analytes

Condition 2 Analysis

m/z

m/z

Figure 1. SILAP diagram

1.4

Conclusions

The following chapters of this dissertation describe the development of
potential biomarkers of pancreatic cancer.

My approach began with the

identification of potential protein biomarkers through the application of
shotgun proteomics to study the secretome of the tumor microenvironment
in vitro. Chapter 2 details the cell culture models used to simulate the tumor
microenvironment and the mass spectrometric and bioinformatic techniques
used to analyze the secreted proteins.
14

The mass spectral data acquired in the discovery phase was then used to
direct the development of a targeted analytical LC-MS method for the
quantitation of these candidate biomarkers in human serum.

Chapter 3

serves as a template for the development of targeted methods and details
potential pitfalls in such analyses.
Finally, the targeted method is applied to the analysis of a training set of
human serum samples, comparing pancreatic cancer patients and controls.
Chapter 4 is the reward of years of development work, as differential
proteins with the potential to diagnose pancreatic cancer were discovered.
By analyzing a panel of protein biomarkers in parallel, as afforded by LC-MS
analysis, we were able to establish a diagnostic panel with levels of
sensitivity and specificity not previously reported.
While this work provides a set of detailed methods that may direct LC-MS
analyses, it also serves to provide proof of principle for cell-based LC-MS
cancer biomarker discovery. By using a cell culture model of disease we are
able to rapidly identify a list of potential biomarkers, the data of which is
easily translated to the development of a targeted method, which is made
more robust by the internal standard generated in the cell culture model that
started it all. Ultimately it is the robustness of the method that permits us to
discriminate the differences observed in protein concentration in human
samples. Thus, this dissertation provides a strategy for biomarker discovery
and stands to impact the way we detect cancer and many other diseases.
15

2 Chapter 2 – Proteomic Profiling of the Pancreatic Cancer
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2.1

Abstract

Objective: PSCs are important players in pancreatic fibrosis and are major
contributors to the extracellular matrix proteins observed with the stromal
response characteristic of PDAC. PSCs are also believed to secrete soluble
factors that promote tumor progression; however no comprehensive analysis
of the PSC proteome in either the quiescent or activated state has been
reported.
Methods: Using two-dimensional MS/MS and the RLT-PSC cell line, we
present the first comprehensive study describing and comparing the
quiescent and activated human PSC secreted proteomes.
Results: Very few proteins are secreted in the quiescent state. In stark
contrast, activated PSCs secreted a vast array of proteins. Many of these
proteins differed from those secreted by PDAC derived cell lines. Proteins
associated with wound healing, proliferation, apoptosis, fibrosis and invasion
were characterized. Selected proteins were verified in human tissue samples
16

from PDAC, dysplastic pancreas, and normal pancreas using Western blot
analysis and immunohistochemical staining.
Conclusions: Our study represents the first comprehensive analysis of
proteins

secreted

by

PSCs.

These

findings

lay

the

foundation

for

characterizing PSC derived proteins involved in stroma-tumor interactions
and the promotion of pancreatitis and PDAC.

2.2

Introduction

Since their initial description in 199810,11, PSCs have become increasingly
recognized as important players in pancreatic fibrosis as seen in pancreatitis
and PDAC. An exuberant stromal response is a defining feature of PDAC.
Indeed, cancer cells compose on average less than 40% of PDAC tumors6
and accumulating evidence supports PSCs as a major contributor to the ECM
proteins observed with this stromal response8,12.
Under normal conditions, PSCs reside in the exocrine pancreas in a quiescent
state, characterized by the expression of desmin, vimentin, and GFAP and
the ability to store vitamin A8. PSCs become activated in vivo in response to
pancreatic injury10,11. Upon activation, PSCs proliferate, lose the ability to
store vitamin A, and express -SMA and collagen I11,12. It has been reported
that activated PSCs produce autocrine factors such as PDGF, TGF-β,
cytokines, and cyclooxygenase-2 to perpetuate the activated phenotype

13-17

;

however, no comprehensive analysis of the PSC proteome in either the
quiescent or activated state has been reported.
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While knowledge of the intracellular proteome is important, it is the secreted
proteome, or secretome, that is of particular interest with regards to
understanding intercellular interactions, for example with tumor cells. It
remains difficult to characterize proteins secreted by a single cell type to the
exclusion of all others in vivo. One solution to this problem is studying cell
lines derived from the cell type of interest in vitro, an approach we have
already used to study the secretome of PDAC cells50.
In the current study, the RLT-PSC cell line, an immortalized cell line derived
from human PSCs, was exploited in order to characterize the secretome of
both the quiescent and activated PSC.

The RLT-PSC cell line can be

maintained in a quiescent state when grown on a soft substrate, or in an
activated state when grown on untreated culture plates82. The first
comparative

proteomic

study

was

conducted,

which

demonstrated

a

remarkable differential secretome upon PSC activation and highlighted the
potential biological functions of these proteins. Expression of selected
proteins were verified in human pancreatic tissue samples.

2.3

MATERIALS AND METHODS

2.3.1 Cell Culture
The human PDAC cell lines MiaPaCa-2 and CAPAN-2, and the immortalized
human PSC line RLT-PSC82 were cultured according to standard practice
using Dulbecco's Modified Eagle Medium (DMEM, Sigma, St. Louis, MO)
supplemented with 10 % fetal bovine serum (Sigma) and 1 % antibiotic
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(penicillin/streptomycin, Invitrogen, Grand Island, NY).

Secreted proteins

were harvested by allowing cells to grow to 80 % confluence, washing with
phosphate buffered saline (Invitrogen), and incubating the cells with serumfree media at 37 °C for 48 h. This media was collected, passed through a
0.22 µm filter, and stored at -80 °C until used. To induce a quiescent
phenotype, 80 % confluent RLT-PSCs were treated with trypsin (Invitrogen),
resuspended in serum-free DMEM supplemented with 1 % antibiotic and 2.5
mM N-acetyl cysteine (Sigma), then plated at a concentration of 20,000
cells/cm2 on collagen I coated cover-slips or plates (BD Biosciences, San
Jose, CA) and incubated at 37 °C for 24 h. RLT-PSCs were plated on
uncoated tissue culture plates to achieve an activated state.

2.3.2 Cell culture immunocytochemistry
RLT-PSCs were plated on either uncoated (activated cells) or collagen I
coated (quiescent cells) coverslips and incubated at 37 °C for at least 24 h to
allow attachment.

Cells were formalin fixed, washed with propylene glycol

(PolyScientific, Bay Shore, NY) and incubated with oil red O (0.5 % in
propylene glycol, PolyScientific) for 1 hr at RT. Cells were then washed with
85 % propylene glycol, blocked with 1 % bovine serum albumin/PBS
(Sigma), and labeled overnight at 4 °C with antibodies against either α-SMA
(mouse, Sigma) or GFAP (rabbit, Sigma) diluted 1:1,600 and 1:600,
respectively, in blocking solution. Cells were incubated with a Cy2 conjugated
secondary

antibody

(donkey

anti-mouse

or

anti-rabbit,

Jackson

ImmunoResearch, West Grove, PA) diluted 1:600 in blocking solution for 1 hr
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at RT. Finally, cells were incubated with DAPI (Sigma), diluted 1:10,000 in
water, for 45 sec. Fluorescence was visualized using a Nikon (Melville, NY)
E600 fluorescent microscope equipped with a CCD camera and IPLab image
analysis software (BD Biosciences).

2.3.3 2D LC-MS/MS
Two biological replicates were analyzed for each cell line. Secreted proteins
were concentrated using 3 kDa MW cutoff spin-filters (Millipore, Billerica,
MA), and then precipitated using methanol-chloroform extraction. 100 µg of
protein

from

each

cell

line

was

digested

and

separated

by

SCX

chromatography using standard methods as previously described83. SCX
fractions were subjected to reversed phase chromatography using a C18
column (0.3 x 150 mm, 4 µ, 90 Å Jupiter Proteo, Phenomenex, Torrence, CA)
on a microflow high pressure liquid chromatography system (Eksigent,
Dublin, CA). A chromatographic gradient increasing mobile phase B (95 %
acetonitrile, 0.1 % formic acid) from 0 to 60 % over 30 min at a flow rate of
12 µl/min was used to elute peptides online to a linear ion trap mass
spectrometer (LTQ, ThermoFisher, San Jose, CA) with positive ESI.

Data

dependent scanning was used to identify the 5 most intense precursor
masses, which were then subjected to collision-induced dissociation to
produce product ion spectra.
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2.3.4 Protein identification
Raw data were submitted to Bioworks Browser version 3.2 (ThermoFisher)
and batch searched through SEQUEST™ against the NCBI RefSeq human
reference sequence database (version updated 03/17/09) containing 75,484
sequences consisting of 37,742 proteins and 37,742 decoy entries (1 reverse
sequence for each real entry). The database was indexed using the following
criteria: precursor and fragment mass tolerance of 1 amu, strict trypsin
cleavage

rules

with

up

to

two

internal

cleavage

sites;

differential

modifications of methionine oxidation and carboxyamidomethylation on
cysteine. Sequences were further processed using the Trans-Proteomic
Pipeline software (version 2.8, Institute for Systems Biology, Seattle, WA) for
analysis and validation of peptides and proteins using Peptide Prophet™
(version

3.0)

and

ProteinProphet™

(version

2.0),

respectively.

ProteinProphet™ results were filtered using a minimum probability score of
0.6, translating to a false discovery rate of 5 %. Proteins identified by fewer
than two unique peptide sequences were discarded. Proteins that contained
similar peptides and could not be differentiated based on MS/MS analysis
alone were grouped to satisfy the principles of parsimony.

The remaining

proteins in each replicate were recombined to generate a complete list of
secretome proteins for each cell line.
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2.3.5 Bioinformatics
Pathway analysis was performed on proteins using the Kyoto Encyclopedia of
Genes and Genomes (KEGG) database

84

as a reference using methods

previously described50.

Gene ontology (GO) analysis was also conducted

using

annotation

the

functional

tool

available

through

the

DAVID

Bioinformatics Database85,86.

2.3.6 Western blot analysis
The following primary polyclonal rabbit anti-human antibodies were obtained:
pyruvate dehydrogenase kinase (PKM2) (GenWay, San Diego, CA), urokinase
plasminogen activator preproprotein (PLAU) (Abgent, San Diego, CA) and
transforming growth factor, beta-induced, 68kDa (TGFBI) (Proteintech
Group, Inc., Chicago, IL).

Primary goat anti-human serpin peptidase

inhibitor, clade I (pancpin), member 2 (SERPINI2) antibody was obtained
(Everest, Oxfordshire, UK). The following mouse monoclonal antibodies were
obtained:

ubiquitin

carboxyl-terminal

esterase

L1

(UCHL1),

matrix

metallopeptidase 2 (MMP2), plasminogen activator inhibitor-1 (SERPINE1),
non-metastatic cells 1, protein (NM23A) (NME1), ezrin (EZR), annexin A2
(ANXA2),

and

galectin-3-binding

protein

(LGALS3BP)

(Santa

Cruz

Biotechnology, Santa Cruz, CA). Alexa Fluor 680 conjugated secondary
donkey anti-mouse, anti-rabbit, and anti-goat antibodies were obtained
(Invitrogen).

Cells were lysed in either 25 % sample loading buffer (LDS,

Invitrogen) or 6 M urea/2 M thiourea containing HALT™ Protease Inhibitor
22

Cocktail (Pierce, Rockford, IL). Secreted proteins were concentrated using 3
kDa MW cutoff spin filters, precipitated using methanol-chloroform, then
resuspended in 6 M urea/2M thiourea. Protein concentration of reconstituted
whole cell lysates and secreted proteins was determined according to the
Bradford method. 8 µg of protein was loaded per well on NuPAGE® 4-12 %
Bis-Tris gels (Invitrogen) then separated in MOPS buffer (Invitrogen).
Proteins were transferred to a PVDF membrane (Millipore, Billerica, MA),
blocked with 5 % powdered milk in TBST (Teknova, Hollister, CA), then
incubated with primary antibody overnight at 4 °C at a dilution of 1:200.
After washing with TBST, membranes were incubated with secondary
antibody for 30 min at RT at a dilution of 1:10,000 in the dark, and then
washed again with TBST.

Fluorescence was measured used the Odyssey®

Imaging System (LI-COR Biosciences, Lincoln, NE).

2.3.7 Tissue immunohistochemistry
The following primary polyclonal rabbit anti-human antibodies were obtained:
PKM2 (GenWay, San Diego, CA), and TGFBI (Proteintech Group, Inc.,
Chicago, IL).

Primary goat anti-human SERPINI2 antibody was obtained

(Everest, Oxfordshire, UK). The following mouse monoclonal antibodies were
obtained: MMP2 (Calbiochem, San Diego, CA), NME1, EZR, ANXA2, and
LGALS3BP (Santa Cruz Biotechnology, Santa Cruz, CA), -SMA, vimentin,
CD31, and UCHL1 (Dako, Glostrup, Denmark).

Biotinylated secondary

donkey anti-mouse, -rabbit, or -goat antibodies were obtained (Vector,
Burlingame, CA). Formalin-fixed paraffin embedded human pancreatic tissue
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was obtained from patients treated at the Hospital of the University of
Pennsylvania through Institutional Review Board approved protocols.

In

total, 5 tissue samples of normal human pancreas, 5 tissue samples of
human PDAC, and 2 tissue samples of PDAC metastasis to lymph node were
analyzed. 4 µm serial sections were dewaxed, slides were microwaved in 10
mM citric acid pH 6 solution to achieve antigen retrieval, then endogenous
peroxidases were quenched using 30 % hydrogen peroxide solution. Slides
were incubated with successive solutions of avidin and biotin blocking
solutions (Vector) and StartingBlock blocking buffer (Pierce, Rockford, IL) for
15 min each at RT and primary antibody overnight at 4 °C.

Slides were

incubated with biotin conjugated secondary antibody followed by the
VECTSTAIN® HRP-ABC reagent (Vector, Burlingame, CA), each for 30 min at
37 °C. After developing the signal with diaminobenzadine (Vector), slides
were washed with water and counterstained with hematoxylin. Images were
captured using a Nikon (Melville, NY) E600 fluorescent microscope equipped
with a CCD camera and IPLab image analysis software (BD Biosciences).

2.4

RESULTS

2.4.1 RLT-PSCs recapitulate primary human PSCs
RLT-PSC is a human PSC line immortalized via transfection with SV40 large T
antigen82. When cultured on Matrigel plus N-acetyl cysteine treatment, RLTPSCs exhibit a quiescent phenotype82.

RLT-PSCs cultured on collagen I

coated cover slips or plates also maintained a quiescent phenotype denoted
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by morphology (Figure 2a), expression of GFAP (Figure 2d), presence of lipid
droplets and absence of α-SMA (Figure 2e). The quiescent PSCs could then
be activated by application of conditioned media harvested from MiaPaCa-2
pancreatic cancer cell lines.

This activation is illustrated by morphology

(Figure 2b), loss of oil red O staining, and expression of -SMA (Figure 2f).
PSCs cultured on uncoated tissue culture plates yielded an activated
phenotype as well (Figure 2c).

These results show that RLT-PSCs

recapitulate features typical of primary human PSCs.
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Figure 2. Brightfield and fluorescence microscopy demonstrating morphology of
PSCs. RLT-PSCs are shown in (A) the quiescent state, and activated by (B) exposure to
PCC CM, or (C) growth on a tissue-culture treated plate.

Fluorescent microscopy

demonstrating (D) quiescent PSC lipid droplets (red), GFAP Expression (green), and
nucleus (blue); (E) quiescent PSC lipid droplets (red), -SMA (green), and nucleus
(blue); and (F) activated PSC loss of lipid droplets (red), -SMA Expression (green), and
nucleus (blue).

2.4.2 PSC secretion is altered upon activation
Proteomic profiling of the media harvested from cells in culture was
undertaken to assess changes in the secretome of PSCs upon activation.
Proteins identified by fewer than two different unique peptide sequences
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within a replicate were excluded. Reverse database analysis revealed a false
discovery rate of less than 4 %.

A list of all quiescent and activated PSC

proteins and pancreatic cancer cell proteins is provided in Appendix 1.
Duplicate analyses were used in an effort to include as many potential
biomarkers and therapeutic targets as possible, a reasonable approach given
that any leads would be subject to further validation. A total of 641 unique
proteins were identified in the secretome from activated PSCs.

This is

significantly higher than the 46 unique proteins indentified in the secretome
from quiescent PSCs. The secretomes from CAPAN-2 and MiaPaCa-2 cancer
cell lines contained 432 and 529 unique proteins, respectively.

Proteins

identified in the quiescent PSCs, activated PSCs, and cancer cell lines were
compared to identify unique and shared proteins (Figure 3).
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Figure 3. Venn diagram of secreted proteins identified from PSCs and cancer cells
in cell culture. All identifications were made in the conditioned media derived from cells
in culture.
The activated PSC data set was sorted by total number of spectra per protein
to estimate relative abundance.

A literature search was conducted on the

most abundant proteins to identify those previously linked to cancer
progression, including roles in angiogenesis, invasion, and apoptosis. These
proteins (Table 2) were then chosen for further validation studies.
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Table 2. PSC secreted proteins selected for immunologic validation
GI no

Abbreviation

gi|5453886

SERPINI2

gi|4505863
gi|10835159
gi|11342666
gi|4507467
gi|5031863
gi|33286418
gi|66392203
gi|161702986
gi|50845386
gi|21361091

PLAU
SERPINE1
MMP2
TGFBI
LGALS3BP
PKM2
NME1
EZR
ANXA2
UCHL1

Protein Name
serpin peptidase inhibitor, clade I (pancpin),
member 2
urokinase plasminogen activator preprotein
plasminogen activator inhibitor 1
matrix metallopeptidase 2
transforming growth factor, beta-induced, 68kDa
galectin-3-binding protein
pyruvate kinase, muscle isoform 1
nucleotide diphosphate kinase 1
ezrin
annexin A2
ubiquitin carboxyl-terminal esterase L1

2.4.3 Western blot analysis confirms MS results
Expression of proteins secreted by activated RLT-PSCs (Table 2) was verified
by Western blot analysis (Figure 4). Protein expression was also assessed in
RLT-PSC whole cell lysate. Relative protein levels varied greatly. SERPINI2,
PLAU, SERPINE1, MMP2, TGFBI, and EZR were undetected and LGALS3BP,
PKM2, and UCHL1 showed faint bands in the activated RLT-PSC whole cell
lysate. ANXA2 showed similar levels in the whole cell lysate and secretome.
NME1 was expressed at higher abundance in the whole cell lysate than the
secretome.

All proteins were undetected in the quiescent RLT-PSC

secretome. All proteins observed in the activated RLT-PSC whole cell lysate
were also seen in the quiescent whole cell lysate.
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Figure 4. Western blot demonstrating expression of PSC proteins in cell culture.
Conditioned media (S) and lysate (L) from activated or quiescent PSCs were analyzed.
Equal amounts of protein were added to each well.

2.4.4 IHC analysis confirms in vitro results
IHC analysis conducted on human tissue samples from patients with PDAC or
normal controls was used to confirm and localize expression of selected
proteins in relation to PSCs. PSCs were visualized by staining serial sections
of tissue using PSC markers α-SMA and vimentin (Figure 5). To differentiate
PSCs from endothelial cells, which also express α-SMA and vimentin, the
endothelial cell marker, CD-31, was used.87 Therefore PSCs could be readily
identified by the presence of α-SMA and vimentin and the absence of CD-31.
Staining of serial sections was organized such that IHC staining of proteins of
interest were performed in a tissue section immediately adjacent to a set of
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PSC markers (Table 3).

Table 3. Serial pancreatic tissue section staining scheme for
immunohistochemistry

Slide #
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Protein
SERPINI2
-SMA
CD-31
vimentin
PKM2
TGFBI
-SMA
CD-31
vimentin
EZR
LGALS3BP
-SMA
CD-31
Vimentin
UCHL1
NME1
-SMA
CD-31
vimentin
ANXA2

In PDAC tissue sections, SERPINI2, PKM2 (Figure 5), LGALS3BP, and NME1
(Figure 6), were detected in the cytosol of cancer cells and PSCs (Figure 5).
In the dysplastic human pancreas, SERPINI2, PKM2 (Figure 5), LGALS3BP,
and NME1 (Figure 6) were detected in ductal cells and PSCs. These proteins
were also detected within the cytosolic region of acinar and ductal cells in
normal human pancreas. UCHL1 was detected distinctly in the nuclei of PSCs
in PDAC tissue sections and at low levels in the nuclei of some ductal cells
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and PSCs in the dysplastic pancreas and some acinar and ductal cells in
normal pancreas (Figure 6). TGFBI was the only protein detected distinctly
in stromal regions, to the exclusion of cancer cells in PDAC tissue (Figure 5).
In the dysplastic pancreas, TGFBI was found in the fibrotic region containing
PSCs (Figure 5).

Interestingly, TGFBI was also observed in vesicles in

normal pancreatic tissue. In PDAC tissue, EZR was detected in the cytosol of
cancer cells, but also was distinctly present at the luminal membrane of
ductal cells and the nuclei of PSCs (Figure 6). EZR was also detected in the
cytosol of ductal cells with strong localization to the luminal surface of ductal
cells in dysplastic pancreas.

In normal pancreas, EZR was detected in the

centroacinar space and within a few acinar cells in the cytosolic region
bordering the centroacinar space. In PDAC tissue, ANXA2 was detected in the
cytosol of cancer cells and PSCs. Similar to EZR, ANXA2 was detected along
the luminal membrane of ductal cells.

ANXA2 was also detected in the

cytosol of ductal cells and PSCs in the dysplastic pancreas.

ANXA2

localization in normal pancreas was similar to that of EZR with strong
staining observed in the centroacinar space and the bordering cytosol of
acinar cells.
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Figure 5. IHC staining of serial sections of pancreatic tissue.

Normal human

pancreas tissue (first column), dysplastic human pancreas tissue (middle column), and
human pancreatic ductal adenocarcinoma (last column) are stained. Positive stain is in
brown. PSCs were visualized by the expression of markers -SMA and vimentin and
the absence of CD31.
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Figure 6. IHC staining of serial sections of pancreatic tissue.

Normal human

pancreas tissue (first column), dysplastic human pancreas tissue (middle column), and
human pancreatic ductal adenocarcinoma (last column) are stained. Positive stain is in
brown.
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2.4.5 Bioinformatics analysis
Of the 641 proteins identified in the RLT-PSC secretome 174 (27%) were
implicated in at least one biological pathway according to analysis against the
KEGG database (Table 4).
metabolism.

Most classifiable proteins were involved in

As expected for secreted proteins, none were classified as

involved with transcription pathways.

The most highly populated pathway

was cell communication followed closely by the immune system.
proteins were also identified within the cell motility pathway.

Many

17 proteins

have been implicated in various cancers, of which 14 were implicated in
pancreatic cancer.
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Table 4. Activated PSC proteins identified within KEGG pathways
Pathways
Metabolism
Genetic Information Processing
Transcription
Translation
Folding, Sorting and Degradation
Proteasome
Replication and Repair
Environmental Information Processing
Membrane Transport
Signal Transduction
MAPK Signaling pathway
Signaling Molecules and Interaction
Cellular Processes
Cell Motility
Cell Growth and Death
Cell Communication
Focal adhesion
Insulin signaling pathway
Immune System
Leukocyte transendothelial migration
Nervous System
Sensory System
Development
Behavior
Human Diseases
Cancers
Immune Disorders
Neurodegenerative Diseases
Metabolic Disorders
Infectious Diseases

Number of Gis
48
0
7
18
11
10
0
15
7
14
22
12
31
21
10
30
5
6
2
5
0
17
8
9
2
14

GO analysis was conducted to elucidate biological function (data not shown).
As was seen with the KEGG analysis, the majority of proteins were related to
cellular metabolic processes; however, a significant number of proteins were
involved in fibrosis, invasion, inflammation, cell division, and apoptosis. PSCs
are believed to play important roles in wound healing, inflammation, fibrosis,
tumor progression and invasion through matrix remodeling (Figure 7).

To

identify activated PSC proteins that effect these changes, GO terms that
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relate to these functions were probed and the resulting list of proteins is
presented in Appendix 2.

Some functions, such as wound healing,

inflammation, and apoptosis relate readily to the GO terms available. Other
important pathways, such as fibrosis, cannot be studied using GO terms
currently available.

Fibrotic tissue consists largely of ECM proteins and

proteases control the remodeling of these proteins. For this reason, proteins
relating to the ECM or protease inhibitors are listed under the category of
fibrosis in Appendix 2. To identify proteins associated with proliferation, all
proteins classified as relating to the cell cycle, mitogens, or cell proliferation
were grouped together (Appendix 2). Finally, to identify proteins that play a
role

in

invasion,

proteins

relating

to

cell

motility

and

vasculature

development were compiled and are presented in Appendix 2.

Figure 7.

Diagram illustrating proposed activated stellate cell functions.

The

number of proteins identified within a function is given in parentheses. Proteins selected
for validation are listed below the function.
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2.5

DISCUSSION

The crucial role of PSC activation in the pathobiology of PDAC has only
recently begun to be appreciated.

PSCs potentiate pancreatic tumors

implanted in vivo21,88, and conditioned media from activated PSCs enhances
proliferation and invasion of PCCs in vitro89,90.

These observations support

the hypothesis that PSCs secrete soluble factors that promote tumor
progression.

Therefore, this first characterization of the secretome from

activated PSCs could provide insight into mechanisms of tumor progression.
While PSCs secrete few proteins in the quiescent state, activation results in a
rich and complex mixture of secreted proteins. It is likely that the secretome
of immortalized PSCs differ in some ways from freshly isolated PSCs.

A

comparison of gene expression profiles demonstrated few differences
following immortalization, involving extracellular matrix proteins, integrins,
intermediate filament proteins and cytokines21.

In our study the protein

MMP2, which has previously been described as expressed at low levels in the
quiescent PSC,22 was not identified in the quiescent RLT-PSC secretome. A
number of factors are likely at play, such as differences resulting from
immortalization and across species. Most importantly, previous studies have
used cell lines which are only transiently quiescent, whereas the RLT-PSC cell
line can be stably maintained in a quiescent state indefinitely. It is possible
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that the low level of MMP2 expression previously observed reflects low level
PSC activation.
It is likely that the proteins secreted by activated PSCs are dependent upon
the activating stimulus. Future studies could examine proteins secreted by
PSCs activated in response to other stimuli, such as PDAC cells, to study
these differences. Interestingly, many proteins secreted by activated PSCs
are also secreted by the cancer cell lines studied. Approximately 60% of the
proteins identified in the activated PSC secretome and one half to threequarters of the cancer cell line secretomes were found common to both cell
types (Figure 3).
Many

proteins

secreted

by

activated

PSCs

play

important

roles

in

proliferation, invasion, inflammation and fibrosis, pathways important for the
proposed role of PSCs in supporting tumor growth and metastasis. The
potential roles of individual proteins present within the identified PSC
secretome are discussed below.

2.5.1 Wound healing
Wound healing is a primary function of PSCs. It has been hypothesized that
cancer cells exploit this PSC function to support tumor growth. Thus, 21
proteins associated with wound healing were identified, including PLAU and
SERPINE1. SERPINE1 inhibits tissue plasminogen activator

(tPA)

and

urokinase (uPA), the activators of PLAU, a key enzyme in fibrinolysis. High
levels of SERPINE1 have been correlated with a poor outcome in PDAC91.
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Expression of PLAU and SERPINE1 have been previously reported in
desmoplastic regions of PDAC tissue92-95.

2.5.2 Inflammation
Some

33

proteins

associated

with

inflammation

were

identified.

Inflammation is one of the primary activators of PSCs in the pancreas.
Chronic pancreatitis, a condition of prolonged inflammation, is one of the risk
factors for PDAC.
through
damage.

Inflammatory processes are thought to potentiate PDAC

classical mechanisms,

such

as

oxidative-stress

induced

DNA

Another recently proposed mechanism implicates recruitment of

immunosuppressive

cells

as

a key

pathway for evasion of

surveillance early in pancreatic carcinogenesis96.

immune

Our findings support the

hypothesis that PSCs play a role in perpetuating a state of inflammation in
the tumor microenvironment.

2.5.3 Proliferation
Accumulating evidence supports the presence of factors secreted by
activated PSCs that enhance cancer cell proliferation.

Among the 68

secreted PSC proteins involved in proliferation, NME1 and UCHL1 expression
was verified in the current study. NME1, a nucleoside diphosphate kinase,
was observed at higher levels in cervical, thyroid97,98, and metastatic ovarian
tumors99, suggesting a role in enhancing cancer cell proliferation.
UCHL1 is an enzyme whose function varies with dimerization and posttranslational modifications100.

In some cancers, the gene for UCHL1 is
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methylated, and restoration of UCHL1 expression inhibited proliferation in
hepatocellular carcinoma101.

Other studies have shown that UCHL1 is

upregulated in lung cancer, invasive colorectal cancer, and PDAC102-104.

2.5.4 Apoptosis
Inhibition of apoptosis is a key mechanism in tumor growth.

Some 49

proteins associated with apoptosis were identified, including NME1.

NME1

has shown the ability to limit the expression of the apoptotic protein Bcl-2105.
Thus, in addition to promoting PCC proliferation, NME1 may support PDAC
progression through inhibition of apoptosis.

2.5.5 Fibrosis and invasion
Activated PSCs are known to secrete ECM proteins such as collagens I, III,
and IV, and fibronectin10,11. This matrix then serves to promote cell proliferation
and migration to heal wounded areas. Chronic activation, as seen in chronic
pancreatitis or PDAC, results in the accumulation of fibrotic tissue. PSCs are
also known to produce factors that break down ECM, which may play a role
in promoting invasion. Indeed, PDAC lymph node metastases were observed
to contain stroma and PSCs (Figure 8).

In addition, 24 ECM proteins and

proteases and 40 proteins associated with cell motility and vasculature
development were identified.
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Figure 8. IHC staining of PDAC lymph node metastasis. PSCs are visualized by the
expression of markers -SMA (A) and vimentin (B) and the absence of CD31(C).
Positive staining is in brown.
ANXA2, a phospholipid binding protein, is believed to play a role in
angiogenesis, invasion, and metastasis, and its expression has been best
described in colon cancer106,107, ANXA2 has also been reported to serve as a
receptor for plasminogen108 and as such may play a role in the plasminogen
activator pathway The urokinase plasminogen activator pathway is believed
to play a role in cancer cell invasion in the pancreas92,94 and includes the
proteins MMP2 and SERPINE1, along with PLAU. SERPINI2 is a protein
specific to the pancreas and to breast cancer stroma109,110. The function of
SERPINI2 is poorly understood, however its sequence identifies it as a serine
protease inhibitor in the same family as SERPINE1, suggesting a role in the
plasminogen activator pathway, as well. LGALS3BP, a protein expressed in
advanced gastric cancer111, binds the receptor galectin-3, a protein highly
expressed in PDAC metastases112.

LGALS3BP modulates cell-integrin

interactions to either promote or inhibit cell attachment113. NME1 has been
implicated as a suppressor of tumor metastasis in melanoma and breast
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cancer114,115.

In vitro studies have shown that NME1 suppresses tumor

metastatic potential and negatively regulates cell migration, possibly via
regulation of integrin expression or trafficking116-118.

TGFBI is a secreted

RGD-containing protein and has anti-adhesive properties119,120.

TGFBI is

upregulated in renal cell carcinoma and esophageal adenocarcinoma121,122,
and has been reported to inhibit cell attachment in vitro119.
Finally, UCHL1 and EZR are believed to enhance invasion. UCHL1 is thought
to

modify

pathway123.

cell

morphology

through

modulation

of

the

Akt-signaling

EZR is a mediator of cell-integrin interactions and high

expression of EZR has been associated with prostate and pancreatic cancer
progression124,125.

By organizing the interaction between the cytoskeleton

and the cell membrane EZR regulates cell adhesion, migration and
invasion126.

Furthermore, EZR has been found to be essential to the

metastatic potential of some cell lines127,128.

Taken together, our results

demonstrate PSCs are an important source of proteins that regulate ECM
remodeling, cell motility and invasion.
The proteins discussed here are a sampling of the many secreted proteins
identified from the activated PSC secretome.

It is clear that the PSC

secretome is an important source of proteins that regulate proliferation,
inflammation, and ECM remodeling as well as cell motility and invasion.
Characterization of the activated PSC secretome is an important first step in
elucidating the complex role of PSCs in PDAC progression. These results lay
the foundation for future studies, for example, characterizing the proteins
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involved in paracrine signaling with PDAC cells.

Further studies would

determine whether secreted PSC proteins identified here can serve as
biomarkers of PDAC progression or potential new therapeutic targets.
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3 Chapter 3 – Development of an LC-MS method for the relative
quantitation of potential biomarker proteins
For submission as:
Wehr AY, Blair IA, Yu KH. Relative quantitation of serum pancreatic cancer
biomarker proteins by stable isotope dilution liquid chromatography-mass
spectrometry. JPR 2011

3.1

Abstract

An innovative multiplexed LC-MRM/MS-based assay for rapidly measuring a
large number of disease specific protein biomarkers in human serum has
been developed.

This approach is based on stable isotope dilution

methodology in order to reliably quantitate candidate protein biomarkers.
Human serum was diluted using a SILAP standard prepared from the
secretome of pancreatic cell lines, subjected to immunoaffinity removal of
the most highly abundant proteins, trypsin digested, and analyzed by LCMRM/MS.

The method was found to be precise, linear, and specific for

relative quantitation of 72 proteins when analyte response was normalized to
the relevant internal standard (IS) from the SILAP.

The method made it

possible to determine statistically different concentrations for 3 proteins in
control and PDAC patient samples. This method proves the feasibility of using
SILAP dilution with MRM analysis of tryptic peptides as a means to compare
changes in the concentration of candidate protein biomarkers in human
serum.
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3.2

Introduction

Many methods have been developed to characterize differential proteomes,
resulting

in

vast

lists

of

candidate

biomarker

proteins

which

await

quantitation in human samples for validation48-55. ELISA is the most common
method used for the quantitation of proteins in serum due to its high
sensitivity and specificity.

However, this method becomes expensive and

labor intensive when applied to a large number of proteins and samples.
Furthermore, high quality monoclonal antibodies are not available for the
vast majority of candidate biomarkers identified.

As a result, most

biomarker validation studies are limited to single or several proteins56-59.
Stable isotope dilution with detection by MS has been the mainstay of
bioanalytical analyses for the past two decades69-71, due to both the
specificity and sensitivity with which this methodology can measure the
concentration of small molecules. With developments in MS technology, such
an approach has provided the speed and sensitivity to allow for detection of
low abundance proteins in serum72,73.
Compared with small molecule LC-MS, the analysis of proteins has some
specific challenges. Intact proteins can be difficult to separate on traditional
LC columns, especially those designed to work at the decreased flow rates
required to achieve high sensitivity microflow electrospray.

However, the

peptides that result from tryptic digestion behave much more like small
molecules and are easier to separate by RP LC with MS-compatible mobile
phases.

Tryptic peptides terminating in lysine and arginine are also
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amenable to multiple charging by ESI.
products

ions of a

lower charge

This makes it possible to generate

state

and higher

m/z than

their

corresponding precursor ions, which helps to minimize background noise, a
key concern when working in a complex matrix like human serum.
The protein load in human serum poses another concern. The LC columns
used with microflow ESI/MS are limited in the amount of protein that can be
loaded onto the column.

The concentration range of proteins in human

serum spans over 10 orders of magnitude74 and 99% of the protein by mass
in serum is made up of 22 highly abundant proteins such as albumin and
immunoglobulins75.

SISCAPA has been developed as a system to purify

proteins of interest from the biological matrix76. However, antibodies specific
to each protein of interest must first be developed, and thus is limiting in a
similar fashion to ELISA. Commercially available immunoaffinity columns can
be used to remove these proteins from the serum, reducing the protein
concentration and effectively increasing the loading capacity of the LC
column77-79.
The processes of digestion and immunoaffinity removal of abundant proteins
are not without drawbacks and both have been associated with high
variability which can confound studies intended to compare the concentration
of an analyte across different samples83,129.

Dilution with a stable isotope

labeled IS is commonly used in bioanalytical assays to correct for losses
during sample preparation or variability in chromatographic separation or
ionization72,80. The Blair group has previously reported the use of SILAC as a
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means to normalize proteomic profiling, a methodology that was termed
SILAP50,73,81. The current study represents a novel implementation of SILAP
for the relative quantitation of a panel of potential serum protein biomarkers.
Stable isotope labeled secreted proteins from human pancreatic cell lines in
culture were used as the SILAP standard. The development and validation of
a quantitative method, using relevant IS from the SILAP to normalize the
analyte response in human serum has now been completed.

3.3

Experimental Procedures

3.3.1 Cell culture
The human PDAC cell lines MiaPaCa-2 and CAPAN-2, and the immortalized
human PSC line RLT-PSC82 were cultured according to standard practice
using DMEM (Sigma, St. Louis, MO) supplemented with 10 % fetal bovine
serum (Sigma) and 1 % antibiotic (penicillin/streptomycin, Invitrogen, Grand
Island, NY). SILAC labeling was achieved using leucine and lysine free DMEM
supplemented with

13

C,15N-labeled leucine and lysine (Cambridge Isotopes,

Andover, MA), 10 % dialyzed fetal bovine serum (Sigma), and 1% antibiotic
(penicillin/streptomycin, Invitrogen).

Cells were passaged a minimum of 7

times to achieve amino acid labeling exceeding 99 %.

Secreted proteins

were harvested by allowing cells to grow to 80 % confluence, washing with
phosphate buffered saline (Invitrogen), and incubating the cells with serumfree SILAC media at 37 °C for 48 h. This media was collected, passed
through a 0.22 µm filter, and stored at -80 °C.
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3.3.2 Immunoaffinity removal of abundant proteins
Human serum was first diluted with SILAP internal standard prior to
processing with either the IgY-14 LC2 column (Seppro®, Sigma) alone, or in
tandem

with

the

SuperMix

column

(Seppro®,

Sigma),

according

to

manufacturer instructions. Briefly, the serum and internal standard mixture
was diluted 1:4 with dilution buffer (Seppro®, Sigma) centrifuged through a
0.45 m filter, then injected onto the immunoaffinity column(s).

Dilution

buffer was used to elute the flowthrough, or low-abundance, fraction which
was monitored at 280nm, collected, and stored on ice. The bound, or highabundance, fraction was eluted with stripping buffer (Seppro®, Sigma),
collected, and stored on ice.

The columns were regenerated with

neutralization buffer (Seppro®, Sigma). The protein was then concentrated
using 3 kDa molecular weight cutoff spin-filters (Millipore, Billerica, MA), and
precipitated using methanol-chloroform extraction.

3.3.3 Tryptic digestion
The precipitated protein mixture was dissolved in 10 % 6 M urea, 2 M
thiourea in 25 mM ammonium bicarbonate, reduced in 5 mM dithiothreitol for
45 min at 60°C, alkylated in 15 mM iodoacetamide for 30 min at room
temperature in the dark, and digested using sequencing grade trypsin
(Promega, Madison, WI) at a ratio of 1:20 by weight at 37 °C overnight.

49

3.3.4 LC-MS/MS analysis
Peptides were acidified to 0.1 % formic acid and desalted with disposable
C18 spin filters (Nest Group, Southborough, MA). Peptides were separated
by reversed phase chromatography using a C18 column (0.3 x 150 mm, 3
µm, 200 Å C18AQ, Michrom Bioresources, Auburn, CA) on a microflow HPLC
system (Eksigent, Dublin, CA). After a 5 min isocratic hold at 95 % mobile
phase A (2 % acetonitrile, 0.1 % formic acid), a linear gradient increasing
mobile phase B (95 % acetonitrile, 0.1 % formic acid) from 5 to 60 % over
55 min at a flow rate of 5 µl/min was used to elute peptides online to a triple
quadrupole mass spectrometer (Vantage, ThermoFisher, San Jose, CA) with
positive ESI and MRM.

Raw files were imported to Skyline

130,131

and

integration was manually verified by retention time of all six transitions per
peptide.

3.3.5 Sample Analysis
Human serum samples were collected in accordance with an IRB approved
protocol. Samples were matched for age, race, and gender. Samples were
classified as PDAC if the patient was determined to have cytopathological or
surgical

pathological

confirmation

of

pancreatic

adenocarcinoma

as

performed by gastrointestinal pathologists as the Hospital of the University of
Pennsylvania. With the exception of one patient, whose tumor was removed
4 months prior to blood collection, control samples were taken from patients
with a distant history of solid tumor malignancy deemed cured based upon
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greater than five year interval free of disease based on CT scans.
Furthermore, greater than 2 year follow up with CT scans following collection
of blood sample confirmed no measurable recurrence of disease.

Samples

were analyzed in batches, each batch contained a mixture of PDAC and
control samples.

Samples were assigned a unique identifier to blind the

analyst during processing. Statistical analysis was conducted using Prism 5
(GraphPad Software, Inc., La Jolla, CA). A two-tailed, unpaired t-test with
Welch’s correction for unequal variances, and a confidence interval of 95%
was used to determine statistical significance.

3.4

Results

3.4.1 Transition List Development
Peptide sequences were selected from a spectral library generated in
house50,132. The peptide list was filtered to remove those redundant to more
than one protein, lacking lysine and leucine, singly charged, possessing an
Xcorr score less than 2, or a precursor m/z below 450 or above 1900. The
spectral library was then used to generate a transition list for a selected
number of filtered peptides.

Three transitions were selected per peptide

using the 3 most intense y-ions with m/z greater than the precursor m/z.
Based on this list of transitions, an IS transition list was created using the
calculated mass of each peptide assuming

13

C,15N labeling of all lysines and

leucines. The final transition list is provided in Appendix 3.
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3.4.2 Scheduling Development
The IS transition list was split into smaller lists, each composed of no more
than 90 transitions. Each list was then used to analyze the IS, monitoring all
transitions for the duration of the chromatographic run. Using a dwell time
of 10 ms, the cycle time was maintained under 1 sec. SkyLine software was
then used to identify the correct peak and retention time for each peptide
based on the co-elution of all three transitions as well as predicted elution
time.

SkyLine software was then used to generate a scheduled method,

encompassing the entire list of transitions, both analyte and IS, using a 4
min window for each peptide.

A four min window provided a maximal

overlap of 180 transitions, corresponding to a cycle time of 1.8 sec (Figure
9A).

Analysis of the effect of dwell time on peak area revealed that no

further gain is achieved beyond a dwell time of 20 ms, yet the dwell time can
be reduced to 10 ms without significant loss of signal (Figure 9B). At a dwell
time of 10 ms, no difference in peak area was seen when varying the number
of points across the peak from 10 to 50 (Figure 9C).

Thus a scheduled

method utilizing a dwell time of 10ms and 10 points per peak, as provided by
the

scheduled

method

resulting

in

a

1.8

sec

cycle

time

with

a

chromatographic method producing 18 sec wide peaks, was deemed
acceptable.
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Figure 9. Transition list development of window size, dwell time and points per
peak.

3.4.3 Depletion Development
Two immunoaffinity methods were compared for removal of abundant
proteins, both based on the Seppro system. The IgY-14 LC column alone,
designed to remove the 14 HAP present in human plasma, was compared
with the IgY-14 LC column used in tandem with the SuperMix LC column,
designed to remove a large subset of moderately abundant proteins (MAP)
present in human plasma.

To test the ability of the immunoaffinity

column(s) to selectively remove only the highly and moderately abundant
proteins from serum, the enzyme MMP2 was used as a surrogate. MMP2 was
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added to human serum and processed by each LC removal method. MMP2
was only detected in the unbound flowthrough fraction of each method as
demonstrated by both western blot and LC-MRM/MS analysis (Figure 10).
MMP2 was not detected by LC-MRM/MS in the any of the bound, high
abundance fractions.

Although some interference is observed in the

chromatogram of peptide VDA when using the IgY-14 column alone, this
method was chosen for subsequent analyses.
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(A) Western blot of MMP2 in human serum. Lanes 1 and 2 display the unbound and
bound fractions, respectively derived from the LC IgY-14 column alone. Lanes 3, 4, and
5 contain the unbound, IgY-14 bound, and SuperMix bound fractions from the tandem
LC.
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Based on the results of the development, a final workflow (Figure 11) was
adopted. Elements of the process were validated with respect to precision,
linearity, sensitivity, and specificity.
Serum
Sample

+

SILAP
standard

Deplete HAP

Trypsin Digest

Separate by C18

Quantitate by
LC-MRM/MS

Figure 11. The final workflow consisted of dilution of the serum sample with
SILAP standard, followed by depletion of highly abundant proteins, trypsin
digestion, and LC-MRM/MS analysis.

3.4.4 LC-MS validation
A tryptic digest of both light and heavy proteins derived from the cell culture
secreted proteome was analyzed by LC-MRM/MS in triplicate. The precision
of the peak area response was plotted as a function of several factors
including retention time, peak area, peak width, and precursor m/z.

Peak

area and precursor m/z had the most striking effects (Figure 12).

When

precision was plotted as a function of peak area it became clear that below a
peak area of 10,000, the percent relative standard deviation (%RSD) was
consistently above 15%. Similarly, when plotting precision as a function of
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parent m/z, the % RSD was above 15 % for parent m/z below 500, and with
the exception of one analyte, below 15 % when the precursor m/z was above
600.

These data were used to drive the selection of peptides for further

analysis.
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Figure 12. LC-MS precision, linearity, and sensitivity. The impact of peak area (A)
and precursor m/z (B) on precision are demonstrated. The response is linear over the
range 10 to 100 fmol protein(C) and both peptides are easily detected at 10 fmol by LCMRM/MS (D).
The linearity of the response was assessed by preparing a tryptic digest of
MMP2, which was then diluted over a range of 2 to 100 fmol and spiked with
digested SILAP internal standard.

The peptide response is measureable at
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10 fmol and the response is linear over the range of 10 to 100 fmol (Figure
12).

3.4.5 Digestion validation
The SILAP internal standard was spiked into a light protein sample, derived
from the cell culture secreted proteome, to test the precision of the trypsin
digestion. From this pool, 5 replicates were trypsin digested and analyzed by
LC-MRM/MS. Using analyte peak area alone, the %RSD was less than 20%
for all proteins. When normalized using the IS peak area, the %RSD of the
analysis was below 15% for all proteins (Figure 13) which conforms to
commonly observed acceptance criteria for bioanalytical methods. Linearity
of the digestion was tested by spiking a fixed amount of the SILAP standard
into increasing amounts of MMP2 in the range 10 to 250 fmol. Samples were
then trypsin digested and analyzed by LC-MRM/MS. The response was found
to be linear across the range of 10 to 250 fmol (Figure 13).

Replicate

analysis at the lower limit of quantitation (LLOQ) of 10 fmol resulted in a %
RSD less than 20 % for both peptides which conforms to bioanalytical
acceptance criteria.
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Figure 13. Digestion precision, linearity, and sensitivity. The precision of digestion is
improved when normalized to the internal standard response (A). The response after
digestion remains linear over the range of 10 to 250 fmol (B). And both peptides remain
easily detected at 10 fmol by LC-MRM/MS (C).

3.4.6 Validation of immunoaffinity removal of abundant proteins
Five replicates of serum mixed with SILAP internal standard were processed
by LC immunoaffinity removal of the HAP (IgY-14), trypsin digested, and
analyzed by LC/MS. The precision of the peak areas and peak area ratios for
26 endogenous proteins present in the serum is plotted in Figure 14A. The
precision of the analyte area alone is unacceptable for many proteins, with
%RSD over 20%.

However, when the peak areas are normalized to the

internal standard, the %RSD of the ratio is below 20% for all proteins.
Linearity of the analysis was determined by spiking SILAP internal standard
into a 10 – 60 L serum curve.

The curve was then processed by LC

immunoaffinity removal of the HAP (IgY-14), trypsin digested, and analyzed
by LC-MS. The area ratio response for one protein is given as an example
(Figure 14B). The curves for all proteins were linear with R squared values
all above 0.8.

To determine the specificity of the analyte response, the

response of the endogenous protein in serum was compared to the response
in the SILAP internal standard. Similarly, the specificity of the IS response
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was determined by comparing the response of the heavy protein in the IS to
the response in blank serum lacking IS. Representative chromatograms are
given in Figures 14C and 14D.

The IS does not interfere with the analyte

signal, nor does the blank serum possess any compounds interfering with the
IS. This finding was consistent for all proteins. The interference, if any, is
less than 20% for all proteins.
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Figure 14. Depletion precision, linearity, and specificity. The precision of depletion
is dramatically improved when normalized to the internal standard response (A). The
response after depletion is linear over the range of 10 to 60 mL serum (B). To test the
specificity of the response, blank serum lacking internal standard (top chromatograms),
and the SILAP internal standard lacking serum (bottom chromatograms), were
independently analyzed. The results for insulin-like growth factor binding protein 7 are
shown as an example. The specificity of the analyte response is demonstrated by the
lack of response in the analyte channel of an LC-MRM/MS chromatogram from the
internal standard sample (C). Similarly, the specificity of the internal standard response
is demonstrated by the lack of response in the internal standard channel in the LCMRM/MS chromatogram from the blank serum sample (D).
61

3.4.7 Sample Analysis
Prior to the start of any LC-MRM/MS sample analysis, a test injection was
used to verify peptide retention times. During the test injection, 10 peptides
were monitored for the duration of the LC gradient. Any retention time shifts
seen in these peptides were used to correct the MRM windows for all other
peptides.

The method was used to quantitate 72 proteins in 40 serum

samples, 20 samples taken from patients with PDAC, and 20 samples taken
from control patients. Comparison of the scatter plots as prepared from the
analyte peak area alone versus the peak area ratio after normalization with
the

SILAP

IS,

revealed

tighter

clustering

than

observed

without

normalization(Figure 15). A t-test was used to look for differences in the two
cohorts. Statistical analysis was also improved when using normalized data.
The difference in the average response of 3 proteins was discernable when
using the normalized response (Table 5). Cystatin M, IGF binding protein 7,
and villin 2 were all significantly lower in the PDAC patients, with p values <
0.04 when compared with relevant control subjects.
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Figure 15. Scatter plots of cystatin M, IGF binding protein 7, and villin 2. Statistical
analysis of the peak area ratios using a t-test revealed differences between cancer
(PDAC) and control patients when response was normalized to the internal standard (top
row) but not when comparing analyte area alone (bottom row).
Table 5. Statistical analysis of cystatin M, IGF binding protein 7, and villin 2

Protein

Response

PDAC Mean ±
SEM

Control Mean ±
SEM

Difference between
means

95% confidence
interval

R
squared

P value

Cystatin M

Peak area

17190 ± 2498

19680 ± 2292

-2487 ± 3390

-9360 to 4386

0.01433

0.4679

Area ratio

0.124 ± 0.0102

0.186 ± 0.0156

-0.0620 ± 0.0187

-0.100 to -0.0240

0.2562

0.0023

IGF binding

Peak area

32110 ± 3565

26670 ± 3871

5440 ± 5263

-5230 to 16110

0.02806

0.308

protein 7

Area ratio

0.0762 ± 0.00365

0.106 ± 0.0126

-0.0303 ± 0.0131

-0.0574 to -0.00308

0.1951

0.0307

Villin2

Peak area

7164 ± 912.1

10800 ± 1393

-3635 ± 1665

-7027 to -242.2

0.1297

0.0365

Area ratio

0.243 ± 0.0173

0.347 ± 0.0317

-0.104 ± 0.0361

-0.178 to -0.0302

0.2226

0.0074
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3.5

Discussion

A method for the relative quantitation of 72 endogenous proteins in human
serum has been developed.

The method was validated with respect to

precision, linearity, and specificity.

3.5.1 Development
Development studies

resulted

in a workflow consisting

of depletion,

digestion, chromatographic separation and stable isotope dilution LCMRM/MS analysis.

Certain elements of this approach to the development

enhanced chances for success. First, a spectral library developed in house
for the derivation of our transition list.

All of the peptides we sought to

monitor had previously been identified by LC-MS in our laboratory. This
approach made it possible to pursue peptides known to endure the processes
of digestion, chromatographic separation, and ionization well, which may
have conferred an advantage during the validation of these processes.
Second, three MRM/MS transitions were monitored per isotopic peptide.
Comparison of quantitation using either the single best transition, or the sum
of all three, gave comparable results with respect to precision, linearity, and
specificity (results not shown).

However, the use of six transitions per

peptide (three for the labeled, three for unlabeled), enabled the accurate
identification of chromatographic retention time.

This step was critical to

MRM/MS window scheduling, and peak integration. Scheduling reduced the
number of concurrent transitions enabling a shorter cycle time and thus a
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sufficient number of points per peak for proper peak integration. Finally, we
chose to use our SILAP standard to refine the transition list prior to analysis
of analytes.

This enabled us to ensure that each analyte would possess a

solidly performing IS.
A limitation in the development of the depletion method was the lack of
authentic proteins standards. We selected MMP2 as surrogate for all other
proteins of interest based on its presence in the SILAP internal standard, as
well as its enzymatic activity and the availability of sensitive and specific
antibodies.

By selecting an enzymatically active protein, the chances of

acquiring a recombinant protein with the correct primary sequence and
structure were enhanced.

The commercially available recombinant MMP2

that we obtained was efficiently separated from the HAP and recovered from
the unbound fraction during depletion.

However, it cannot be reasonably

expected that all proteins selected for our analysis would behave analogously
to MMP2.

The apparent MS response may be reduced by either loss of

signal, or an excess of noise. For example, a reduction in signal may occur if
a protein were lost during depletion, due to either nonspecific binding to the
column

or

association

proteins133,134.

with

highly

or

moderately

abundant

plasma

Conversely, the apparent signal of some lower abundance

proteins may benefit from the reduction in noise resulting from tandem
depletion of the MAP and HAP.

Thus, a balance between analyte loss and

background reduction has to be made, which can only properly be
determined by analyzing each protein individually.
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This analysis would be

excessively costly given the preliminary nature of the study.

Therefore a

surrogate protein was used during development, in the anticipation that it
would approximate the behavior of the average analyte.

3.5.2 LC-MS validation
When studying the sources of imprecision in the LC-MS analysis, the
determination that retention time had little effect on precision could be
expected due to the well crafted scheduled method developed with dwell
time and cycle time in mind. The poor precision below 10,000 area counts
can be expected as well since low intensity analytes often suffer from poor
precision. These data established 10,000 area counts as the lower limit of
detection for the Thermo Vantage triple quadrupole mass spectrometer.
However, the observation that precision was improved above precursor m/z
600 was somewhat surprising and may reflect either the performance of our
instrument or the impact of background noise as fewer small molecules
might interfere at this elevated m/z. Overall, the LC-MS analysis performed
well with respect to precision and linearity.

While the establishment of a

linear range of only one order of magnitude might seem small, it was
expected that the concentration of endogenous proteins would vary by far
less than this amount and so the range was suitable for our application.

3.5.3 Digestion validation
The reproducibility and linearity of the digestion was unexpectedly good.
Trypsin digestion can vary in the degree of completion, confounding the use
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of peptide internal standards

129

.

Normalization using the intact protein

SILAP internal standard clearly improved the precision and is responsible for
bringing the analysis into conformance with the commonly accepted criteria
of %RSD less than 15%. However, even without normalization, the digestion
was remarkably reproducible. This may be due to use of the spectral library
in forming the peptide list, as only stable and easily digested proteins were
included in the library.

3.5.4 Depletion validation
Validation of the depletion method was anticipated to be the most
problematic and drove home the importance of the SILAP internal standard.
Without normalization, the precision of the analyte area is unacceptable for
many proteins. However, this is corrected when normalized to the internal
standard.

This can be attributed to the ability of the intact protein SILAP

internal standard to mimic the endogenous analyte. Since the proteins in the
SILAP standard are all native proteins produced in nontransduced

human

cells, they all possess the correct primary sequence and are properly folded
and post-translationally modified, enabling them to properly track each
analyte during depletion and digestion, a feat not possible with recombinant
or synthetic proteins or peptides. Again, the linear range as determined by
this analysis is small, spanning less than an order of magnitude. However,
we expect endogenous protein levels to vary by less than 4-fold, so this
range was considered to be suitable for our analyses.
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The specificity of the analysis was excellent and most likely due to the use of
precursor ions with m/z above 600 and product ions with m/z greater than
the relevant precursor ion.

It is important to note the importance of

ensuring the purity of the SILAP standard.

If the cells are not passaged

sufficiently in the heavy media, contamination with unlabeled protein could
lead to high background in the analyte channel, reducing the ability to detect
changes in abundance.
A limitation of this study has been the lack of protein standards with known
concentrations, preventing the assessment of accuracy and a definitive lower
limit of quantitation. However, by studying the endogenous proteins present
in our serum, we were able to determine the precision, linearity, and
specificity of the method, which is sufficient for the relative quantitation of
proteins necessary to evaluate potential biomarkers.

3.5.5 Sample Analysis
The method performed well for the duration of sample analysis. Of the 72
proteins quantitated in 40 serum samples, 3 showed a significant difference
in average response when comparing PDAC and control samples.

The

simultaneous analysis of 72 proteins enabled us to quickly evaluate our list of
potential biomarkers to identify those appropriate for further analysis. The
method is sufficiently fast and inexpensive to permit the analysis of many
proteins, while retaining the rigor required to achieve statistical significance.
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3.6

Conclusion

This method proves the feasibility of using stable isotope dilution LC-MRM/MS
analysis of tryptic peptides as a means to compare difference in the
concentration of endogenous proteins in human serum for the selection of
potential biomarkers for further validation.

Moreover, the thorough

investigation of the method illustrates the power of the SILAP standard to
enhance method performance. A major limitation in the use of stable isotope
labeled tryptic peptides ISs or AQUA peptides135,136 is that they are not
affected by differences in extraction and digestion efficiency in the same way
as the intact proteins. This can lead to inaccurate quantitation even though
excellent standard curves can be generated from the unlabeled peptides.
Our method could easily be expanded to cover a larger set of proteins or
validated for the absolute quantitation of multiple proteins simply through
the addition of a standard curve derived from an authentic protein standard.
This precise, linear, and specific method could have far reaching implications
in the study of many human disease biomarkers.
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4 Chapter 4 - Identification of a panel of protein biomarkers for
the detection of pancreatic cancer in serum
For submission as:
Wehr AY, Hwang W, Blair IA, and Yu KH. Multiplexed serum biomarker
analysis for the detection of pancreatic cancer in human serum. Cancer
Epidemiology and Biomarkers, 2011

4.1

Abstract

Current biomarkers for the detection of pancreatic cancer lack the specificity
and sensitivity needed for use as a screening diagnostic. We used a targeted
multiplexed LC-MS method to quantitate 72 proteins in human serum. The
method relies on a SILAP internal standard to normalize the response and
correct for losses during sample preparation. By comparing the response of
these proteins in cancer serum (n=31) and control serum (n=20) samples
we identified 15 differentially-secreted proteins:

anterior gradient 2

homolog, cystatin C, cystatin M, heparan sulfate proteoglycan 2, IGF binding
protein 7, kallikrein-related peptidase 10, lamin A/C, lipocalin 2, myosin,
heavy polypeptide 9, non-muscle, SMT3A, profilin 1, S100 A6, transgelin 2,
tropomyosin 3, and villin 2. A receiver operating characteristics (ROC) curve
based on this panel resulted in 95% sensitivity and 94% specificity in the
ability to detect pancreatic cancer.
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4.2

Introduction

Pancreatic cancer is the 4th leading cause of cancer death in the United
States even though it accounts for only 3% of new cancer diagnoses 1. One
reason for the high mortality rate is the late stage of progression at
presentation due to the asymptomatic nature of early disease.

For the

fortunate few who present with early stage disease, resection via the Whipple
procedure is a highly effective treatment137,138.

Thus, a screening test for

pancreatic cancer could dramatically impact the way that this devastating
disease is treated.
Endoscopic procedures are expensive, carry significant risk of complications
and have shown only limited success

26,27

. Proteomic analysis of pancreatic

cyst fluid has identified potential biomarkers, but again relies on invasive
testing that is not feasible for general screening28.

A method to detect a

biomarker or panel of biomarkers in the serum would provide a minimally
invasive technique that could be easily applied to the population.
The carbohydrate CA19-9 is the only serum biomarker currently used for
PDAC and lacks sufficient sensitivity and specificity for screening24,25.
such it is currently used as a marker of response to therapy29-31.

As

Some

protein biomarkers that have been reported include MIC-1, PAM4, OPN,
HSP27, TPS, TSGF, CAM17.1, PF4, CEACAM1, annexin A8, Claudin 18,
lactose binding protein, and plectin-1, yet all lack the necessary levels of
sensitivity and specificity26,38-42. Panel testing has been conducted as well on
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up to four potential markers, but will little to no improvement in the
specificity and sensitivity38.
The Blair laboratory has previously identified over 1000 proteins secreted by
pancreatic cancer and stromal cell lines50,132. By using a mixture of cell types
that constitute the tumor microenvironment, it was possible to identify a
comprehensive set of candidate biomarkers with the potential to seep into
the blood.

This set of candidate biomarkers was used to direct the

development of a targeted method for their relative quantitation in human
serum. Subsequently, an LC-MRM/MS method capable of monitoring up to
100 proteins simultaneously was developed (Chapter 3). The method relies
on a SILAP internal standard to track each protein through the process of
depletion, digestion, chromatographic separation, ionization, and MRM
analysis.

We used this method to test the ability of a set of candidate

biomarkers to discern pancreatic cancer from control in a training set of
serum samples. By using a significantly larger panel of biomarkers in a large
training set of human serum samples, as afforded by this unique LC-MRM/MS
method, it was possible to identify a panel of biomarkers possessing a level
of specificity and sensitivity previously unreported for this disease. Analysis
of 72 candidate biomarker proteins in PDAC serum and control serum
samples has been conducted.
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4.3

Materials and Methods

4.3.1 Sample collection
Human serum samples were collected in accordance with an IRB approved
protocol. Samples were matched for age, race, and gender. Samples were
classified as PDAC if the patient was determined to have cytopathological or
surgical

pathological

confirmation

of

pancreatic

adenocarcinoma

as

performed by gastrointestinal pathologists as the Hospital of the University of
Pennsylvania. With the exception of one patient, whose tumor was removed
4 months prior to blood collection, control samples were taken from patients
with a distant history of solid tumor malignancy deemed cured based upon
greater than five year interval free of disease based on computerized axial
tomography (CT) scans. Furthermore, greater than 2 year follow up with CT
scans following collection of blood sample confirmed no measurable
recurrence of disease.
Whole blood samples were collected preoperatively in glass tubes without
additive (10 mL BD Vacutainer™ No Additive, BD, Franklin Lakes, NJ) and
allowed to clot at room temperature for 40 min. Serum was separated by
centrifugation at 1500 rpm for 15 min. 1 mL aliquots of serum were taken
and stored at -80 °C until ready for use. The time from collection to frozen
storage was no more than 60 min. Relevant clinical information was collected
and linked to individual serum samples. The study was conducted as part of
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a protocol approved by the Institutional Review Board of the University of
Pennsylvania.

4.3.2 Internal Standard
The SILAP internal standard was prepared as described in Chapter 3.

4.3.3 Sample analysis
Samples were prepared as previously described in Chapter 3.

Briefly, 45

microliters of serum was mixed with SILAP internal standard and dilution
buffer (Seppro, Sigma).

The sample was depleted of the most highly

abundant proteins using the IgY-14 LC column (Seppro, Sigma).

The

depleted fraction was concentrated by molecular weight filtration through a
3kDa filter (Millipore, Billerica, MA) and methanol/chloroform extraction. The
protein was redissolved in 6M urea/2M thiourea and 25mM ammonium
bicarbonate, reduced with dithiothreitol, alkylated with iodoacetamide, and
digested with trypsin. The peptides were desalted using C18 spin columns,
separated by reverse phase (0.3 x 150 mm, 3 µm, 200 Å C18AQ, Michrom
Bioresources, Auburn, CA) on a microflow LC system (Eksigent, Dublin, CA),
and analyzed by positive ESI with scheduled MRM on a triple quadrupole
mass spectrometer (Vantage, ThermoFisher, San Jose, CA).
transitions is provided in Appendix 3.

A list of

Raw files were imported to

Skyline130,131 and integration was manually verified by retention time of all six
transitions per peptide.

Samples were analyzed in a series of batches

containing roughly 10 samples per batch. Each batch contained a mixture of
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cancer and control samples and samples were assigned a unique identifier to
blind the analyst during analysis.

4.3.4 Statistical analysis
Descriptive statistics including mean, standard deviation for continuous
variable and proportions for categorical variables were produced. To
determine the univariate association between the proteins level and the
PDAC case status, we used two-sample t-test with unequal variances using
Satterthwaite's approximation139 . Proteins that were found to have a
significant

univariate

association

at

0.05

level

were

included

in

a

multivariable logistics regression model where binary PDAC case status were
modeled as the outcome variable. Only proteins that retained their
significance

in

the

adjusted

model

remained

in

the

final

model.

Discrimination of the model was evaluated by the mean of area under the
ROC curve

(AUC)140. Calibration was

goodness-of-fit χ2 statistics141.

assessed by Hosmer-Lemeshow

A two-tailed P-value of less than 0.05 was

considered statistically significant. All statistical calculations were performed
using STATA software version 11 (College Station, TX)

4.4

Results and Discussion

4.4.1 Training set statistics
The demographics of the patients used in this study are presented. Serum
samples collected from cancer patients and controls were analyzed for sex,
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age, and diagnosis (Table 6).

Subjects were well matched for age.

The

demographics are representative of the patients treated at the University of
Pennsylvania.
We have used a larger sample size for our training set than is seen in other
reports. By using larger sample groups, we have reduced the likelihood of
false positive and negative results. We have also taken care to reduce the
possibility of bias in sample collection, handling, and analysis. Our sample
groups are well matched with respect to age and gender and samples were
stored concomitantly. Samples were analyzed in batches containing samples
from both groups and samples were assigned unique identifiers to blind the
analyst to the grouping. The classification of the samples was not revealed
until all data processing was complete.

Table 6. Training set patient demographics.

No. of patients
Sex
Male
Female
Age, mean (SD)
Clinical stage
1
2
3
4
No info

Healthy control
20

Cancer
31

11
9
63 (10)

19
12
64 (14)

n/a
n/a
n/a
n/a
n/a

0
8
8
13
2
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4.4.2 LC-MS analysis
Of the 72 proteins monitored by LC-MRM, 52 were successfully measured in
the training set.

20 proteins were removed from the analysis post-

acquisition due to erratic detection or signal below the limit of quantitation
for all samples.

The internal standard response was sufficient for all 52

proteins in the training set. The retention time was adjusted for all analytes
at the beginning of each batch based on a test injection. The retention time
did not shift by more than 0.7 minutes in a given run and shifted by less than
1.5 minutes over the course of all analyses. The peak area of each analyte
was normalized to the respective internal standard peak area.
It is important to note the impact of the SILAP internal standard which
permitted us to correct for variability in sample preparation.

The SILAP

method uses culture of human cells in stable isotopically labeled media to
produce full length, properly folded and modified proteins that may be used
as an internal standard when coupled to mass spectrometric detection. Since
the isotopically labeled protein is identical to the analyte in sequence and
structure, it is able to track the analyte through the potentially variable
procedures of depletion, digestion, separation, and ionization.

We have

previously shown (Wehr JPR 2011) that this internal standard dramatically
improves the precision of the method.

The enhanced precision of our

analytical method likely reduced the variability of the responses, amplifying
the ability of the biomarkers to discern the disease state.
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4.4.3 Statistical analysis
The mean ratios were compared using a two-tailed t-test with Welch’s
correction. Statistical analysis revealed 15 proteins with differential means in
the two data sets (Table 7). The individual scatter plots and ROC curves are
provided for each of the 3 most predictive proteins (Figure 16).

Anterior

gradient homolog 2 is the best predictor of PDAC with 87.1% sensitivity,
54.6% specificity, and an AUC of 0.789. However, the power of the test to
detect PDAC is seen when combining multiple proteins into one analysis. By
combining the top 3 performing proteins, cystatin M, anterior gradient 2
homolog, and transgelin 2, the ROC results in 87.1% sensitivity, 70.0%
specificity and an AUC of 0.879 (Figure 17A). By combining the results of all
15 differential proteins, the ROC achieves 93.6% sensitivity, 95.0%
specificity, and the AUC is increased to 0.968(Figure 17B).
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Table 7. Statistical analysis of the 15 differential proteins.

Protein Name
anterior gradient 2
homolog
cystatin C
cystatin M
heparan sulfate
proteoglycan 2
insulin-like growth
factor binding
protein 7
kallikrein-related
peptidase 10
lamin A/C isoform 2
lipocalin 2
myosin, heavy
polypeptide 9, nonmuscle
SMT3A
profilin 1
S100 calcium
binding protein A6
transgelin 2
tropomyosin 3
isoform 4
villin 2

PDAC Mean ±
SEM

Control Mean ±
SEM

Difference between
means

95% confidence
interval

R squared

P value

0.124 ± 0.0160
2.34 ± 0.108
0.130 ± 0.00853

0.342 ± 0.0813
2.84 ± 0.197
0.193 ± 0.0155

-0.218 ± 0.0828
-0.506 ± 0.225
-0.0636 ± 0.0177

-0.389 to -0.0459
-0.964 to -0.0481
-0.0998 to -0.0275

0.239
0.137
0.294

0.0154
0.0313
0.0011

0.283 ± 0.0314

0.390 ± 0.0393

-0.107 ± 0.0502

-0.208 to -0.00557

0.0975

0.0391

0.0847 ± 0.00471

0.119 ± 0.00962

-0.0347 ± 0.0107

-0.0566 to -0.0128

0.266

0.003

0.110 ± 0.0167
0.0604 ± 0.00446
0.0334 ± 0.00363

0.0544 ± 0.0124
0.0451 ± 0.00384
0.0489 ± 0.00642

0.0559 ± 0.0208
0.0140 to 0.0978
0.0153 ± 0.00589
0.00347 to 0.0272
-0.0155 ± 0.00738 -0.0306 to -0.000487

0.128
0.121
0.122

0.0099
0.0123
0.0433

0.272 ± 0.0443
0.0235 ± 0.00142
0.234 ± 0.0305

0.497 ± 0.0623
0.0311 ± 0.00266
0.350 ± 0.0470

-0.225 ± 0.0764
-0.380 to -0.0699
-0.00756 ± 0.00302 -0.0137 to -0.00141
-0.116 ± 0.0561
-0.230 to -0.00231

0.185
0.169
0.106

0.0056
0.0176
0.0456

0.152 ± 0.0131
0.261 ± 0.0530

0.226 ± 0.0328
0.460 ± 0.0715

-0.0739 ± 0.0354
-0.199 ± 0.0890

-0.147 to -0.00115
-0.379 to -0.0186

0.144
0.113

0.0467
0.0314

0.0706 ± 0.0104
0.188 ± 0.0140

0.117 ± 0.0179
0.251 ± 0.0235

-0.0459 ± 0.0207
-0.0634 ± 0.0274

-0.0880 to -0.00378
-0.119 to -0.00761

0.13
0.14

0.0335
0.0271

The AUC for a given model is the probability that the predicted value for the
PDAC subject is greater than that for the control subject. AUC takes values
between 0 to 1, with a value of 1 representing perfect prediction and a value
of 0.5 representing chance prediction. AUC value between 0.70 and 0.80 is
acceptable and a value greater than 0.80 is excellent141.

While external

validation and statistical internal validation have not yet been conducted,
given the limited sample size, such analysis is not warranted given the
preliminary nature of the current study.
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Figure 16. Scatter plots and ROCs of the 3 most predictive proteins.
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Figure 17. Combined ROC curves. The combined 3 most predictive proteins, AUC =
0.88 (A), and 15 proteins, AUC = 0.97 (B), are shown.

4.4.4 Differential proteins
The result that many of the differential proteins had a lower response in
PDAC than in control might be surprising upon initial inspection. The original
hypothesis had been the opposite, given that the candidate biomarker
proteins were derived from PDAC and pancreatitis cell lines and selected
based on their high abundance in the culture media.

Only two of the

differential proteins were elevated in PDAC serum, lamin A/C and kallikreinrelated peptidase 10, and study of their functions suggests this is to be
expected. Lamins A and C are splice variants of the LMNA gene. They are
intermediate filament proteins localized to the nucleus and most commonly
associated with nuclear structure, however studies have shown it plays a role
in TGF-, Erk, and Wnt signaling142-146.

Disregulation of lamin A/C is

associated with an imbalance in differentiation and proliferation and has
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previously been reported to be upregulated in lung cancer cells and
progressive tumor cells

147-149

. Kallikrein-related peptidase 10 is a secreted

serine protease and as such may be expected to play a role in invasion and
angiogenesis

150

.

and ovarian cancer

It has previously been associated with colorectal, renal,
151-153

.

Further inspection of the lower abundance proteins in our study reveals that
a decreased level of some of these proteins may not be unexpected.
Previous studies show a decrease in the cystatins is to be expected.
Cystatins are secreted non-specific inhibitors of cysteine proteases and are
involved in extracellular matrix degradation, a process crucial to invasion and
angiogenesis. Therefore a decrease in cystatins C and M might be expected
in metastatic disease and has been seen in association with breast cancer

154

.

Cystatins are epigenetically silenced via methylation in various cancers and
suitably, immunohistochemical staining of pancreatic tissue shows low
expression of cystatin C in PDAC as compared to other pancreatic tissue
155,156

.

The expected levels of some proteins in the serum are less easy to predict.
Heparan sulfate proteoglycan 2 is thought to be a pro-angiogenic factor;
however, studies have found conflicting impact on cancer cell lines; while
silencing decreased the angiogenic potential of some tumor cell lines157, it
enhanced the aggressiveness of others158.

Insulin like growth factor (IGF)

binding protein 7 is similarly nuanced. The IGFs are secreted proteins that
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circulate in the blood and help to regulate cellular proliferation. The effects
of their binding proteins, such as IGF binding protein 7, are complex. While
the binding proteins prolong the half life of the IGFs in circulation, they also
compete with cellular receptors for free IGF159.

IGF binding protein 7 has

been described as a tumor suppressor160 and as such has been suggested as
a cancer therapy161, yet its upregulation has been associated with colorectal
cancer162.
An explanation for the reduced serum levels of the remaining proteins in the
panel is not obvious.

Anterior gradient homolog 2 has previously been

described as a relevant factor in many cancers including breast, prostate,
colorectal, and esophageal, in addition to pancreatic.

It serves as an

inhibitor of the tumor suppressor p53 and is involved in drug resistance163.
The finding that the level of anterior gradient 2 homolog is lower in the
serum of PDAC patients is in contrast with reports that found it to be
elevated or unchanged in the plasma of PDAC patients as measured by ELISA
methods

164,165

.

However both of the ELISA studies used much smaller

sample sets that were poorly matched for age and thus may have had less
power to assess the true level of this protein.

Lipocalin 2 is a circulatory

protein binding protein. It serves to scavenge and deliver iron to cells, but
also promotes the activity of matrix metalloproteinase 9166, an enzyme
responsible

for

matrix

remodeling

in

association

with

invasion

and

angiogenesis. Multiple biomarker discovery studies have identified lipocalin 2
as upregulated in pancreatic cancer167-169, so it is surprising to find its serum
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levels suppressed in our study. Myosin, heavy polypeptide 9, non-muscle is
also reported to promote cancer cell migration and invasion170,171, yet was
detected at a lower level in our cancer serum samples. The binding proteins
small ubiquitin-like modifier SMT3A and S100 A6 have been identified in
other biomarker discovery studies as well. SMT3A binds protein targets as a
post-translational modification to direct various cellular processes.

Its

expression has been identified in proteomic analysis of breast cancer172. The
S100 proteins are calcium-binding proteins that interact with annexins and as
such are thought to facilitate cellular interactions. S100 A6 expression has
been reported in melanoma

173

.

Profilin 1, transgelin 2, tropomyosin, and villin are all actin binding proteins
and their association with cancer is complex174. Profilin 1 was identified as
overexpressed in biomarker studies of renal cell carcinoma175 and pancreatic
cancer53.

However, lower profiling expression was found in breast cancer

cells where it is thought to suppress tumorigenicity

176,177

. While the function

of transgelin 2 is unknown, it has been implicated in various cancers
including colorectal, gastric, and pancreatic

52,178,179

.

A decrease in the

expression of tropomyosin 3 was observed previously in proteomic analysis
of lung cancer tissue180. Villin 2(ezrin) is thought to promote metastasis181
and its expression has been associated with breast cancer, hepatocellular
carcinoma, and lung cancer182-184.
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4.5

Conclusion

Great care was taken in this study to reduce the possibility of error in our
analysis.
validation.

Other biomarkers have been proposed before only to fail during
However, the results reported in the present study should be

robust due to several factors. The samples groups in the training set were
larger and well matched in the age of the subjects compared with other
studies. Sample analysis was designed to reduce bias and the SILAP internal
standard provided an extra measure of normalization to correct for sample
loss.
A panel of 15 proteins with statistically different mean concentrations in a
training set of serum samples derived from cancer and control patients was
identified.

By combining the results of these proteins, an ROC curve was

obtained that achieved 93.6% sensitivity and 95.2% specificity, values
greater than any other biomarkers of PDAC reported to date38. This feat was
made possible through the use of our multiplexed LC-MRM/MS method,
which made it possible to routinely monitor 52 proteins. Therefore, a wide
net was cast in order to identify differential proteins. The method may easily
be expanded to study more proteins, and such a study may result in the
identification of additional biomarker proteins. This means that the discovery
of additional differential proteins in the serum could enhance this biomarker
panel further.

Validation of this panel will be an important step in the

evolution of a screening assay for the detection of pancreatic cancer.
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5 Chapter 5 – Conclusions and Future Directions
5.1

Conclusions

Pancreatic cancer is a devastating disease, however early detection has the
ability to dramatically improve the survival rate. While many biomarkers of
pancreatic cancer have been proposed, none meet the specificity or
sensitivity levels required for utility as a screening test.
The research presented here seeks to change this. As reported in Chapter 2,
via in vitro simulation of the tumor microenvironment and LC-MS based
proteomic analysis, a comprehensive list of candidate protein biomarkers was
compiled. The culture of a mixture of pancreatic cancer and stromal cell lines
provided a rich source of proteins for proteomic profiling. Qualitative 2D-LCMS was effective in producing high quality protein identifications which were
validated in culture and human tissue by traditional immunologic methods.
A subset of these candidate biomarker proteins were then validated in a
training set of human serum samples by LC-MRM/MS. Chapter 3 describes
the development of an LC-MRM/MS method for the targeted quantitation of
over 70 proteins in a single assay.

This work was facilitated by the LC-

MS/MS data acquired in the discovery phase and as such was a logical
progression. The probability of detecting the targeted proteins was enhanced
since the peptides monitored in the experiment were those that were most
easily detected by LC-MS/MS during discovery. Spectral libraries generated
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during discovery also provided insight into the best precursor and product
ions for peptide monitoring.
While immunologic methods have prevailed as the mechanism for validating
protein biomarkers, Chapter 3 shows that LC-MS can efficiently quantitate a
large panel of proteins in biological matrix. The application of the traditional
bioanalytical techniques of correction using a stable isotope labeled internal
standard and LC-MRM/MS analysis empowered this methodology.

The

internal standard was critical to the precision of the assay since the depletion
and digestion steps of sample processing have traditionally introduced
significant variability to the analysis.

MRM/MS analysis provided sensitive

and specific detection of a large set of peptide analytes despite the complex
matrix.
The full power of the quantitative LC-MRM/MS method was demonstrated in
Chapter 4. The evaluation of a large set of proteins in parallel enabled the
identification of a panel of protein biomarkers with sensitivity and specificity
superior to any single biomarker reported to date.

Precision of the

quantitative LC-MS was critical to the statistical analysis of the data.
Furthermore, the low variability in the cancer and control data sets made it
easier to discern differences in these two groups.
Based on this research the workflow provided in Figure 18 is proposed for
biomarker development studies.

In the first stage of development, cell

culture models of disease are used to identify candidate biomarker proteins.
The spectral library produced during discovery is then used in the second
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stage of development to direct a targeted MRM method for the quantitation
of candidate proteins.

The cell culture model used in the first stage is

employed again for the production of a stable isotope labeled proteome for
use as an internal standard. In stage 3 the quantitative method is used for
the identification of differential proteins in a training set of human samples.
Any differential proteins identified in stage 3 may then be validated in a
subsequent set of human samples, using the same LC-MS method.
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Figure 18. Biomarker development plan
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5.2

Future directions

The focus of this work has been on the development of a screening method
for the early detection of pancreatic cancer. However, this panel also has the
potential for use in drug development as a means to measure response to
therapy. A training set of human serum samples used to identify differential
proteins compared the serum taken from pancreatic cancer patients to that
derived from survivors of gastrointestinal cancers in remission.

Thus, the

panel might prove to serve well as an indicator of therapy response.
The panel of protein biomarkers identified in this work requires additional
validation prior to implementation as either a screening test or device to
monitor response to therapy. Several phases of biomarker development (as
outlined by Pepe et al.) dictate that studies to prove the ability of the
biomarker to detect disease prior to conventional diagnosis are required43.
Furthermore, it is ultimately necessary to determine whether screening
reduces cancer burden43.

Just as drug development is a lengthy and

expensive process that takes many years to complete, so biomarker
development is a significant process that requires years of study in large
populations.

A panel of biomarkers presented here are still early in the

development process but they show promise.

The next important step in

their development is the validation of their predictive value in a second set of
samples, the procurement of which is under way.
To support such studies, an absolute quantitative assay would be beneficial.
The current method relies on the relative response of the endogenous protein
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to a custom SILAP internal standard produced in house.

This approach

allows us to normalize samples to one another within a study, provided the
same batch of IS is used. However, each new batch of IS needs to be crossvalidated if comparisons are to be made between samples prepared using
different batches of IS.

It would be preferable to develop an authentic

external reference standard that could be used to back calculate the absolute
concentration of each protein in serum. Such an assay would be more easily
applied to large multi-site studies.
Another area for development lies in the list of candidate biomarkers
identified in the discovery stage of this project. Hundreds of proteins have
yet to be explored for their differential potential in human serum samples.
The relative quantitative method described in chapter 3 could easily be
expanded to include more of these candidate biomarkers. Expansion of the
biomarker panel to include additional proteins may increase the sensitivity
and specificity of the method further.
Research presented in this dissertation on biomarkers for PDAC will stimulate
many additional experiments. Studies have yet to be done to validate the
biomarkers proposed and develop a method for absolute quantitation and the
biomarker panel itself is open to expansion. However, studies presented in
this dissertation represent a significant first step in the quest to develop
cancer biomarkers.

Methodology that was developed not only identified a

potential screening system for the early detection of pancreatic cancer, but
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has also laid the foundation for future biomarker discovery and validation
studies.
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APPENDIX 1

q
P
S
C

c
a
P
S
C

P
C
C

X

X

Protein

Description

gi|23308751|ref|NP_689953.1|

3-hydroxyisobutyrate dehydrogenase [Homo
sapiens]
5-aminoimidazole-4-carboxamide ribonucleotide
formyltransferase/IMP cyclohydrolase [Homo
sapiens]
5'-methylthioadenosine phosphorylase [Homo
sapiens]
6-phosphogluconolactonase [Homo sapiens]
acetyl-Coenzyme A acetyltransferase 2 [Homo
sapiens]
acid alpha-glucosidase preproprotein [Homo
sapiens]

gi|20127454|ref|NP_004035.2|
X
gi|47132622|ref|NP_002442.2|

X

X

X

X gi|6912586|ref|NP_036220.1|
gi|148539872|ref|NP_005882.2
X
|
gi|119393891|ref|NP_000143.2
|,gi|119393893|ref|NP_001073
X 271.1|,gi|119393895|ref|NP_00
1073272.1|

X
X

X

X

X

X
X
X
X

X

X
X
X

X
X

gi|5454088|ref|NP_006392.1|
gi|8659555|ref|NP_002188.1|
gi|4501867|ref|NP_001089.1|
gi|23238211|ref|NP_690601.1|,
gi|5031599|ref|NP_005722.1|
gi|5031597|ref|NP_005710.1|

X gi|4501891|ref|NP_001093.1|
gi|4557241|ref|NP_001095.1|
X gi|12025678|ref|NP_004915.2|
gi|30089997|ref|NP_817126.1|,
X gi|30089999|ref|NP_829888.1|,
gi|4757718|ref|NP_004292.1|

X
X

gi|4757714|ref|NP_004291.1|
gi|5453880|ref|NP_006296.1|

X
X

acid phosphatase 1 isoform c [Homo sapiens]
acidic (leucine-rich) nuclear phosphoprotein 32
family, member A [Homo sapiens]
acidic (leucine-rich) nuclear phosphoprotein 32
family, member B [Homo sapiens]
aconitase 1 [Homo sapiens]
aconitase 2 precursor [Homo sapiens]
actin related protein 2/3 complex subunit 2 [Homo
sapiens]
actin related protein 2/3 complex subunit 3 [Homo
sapiens]
actinin, alpha 1 [Homo sapiens]
actinin, alpha 3 [Homo sapiens]
actinin, alpha 4 [Homo sapiens]
actin-like 6A isoform 2 [Homo sapiens],actin-like 6A
isoform 1 [Homo sapiens]

gi|5031571|ref|NP_005713.1|,g
i|53692187|ref|NP_001005386.
1|

actin-related protein 2 isoform b [Homo
sapiens],actin-related protein 2 isoform a [Homo
sapiens]

gi|68163411|ref|NP_001618.2|

activated leukocyte cell adhesion molecule [Homo
sapiens]
activated RNA polymerase II transcription cofactor
4 [Homo sapiens]
activating signal cointegrator 1 complex subunit 3like 1 [Homo sapiens]

gi|19923784|ref|NP_006704.2|
gi|40217847|ref|NP_054733.2|
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q
P
S
C

c
a
P
S
C

Protein

gi|32528282|ref|NP_863654.1|,
gi|32528284|ref|NP_863655.1|,
X gi|32528286|ref|NP_863656.1|,
gi|75709208|ref|NP_009205.3|

X

X

X

gi|4501915|ref|NP_003807.1|,g
X i|54292121|ref|NP_001005845.
1|
gi|22027651|ref|NP_001118.2|,
X gi|22027653|ref|NP_663782.1|
gi|19913414|ref|NP_055018.2|,
gi|19913416|ref|NP_570603.2|

gi|4557469|ref|NP_001273.1|,g
i|71773106|ref|NP_001025177.
X
1|
X
X

X

X
X
X
X
X
X

X

X
X
X

X

X

Description

P
C
C

gi|47078295|ref|NP_000013.2|
gi|4502013|ref|NP_001616.1|,g
X i|7524346|ref|NP_037543.1|
X gi|34577063|ref|NP_001117.2|
gi|157649073|ref|NP_0010990
X 00.1|,gi|5453595|ref|NP_00635
8.1|
gi|4557263|ref|NP_001116.1|
gi|8923417|ref|NP_060295.1|
X gi|54873613|ref|NP_940978.2|
gi|6912280|ref|NP_036243.1|
X
X gi|61743954|ref|NP_001611.1|
gi|109148542|ref|NP_001596.2
X
|
X gi|4502027|ref|NP_000468.1|
X gi|21361176|ref|NP_000680.2|
gi|24497577|ref|NP_697021.1|,
gi|5174391|ref|NP_006057.1|
gi|34577110|ref|NP_908930.1|,
X gi|34577112|ref|NP_908932.1|,
gi|4557305|ref|NP_000025.1|

acyl-CoA thioesterase 7 isoform hBACHb [Homo
sapiens],acyl-CoA thioesterase 7 isoform hBACHc
[Homo sapiens],acyl-CoA thioesterase 7 isoform
hBACHd [Homo sapiens],acyl-CoA thioesterase 7
isoform hBACHa [Homo sapiens]
ADAM metallopeptidase domain 9 isoform 1
precursor [Homo sapiens],ADAM metallopeptidase
domain 9 isoform 2 precursor [Homo sapiens]
adaptor-related protein complex 1 beta 1 subunit
isoform a [Homo sapiens],adaptor-related protein
complex 1 beta 1 subunit isoform b [Homo sapiens]
adaptor-related protein complex 2, alpha 1 subunit
isoform 1 [Homo sapiens],adaptor-related protein
complex 2, alpha 1 subunit isoform 2 [Homo
sapiens]
adaptor-related protein complex 2, beta 1 subunit
isoform b [Homo sapiens],adaptor-related protein
complex 2, beta 1 subunit isoform a [Homo
sapiens]
adenosine deaminase [Homo sapiens]
adenylate kinase 2 isoform a [Homo
sapiens],adenylate kinase 2 isoform b [Homo
sapiens]
adenylosuccinate synthase [Homo sapiens]
adenylyl cyclase-associated protein [Homo
sapiens]
ADP-ribosylarginine hydrolase [Homo sapiens]
ADP-ribosylhydrolase like 2 [Homo sapiens]
agrin [Homo sapiens]
AHA1, activator of heat shock 90kDa protein
ATPase homolog 1 [Homo sapiens]
AHNAK nucleoprotein isoform 1 [Homo sapiens]
alanyl-tRNA synthetase [Homo sapiens]
albumin precursor [Homo sapiens]
aldehyde dehydrogenase 1A1 [Homo sapiens]
aldo-keto reductase family 1, member A1 [Homo
sapiens]
aldolase A [Homo sapiens]
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q
P
S
C

c
a
P
S
C
X

X
X

Description

gi|4501881|ref|NP_001091.1|,g
i|4501883|ref|NP_001604.1|,gi|
4501889|ref|NP_001606.1|,gi|4
885049|ref|NP_005150.1|

alpha 1 actin precursor [Homo sapiens],alpha 2
actin [Homo sapiens],actin, gamma 2 propeptide
[Homo sapiens],cardiac muscle alpha actin 1
proprotein [Homo sapiens]

gi|4501881|ref|NP_001091.1|,g
X i|4885049|ref|NP_005150.1|
gi|89276751|ref|NP_000084.3|
gi|110611233|ref|NP_569712.2
|,gi|110611235|ref|NP_085059.
2|

X

X

Protein
P
C
C

gi|4504345|ref|NP_000508.1|,g
X i|4504347|ref|NP_000549.1|
X gi|48762934|ref|NP_000080.2|
gi|89363017|ref|NP_000384.2|
X
gi|115527062|ref|NP_001840.3
|,gi|115527066|ref|NP_478054.
2|,gi|115527070|ref|NP_47805
5.2|

X

gi|38202257|ref|NP_938148.1|,
X gi|88900491|ref|NP_938149.2|
X

X
X

X

X

X
X

gi|4506019|ref|NP_002708.1|

X gi|66932947|ref|NP_000005.2|
X gi|4501989|ref|NP_001125.1|
X gi|4504009|ref|NP_000160.1|
gi|15451907|ref|NP_006301.2|
X
X

X

gi|21361399|ref|NP_055040.2|

gi|4502147|ref|NP_001633.1|

gi|41406055|ref|NP_958816.1|,
X gi|4502167|ref|NP_000475.1|
gi|91206450|ref|NP_653309.2|
gi|4502107|ref|NP_001145.1|
gi|22165431|ref|NP_665875.1|,
X gi|22165433|ref|NP_665876.1|,
gi|4557317|ref|NP_001148.1|

alpha 1 actin precursor [Homo sapiens],cardiac
muscle alpha actin 1 proprotein [Homo sapiens]
alpha 1 type V collagen preproprotein [Homo
sapiens]
alpha 1 type XVIII collagen isoform 2 precursor
[Homo sapiens],alpha 1 type XVIII collagen isoform
1 precursor [Homo sapiens]
alpha 2 globin [Homo sapiens],alpha 1 globin
[Homo sapiens]
alpha 2 type I collagen [Homo sapiens]
alpha 2 type V collagen preproprotein [Homo
sapiens]
alpha 2 type VI collagen isoform 2C2 precursor
[Homo sapiens],alpha 2 type VI collagen isoform
2C2a precursor [Homo sapiens],alpha 2 type VI
collagen isoform 2C2a precursor [Homo sapiens]
alpha glucosidase II alpha subunit isoform 2 [Homo
sapiens],alpha glucosidase II alpha subunit isoform
3 [Homo sapiens]
alpha isoform of regulatory subunit A, protein
phosphatase 2 [Homo sapiens]
alpha isoform of regulatory subunit B55, protein
phosphatase 2 [Homo sapiens]
alpha-2-macroglobulin precursor [Homo sapiens]
alpha-fetoprotein precursor [Homo sapiens]
alpha-galactosidase A precursor [Homo sapiens]
aminopeptidase puromycin sensitive [Homo
sapiens]
amyloid beta (A4) precursor-like protein 2 [Homo
sapiens]
amyloid beta A4 protein precursor, isoform b
[Homo sapiens],amyloid beta A4 protein precursor,
isoform a [Homo sapiens]
ankyrin and armadillo repeat containing [Homo
sapiens]
annexin 5 [Homo sapiens]
annexin A11 [Homo sapiens]
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q
P
S
C

c
a
P
S
C

P
C
C

X

gi|4757756|ref|NP_004030.1|,g
i|50845386|ref|NP_001002857.
X 1|,gi|50845388|ref|NP_001002
858.1|

annexin A2 isoform 2 [Homo sapiens],annexin A2
isoform 1 [Homo sapiens]

X gi|4502101|ref|NP_000691.1|
gi|4757804|ref|NP_004036.1|
gi|18375501|ref|NP_001632.2|,
X gi|18375503|ref|NP_542379.1|,
gi|18375505|ref|NP_542380.1|

annexin I [Homo sapiens]
antioxidant protein 1 [Homo sapiens]
APEX nuclease [Homo sapiens]

X
X
X

Protein

X
X
X
X
X
X
X

X

X

X gi|4557321|ref|NP_000030.1|
X gi|5729730|ref|NP_006586.1|
gi|11863154|ref|NP_001646.2|
gi|5031573|ref|NP_005712.1|
X gi|4758762|ref|NP_004530.1|
X gi|4504067|ref|NP_002070.1|
gi|73486658|ref|NP_002071.2|
X
gi|38569421|ref|NP_001087.2|,
X gi|38569423|ref|NP_942127.1|
gi|32189394|ref|NP_001677.2|
gi|17136148|ref|NP_001174.2|

X

X

X

X gi|10863945|ref|NP_066964.1|
gi|4503841|ref|NP_001460.1|

X

X

X gi|10835067|ref|NP_003133.1|
gi|21536466|ref|NP_068713.2|,
gi|21536468|ref|NP_001690.2|

X

X

X

X

gi|91984773|ref|NP_658985.2|

gi|41281429|ref|NP_055485.2|

X

gi|4501885|ref|NP_001092.1|,g
X i|4501887|ref|NP_001605.1|
gi|4504349|ref|NP_000509.1|,g
X i|4504351|ref|NP_000510.1|
X gi|4757826|ref|NP_004039.1|
gi|4504981|ref|NP_002296.1|
X

X
X

gi|4502403|ref|NP_001702.1|
X gi|33589854|ref|NP_000703.2|

X
X
X

Description

apolipoprotein A-I binding protein precursor [Homo
sapiens]
apolipoprotein A-I preproprotein [Homo sapiens]
apoptosis inhibitor 5 [Homo sapiens]
archain [Homo sapiens]
ARP3 actin-related protein 3 homolog [Homo
sapiens]
asparaginyl-tRNA synthetase [Homo sapiens]
aspartate aminotransferase 1 [Homo sapiens]
aspartate aminotransferase 2 precursor [Homo
sapiens]
ATP citrate lyase isoform 1 [Homo sapiens],ATP
citrate lyase isoform 2 [Homo sapiens]
ATP synthase, H+ transporting, mitochondrial F1
complex, beta subunit precursor [Homo sapiens]
ATPase, H+ transporting, lysosomal accessory
protein 1 precursor [Homo sapiens]
ATP-dependent DNA helicase II [Homo sapiens]
ATP-dependent DNA helicase II, 70 kDa subunit
[Homo sapiens]
autoantigen La [Homo sapiens]
AXL receptor tyrosine kinase isoform 1 [Homo
sapiens],AXL receptor tyrosine kinase isoform 2
[Homo sapiens]
basic leucine zipper and W2 domains 1 [Homo
sapiens]
beta actin [Homo sapiens],actin, gamma 1
propeptide [Homo sapiens]
beta globin [Homo sapiens],delta globin [Homo
sapiens]
beta-2-microglobulin precursor [Homo sapiens]
beta-galactoside-binding lectin precursor [Homo
sapiens]
biglycan preproprotein [Homo sapiens]
biliverdin reductase A [Homo sapiens]
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X

X

X
X
X

X

Protein

Description

gi|4502419|ref|NP_000704.1|

biliverdin reductase B (flavin reductase (NADPH))
[Homo sapiens]
biotinidase precursor [Homo sapiens]
brain abundant, membrane attached signal protein
1 [Homo sapiens]
brain glycogen phosphorylase [Homo sapiens]
cadherin 2, type 1 preproprotein [Homo sapiens]
calcyclin binding protein isoform 2 [Homo
sapiens],calcyclin binding protein isoform 1 [Homo
sapiens]

P
C
C

X gi|4557373|ref|NP_000051.1|
gi|30795231|ref|NP_006308.3|
X gi|21361370|ref|NP_002853.2|
gi|14589889|ref|NP_001783.2|
gi|60218913|ref|NP_00100721
X 5.1|,gi|7656952|ref|NP_055227
.1|

X

gi|15149463|ref|NP_149130.1|,
gi|15149465|ref|NP_149131.1|,
gi|15149467|ref|NP_149347.1|,
gi|44680105|ref|NP_149129.2|,
gi|4826657|ref|NP_004333.1|

X

gi|4502549|ref|NP_001734.1|,g
X i|58218968|ref|NP_005175.2|,g
i|5901912|ref|NP_008819.1|

calmodulin 2 [Homo sapiens],calmodulin 3 [Homo
sapiens],calmodulin 1 [Homo sapiens]

gi|157389005|ref|NP_001739.2
|
gi|4502565|ref|NP_001740.1|,g
X i|51599151|ref|NP_001003962.
1|

calpain 2, large subunit [Homo sapiens]

gi|109637753|ref|NP_001741.4
|,gi|109637757|ref|NP_775086.
1|,gi|109637759|ref|NP_00103
X 5905.1|,gi|109637761|ref|NP_0
01035906.1|,gi|109637763|ref|
NP_001035907.1|

calpastatin isoform a [Homo sapiens],calpastatin
isoform e [Homo sapiens],calpastatin isoform f
[Homo sapiens],calpastatin isoform g [Homo
sapiens],calpastatin isoform h [Homo sapiens]

gi|41327730|ref|NP_958434.1|,
gi|4758018|ref|NP_004359.1|
gi|4502923|ref|NP_001830.1|
X gi|4757900|ref|NP_004334.1|
gi|57242755|ref|NP_055759.3|,
X gi|57242757|ref|NP_00100956
6.1|

calponin 2 isoform b [Homo sapiens],calponin 2
isoform a [Homo sapiens]
calponin 3 [Homo sapiens]
calreticulin precursor [Homo sapiens]
calsyntenin 1 isoform 2 [Homo sapiens],calsyntenin
1 isoform 1 [Homo sapiens]

X

gi|11545861|ref|NP_071414.1|
X gi|4502551|ref|NP_001210.1|
gi|5453599|ref|NP_006127.1|
X

X
X
X

X gi|4502599|ref|NP_001748.1|
gi|61743916|ref|NP_057436.2|
gi|4503009|ref|NP_001864.1|
gi|62241003|ref|NP_705838.3|

calsyntenin 2 [Homo sapiens]
calumenin precursor [Homo sapiens]
capping protein (actin filament) muscle Z-line,
alpha 2 [Homo sapiens]
carbonyl reductase 1 [Homo sapiens]
carboxypeptidase A4 preproprotein [Homo sapiens]
carboxypeptidase E preproprotein [Homo sapiens]
cardiomyopathy associated 5 [Homo sapiens]

X
X

X

X
X
X
X
X
X

caldesmon 1 isoform 4 [Homo sapiens],caldesmon
1 isoform 5 [Homo sapiens],caldesmon 1 isoform 3
[Homo sapiens],caldesmon 1 isoform 1 [Homo
sapiens],caldesmon 1 isoform 2 [Homo sapiens]

calpain, small subunit 1 [Homo sapiens]
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Protein

gi|119395729|ref|NP_000299.2
|
gi|22538431|ref|NP_680090.1|,
gi|22538433|ref|NP_680091.1|,
X gi|22538435|ref|NP_680092.1|,
gi|22538437|ref|NP_680093.1|,
gi|4503139|ref|NP_001899.1|
X

X

X
X

X
X

X

X
X
X

X
X
X

X gi|4502693|ref|NP_001760.1|
gi|11067747|ref|NP_001244.1|
X gi|8923710|ref|NP_060018.1|
X gi|5901922|ref|NP_008996.1|
gi|33589824|ref|NP_006560.2|
X
gi|87298937|ref|NP_008949.4|
gi|31542947|ref|NP_002147.2|,
X gi|41399285|ref|NP_955472.1|
gi|5453603|ref|NP_006422.1|
X
gi|58761484|ref|NP_00100880
0.1|,gi|58761486|ref|NP_00100
8883.1|,gi|63162572|ref|NP_00
5989.3|
X
X
X

X

gi|4503141|ref|NP_001805.1|

X gi|4503143|ref|NP_001900.1|
gi|22202619|ref|NP_666023.1|,
X gi|4503155|ref|NP_001903.1|
X gi|23110960|ref|NP_001324.2|
X gi|22538442|ref|NP_001327.2|
gi|115529484|ref|NP_598000.2
X
|
gi|48255935|ref|NP_000601.3|,
gi|48255937|ref|NP_00100138
X 9.1|,gi|48255939|ref|NP_00100
1390.1|,gi|48255941|ref|NP_00
1001391.1|

X

X

Description

P
C
C

X

gi|38455427|ref|NP_006421.2|
gi|24307939|ref|NP_036205.1|
gi|4502643|ref|NP_001753.1|
gi|5453607|ref|NP_006420.1|

cathepsin A precursor [Homo sapiens]
cathepsin B preproprotein [Homo sapiens]

cathepsin C isoform a preproprotein [Homo
sapiens]
cathepsin D preproprotein [Homo sapiens]
cathepsin L1 preproprotein [Homo sapiens]
cathepsin L2 preproprotein [Homo sapiens]
cathepsin Z preproprotein [Homo sapiens]
CD109 [Homo sapiens]
CD44 antigen isoform 1 precursor [Homo
sapiens],CD44 antigen isoform 2 precursor [Homo
sapiens],CD44 antigen isoform 3 precursor [Homo
sapiens],CD44 antigen isoform 4 precursor [Homo
sapiens]
CD9 antigen [Homo sapiens]
CDC5-like [Homo sapiens]
CDV3 homolog [Homo sapiens]
cell division cycle 37 protein [Homo sapiens]
cell growth regulator with EF-hand domain 1 [Homo
sapiens]
centrosomal protein 110kDa [Homo sapiens]
chaperonin [Homo sapiens],chaperonin [Homo
sapiens]
chaperonin containing TCP1, subunit 2 [Homo
sapiens]
chaperonin containing TCP1, subunit 3 isoform c
[Homo sapiens],chaperonin containing TCP1,
subunit 3 isoform b [Homo sapiens],chaperonin
containing TCP1, subunit 3 isoform a [Homo
sapiens]
chaperonin containing TCP1, subunit 4 (delta)
[Homo sapiens]
chaperonin containing TCP1, subunit 5 (epsilon)
[Homo sapiens]
chaperonin containing TCP1, subunit 6A isoform a
[Homo sapiens]
chaperonin containing TCP1, subunit 7 isoform a
[Homo sapiens]
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X

X

X

X

X

X
X
X
X
X
X

gi|4506849|ref|NP_002985.1|

gi|6912292|ref|NP_036249.1|
gi|4758012|ref|NP_004850.1|
gi|5901926|ref|NP_008937.1|

X

X

chaperonin containing TCP1, subunit 8 (theta)
[Homo sapiens]
chemokine (C-X-C motif) ligand 1 [Homo sapiens]
chemokine (C-X-C motif) ligand 12 (stromal cellderived factor 1) isoform beta [Homo
sapiens],chemokine (C-X-C motif) ligand 12
(stromal cell-derived factor 1) isoform alpha [Homo
sapiens],chemokine (C-X-C motif) ligand 12
(stromal cell-derived factor 1)
chemokine (C-X-C motif) ligand 5 precursor [Homo
sapiens]
chloride intracellular channel 1 [Homo sapiens]
chloride intracellular channel 4 [Homo sapiens]
chromatin modifying protein 1B [Homo sapiens]
chromatin modifying protein 4B [Homo sapiens]
chromobox homolog 1 (HP1 beta homolog
Drosophila ) [Homo sapiens]
chromobox homolog 3 [Homo sapiens],chromobox
homolog 3 [Homo sapiens],PREDICTED: similar to
Chromobox homolog 3 (HP1 gamma homolog,
Drosophila) [Homo sapiens]
chromobox homolog 5 (HP1 alpha homolog,
Drosophila) [Homo sapiens]
clathrin heavy chain 1 [Homo sapiens]
cleavage and polyadenylation specific factor 5
[Homo sapiens]
CLIP-associating protein 1 [Homo sapiens]
clusterin isoform 1 [Homo sapiens],clusterin
isoform 2 [Homo sapiens]
CNDP dipeptidase 2 [Homo sapiens]
coactosin-like 1 [Homo sapiens]
coatomer protein complex, subunit alpha isoform 2
[Homo sapiens],coatomer protein complex, subunit
alpha isoform 1 [Homo sapiens]

gi|15082258|ref|NP_009207.2|,
gi|20544151|ref|NP_057671.2|,
X
gi|89038889|ref|XP_943872.1|

X

X
X

gi|48762932|ref|NP_006576.2|

X gi|14251209|ref|NP_001279.2|
gi|7330335|ref|NP_039234.1|
gi|31542306|ref|NP_065145.2|
gi|28827795|ref|NP_789782.1|
gi|5803076|ref|NP_006798.1|

X

X

Description

X gi|4504153|ref|NP_001502.1|
gi|10834988|ref|NP_000600.1|,
gi|40316924|ref|NP_954637.1|,
gi|76563933|ref|NP_00102905
8.1|

X
X
X
X
X

Protein

X gi|31563537|ref|NP_056097.1|
gi|42716297|ref|NP_001822.2|,
X gi|42740907|ref|NP_976084.1|
X gi|8922699|ref|NP_060705.1|
X gi|21624607|ref|NP_066972.1|
gi|148536853|ref|NP_004362.2
|,gi|148536855|ref|NP_001091
868.1|
X gi|5031635|ref|NP_005498.1|
gi|14719392|ref|NP_068733.1|,
X gi|33946278|ref|NP_619579.1|
gi|19923969|ref|NP_612451.1|
gi|39930511|ref|NP_597716.1|
X

gi|87196339|ref|NP_001839.2|
gi|93141047|ref|NP_004361.3|

cofilin 1 (non-muscle) [Homo sapiens]
cofilin 2 [Homo sapiens],cofilin 2 [Homo sapiens]
coiled-coil domain containing 124 [Homo sapiens]
collagen and calcium binding EGF domains 1
[Homo sapiens]
collagen, type VI, alpha 1 precursor [Homo
sapiens]
collagen, type XII, alpha 1 long isoform precursor
[Homo sapiens]
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Protein

gi|27262661|ref|NP_000748.3|,
gi|27262663|ref|NP_757349.1|,
gi|27262665|ref|NP_757350.1|,
X
gi|27262667|ref|NP_757351.1|

X

X

X

X

gi|4502491|ref|NP_001203.1|
gi|66347875|ref|NP_001724.3|

X

gi|41393602|ref|NP_958850.1|,
X gi|4502495|ref|NP_001725.1|
gi|115298678|ref|NP_000055.2
X
|
X gi|67782358|ref|NP_001701.2|
gi|4503123|ref|NP_001892.1|
gi|13124873|ref|NP_001746.1|,
gi|13124881|ref|NP_074036.1|

X

X

X
X

X

gi|7656991|ref|NP_055140.1|
gi|20357552|ref|NP_005222.2|,
gi|20357556|ref|NP_612632.1|
gi|29029559|ref|NP_001307.2|

X

X

X

gi|62198241|ref|NP_00101443
3.1|,gi|62526022|ref|NP_00101
4837.1|,gi|62526024|ref|NP_00
X 1014838.1|,gi|62526026|ref|NP
_001014840.1|,gi|7706244|ref|
NP_057005.1|

X
X
X

X gi|4503117|ref|NP_000091.1|
X gi|4503107|ref|NP_000090.1|
gi|31542331|ref|NP_001545.2|
gi|10835051|ref|NP_001742.1|,
gi|21269877|ref|NP_644802.1|,
gi|62240992|ref|NP_00101443
7.1|,gi|62240994|ref|NP_00101
4438.1|

X

X

Description

P
C
C

X

gi|7706497|ref|NP_057392.1|

colony stimulating factor 1 isoform a precursor
[Homo sapiens],colony stimulating factor 1 isoform
b precursor [Homo sapiens],colony stimulating
factor 1 isoform c precursor [Homo sapiens],colony
stimulating factor 1 isoform a precursor [Homo
sapiens]
complement component 1, q subcomponent
binding protein precursor [Homo sapiens]
complement component 1, r subcomponent [Homo
sapiens]
complement component 1, s subcomponent [Homo
sapiens]
complement component 3 precursor [Homo
sapiens]
complement factor B preproprotein [Homo sapiens]
connective tissue growth factor [Homo sapiens]
core-binding factor, beta subunit isoform 2 [Homo
sapiens],core-binding factor, beta subunit isoform 1
[Homo sapiens]
coronin, actin binding protein, 1C isoform 1 [Homo
sapiens]
cortactin isoform a [Homo sapiens],cortactin
isoform b [Homo sapiens]
CSE1 chromosome segregation 1-like protein
[Homo sapiens]
cutA divalent cation tolerance homolog isoform 1
[Homo sapiens],cutA divalent cation tolerance
homolog isoform 2 [Homo sapiens],cutA divalent
cation tolerance homolog isoform 3 [Homo sapiens]

cystatin B [Homo sapiens]
cystatin C precursor [Homo sapiens]
cysteine-rich, angiogenic inducer, 61 [Homo
sapiens]
cysteinyl-tRNA synthetase isoform b [Homo
sapiens],cysteinyl-tRNA synthetase isoform a
[Homo sapiens],cysteinyl-tRNA synthetase isoform
c [Homo sapiens],cysteinyl-tRNA synthetase
isoform d [Homo sapiens]
cytidine monophosphate (UMP-CMP) kinase 1,
cytosolic [Homo sapiens]
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X

X

Protein

X gi|11128019|ref|NP_061820.1|
gi|17017988|ref|NP_001853.2|

X
X
X

gi|32129199|ref|NP_149073.1|
X gi|50428925|ref|NP_001272.2|
X gi|5174539|ref|NP_005908.1|
gi|24850115|ref|NP_733746.1|
X

X

X

X

Description

P
C
C

gi|148529014|ref|NP_001914.3
|
gi|145386531|ref|NP_0010778
X 61.1|,gi|4503291|ref|NP_00134
6.1|
gi|4826686|ref|NP_004930.1|

cytochrome c [Homo sapiens]
cytochrome c oxidase subunit Vb precursor [Homo
sapiens]
cytokine induced protein 29 kDa [Homo sapiens]
cytoskeleton associated protein 1 [Homo sapiens]
cytosolic malate dehydrogenase [Homo sapiens]
cytosolic sialic acid 9-O-acetylesterase homolog
[Homo sapiens]
damage-specific DNA binding protein 1 [Homo
sapiens]
D-dopachrome tautomerase [Homo sapiens]

X

gi|4503423|ref|NP_001939.1|,g
X i|70906441|ref|NP_001020419.
1|

DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 [Homo
sapiens]
DEAD (Asp-Glu-Ala-Asp) box polypeptide 21
[Homo sapiens]
DEAH (Asp-Glu-Ala-His) box polypeptide 9 [Homo
sapiens]
dedicator of cytokinesis 7 [Homo sapiens]
deoxyribonuclease II, lysosomal precursor [Homo
sapiens]
deoxyuridine triphosphatase isoform 2 [Homo
sapiens],deoxyuridine triphosphatase isoform 1
precursor [Homo sapiens]

X

gi|148539846|ref|NP_001932.2
|,gi|148539848|ref|NP_077741.
2|

desmocollin 3 isoform Dsc3a preproprotein [Homo
sapiens],desmocollin 3 isoform Dsc3b
preproprotein [Homo sapiens]

X
X
X
X
X

X
X

gi|50659095|ref|NP_004719.2|
gi|100913206|ref|NP_001348.2
|
gi|54112429|ref|NP_212132.2|
gi|4503349|ref|NP_001366.1|

gi|116534898|ref|NP_001934.2
|
gi|5802966|ref|NP_006861.1|,g
X i|58530848|ref|NP_001011546.
1|

desmoglein 2 preproprotein [Homo sapiens]
destrin isoform a [Homo sapiens],destrin isoform b
[Homo sapiens]

X

gi|119395758|ref|NP_005210.3
|,gi|119395760|ref|NP_001073
280.1|

diaphanous 1 isoform 1 [Homo
sapiens],diaphanous 1 isoform 2 [Homo sapiens]

X

gi|10140853|ref|NP_065438.1|,
gi|120433590|ref|NP_0010733
31.1|,gi|120433593|ref|NP_001
073332.1|

diazepam binding inhibitor isoform 1 [Homo
sapiens],diazepam binding inhibitor isoform 3
[Homo sapiens],diazepam binding inhibitor isoform
2 [Homo sapiens]

X

gi|40548389|ref|NP_056965.3|,
gi|40548393|ref|NP_037385.2|,
gi|66346689|ref|NP_00101806
7.1|

dickkopf homolog 3 precursor [Homo
sapiens],dickkopf homolog 3 precursor [Homo
sapiens],dickkopf homolog 3 precursor [Homo
sapiens]
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X

X gi|14211889|ref|NP_115963.1|
gi|18426913|ref|NP_543157.1|,
X gi|18426915|ref|NP_004386.2|
gi|21361670|ref|NP_054782.2|,
X gi|62198235|ref|NP_00101443
6.1|
gi|33350932|ref|NP_001367.2|

X

X

X

gi|4503337|ref|NP_001354.1|
gi|34577047|ref|NP_899236.1|,
gi|34577049|ref|NP_056363.2|
gi|148539835|ref|NP_004384.2
X
|
gi|86788015|ref|NP_00103443
7.1|,gi|86788132|ref|NP_00103
4438.1|,gi|9665262|ref|NP_004
096.2|
gi|31317224|ref|NP_005702.3|

X
X
X
X

gi|110347457|ref|NP_001400.3
|
X gi|38201714|ref|NP_001410.2|
gi|4826714|ref|NP_005098.1|
gi|5803013|ref|NP_006808.1|
X
X

X

dihydrolipoamide dehydrogenase precursor [Homo
sapiens]
dihydropyrimidinase-like 2 [Homo sapiens]
dihydropyrimidinase-like 3 [Homo sapiens]
dipeptidyl peptidase III [Homo sapiens]

gi|62530384|ref|NP_001910.2|

X

X

gi|91199540|ref|NP_000099.2|

gi|112293277|ref|NP_055095.2
|
gi|27597059|ref|NP_056005.1|

X

X

Description

gi|4503377|ref|NP_001377.1|
gi|4503379|ref|NP_001378.1|
gi|18491024|ref|NP_005691.2|,
X gi|86792661|ref|NP_569710.2|
X gi|31543380|ref|NP_009193.2|
gi|47132600|ref|NP_998731.1|,
gi|4758148|ref|NP_004392.1|
X

X

X

Protein
P
C
C

gi|34335272|ref|NP_006395.2|
gi|4758302|ref|NP_004441.1|

DJ-1 protein [Homo sapiens]
DNA fragmentation factor, 45kDa, alpha
polypeptide isoform 2 [Homo sapiens],DNA
fragmentation factor, 45kDa, alpha polypeptide
isoform 1 [Homo sapiens]
DnaJ (Hsp40) homolog, subfamily C, member 8
[Homo sapiens]
DnaJ homolog, subfamily C, member 9 [Homo
sapiens]
dodecenoyl-Coenzyme A delta isomerase
precursor [Homo sapiens]
dpy-30-like protein [Homo sapiens]
drebrin 1 isoform b [Homo sapiens],drebrin 1
isoform a [Homo sapiens]
drebrin-like isoform a [Homo sapiens],drebrin-like
isoform b [Homo sapiens]
dynein, cytoplasmic, heavy polypeptide 1 [Homo
sapiens]
dyskerin [Homo sapiens]
dystonin isoform 1 [Homo sapiens],dystonin
isoform 1eA precursor [Homo sapiens]
dystroglycan 1 preproprotein [Homo sapiens]
EGF-containing fibulin-like extracellular matrix
protein 1 precursor [Homo sapiens]

EGF-like repeats and discoidin I-like domainscontaining protein 3 [Homo sapiens]
EGF-like-domain, multiple 3 [Homo sapiens]
ELAV-like 1 [Homo sapiens]
endonuclease G-like 1 [Homo sapiens]
endoplasmic reticulum protein 29 isoform 1
precursor [Homo sapiens]
endothelial protein C receptor precursor [Homo
sapiens]
enhancer of rudimentary homolog [Homo sapiens]
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X

X gi|4503571|ref|NP_001419.1|
X gi|5803011|ref|NP_001966.1|
gi|10864017|ref|NP_067027.1|
X gi|4758280|ref|NP_004429.1|
gi|5453678|ref|NP_006423.1|
X

X

X

X

gi|124494254|ref|NP_006182.2
|
gi|4557245|ref|NP_001098.1|
gi|33413400|ref|NP_001975.1|

X

X

X

X

X

X

X

gi|11136628|ref|NP_066944.1|,
gi|148222882|ref|NP_0010833
X 45.1|,gi|4503477|ref|NP_00195
0.1|,gi|83376130|ref|NP_00103
2752.1|

gi|4503471|ref|NP_001393.1|
gi|4503475|ref|NP_001949.1|

X

gi|25453472|ref|NP_001951.2|,
X gi|25453474|ref|NP_115754.2|

X

X

X

X
X

gi|4503481|ref|NP_001395.1|
gi|4503483|ref|NP_001952.1|
gi|4758256|ref|NP_004085.1|
gi|4503507|ref|NP_001406.1|

X

gi|38201619|ref|NP_004944.2|,
gi|38201621|ref|NP_886553.2|,
gi|38201623|ref|NP_937884.1|,
gi|38201625|ref|NP_937885.1|,
gi|38201627|ref|NP_937887.1|

X

gi|4503529|ref|NP_001407.1|

X

X

X

X

X

gi|31563374|ref|NP_852131.1|,
X gi|31563378|ref|NP_852133.1|,
gi|4504771|ref|NP_002203.1|

gi|50053795|ref|NP_001408.2|

enolase 1 [Homo sapiens]
enolase 2 [Homo sapiens]
enolase-phosphatase 1 [Homo sapiens]
ephrin receptor EphA4 [Homo sapiens]
epididymal secretory protein E1 precursor [Homo
sapiens]
ErbB3-binding protein 1 [Homo sapiens]
erythrocyte acylphosphatase 1 isoform a [Homo
sapiens]
esterase D/formylglutathione hydrolase [Homo
sapiens]
eukaryotic translation elongation factor 1 alpha 1
[Homo sapiens]
eukaryotic translation elongation factor 1 alpha 2
[Homo sapiens]
eukaryotic translation elongation factor 1 beta 2
[Homo sapiens],hypothetical protein LOC644820
[Homo sapiens]

eukaryotic translation elongation factor 1 delta
isoform 2 [Homo sapiens],eukaryotic translation
elongation factor 1 delta isoform 1 [Homo sapiens]
eukaryotic translation elongation factor 1 gamma
[Homo sapiens]
eukaryotic translation elongation factor 2 [Homo
sapiens]
eukaryotic translation initiation factor 2, subunit 1
alpha, 35kDa [Homo sapiens]
eukaryotic translation initiation factor 2, subunit 3
gamma, 52kDa [Homo sapiens]
eukaryotic translation initiation factor 4 gamma, 1
isoform 4 [Homo sapiens],eukaryotic translation
initiation factor 4 gamma, 1 isoform 1 [Homo
sapiens],eukaryotic translation initiation factor 4
gamma, 1 isoform 1 [Homo sapiens]
eukaryotic translation initiation factor 4A isoform 1
[Homo sapiens]
eukaryotic translation initiation factor 4B [Homo
sapiens]
eukaryotic translation initiation factor 6 isoform c
[Homo sapiens],eukaryotic translation initiation
factor 6 isoform a [Homo sapiens]
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Description

gi|4885225|ref|NP_005234.1|,g
i|7669490|ref|NP_053733.1|

Ewing sarcoma breakpoint region 1 isoform EWS
[Homo sapiens],Ewing sarcoma breakpoint region
1 isoform EWS-b [Homo sapiens]
exportin 1 [Homo sapiens]
extracellular matrix protein 1 isoform 1 precursor
[Homo sapiens]
extracellular matrix protein 1 isoform 2 precursor
[Homo sapiens]
ezrin [Homo sapiens]
F-actin capping protein alpha-1 subunit [Homo
sapiens]
F-actin capping protein beta subunit [Homo
sapiens]
family with sequence similarity 3, member C
precursor [Homo sapiens],family with sequence
similarity 3, member C precursor [Homo sapiens]

gi|4507943|ref|NP_003391.1|
gi|4758236|ref|NP_004416.1|
gi|12707572|ref|NP_073155.1|

X

X gi|21614499|ref|NP_003370.2|
gi|5453597|ref|NP_006126.1|
X

X

X

X

gi|7661714|ref|NP_055703.1|,g
X i|91807125|ref|NP_001035109.
1|

X

gi|4826659|ref|NP_004921.1|

gi|14149680|ref|NP_056107.1|

X

gi|17402900|ref|NP_003893.2|

X

X

X
X
X

X gi|4503685|ref|NP_001995.1|
gi|31377837|ref|NP_078898.2|
X gi|41872631|ref|NP_004095.4|
X gi|20149498|ref|NP_000137.2|
gi|16933542|ref|NP_002017.1|,
gi|47132551|ref|NP_997640.1|,
gi|47132555|ref|NP_997643.1|,
gi|47132557|ref|NP_997647.1|

X

X
X
X

Protein
P
C
C

X
X

X
X
X
X
X

X gi|34734062|ref|NP_001987.2|
gi|51873053|ref|NP_00100401
9.1|,gi|51873055|ref|NP_00198
9.2|
gi|116063573|ref|NP_001447.2
|
gi|105990514|ref|NP_001448.2
X
|
gi|17149836|ref|NP_463460.1|,
X gi|4503725|ref|NP_000792.1|
gi|4503727|ref|NP_002004.1|
X gi|4503729|ref|NP_002005.1|
gi|4758356|ref|NP_004102.1|
X

X gi|5901956|ref|NP_009016.1|
gi|28376619|ref|NP_064501.1|

family with sequence similarity 62 (C2 domain
containing), member A [Homo sapiens]
far upstream element-binding protein [Homo
sapiens]
farnesyl diphosphate synthase [Homo sapiens]
FAST kinase domains 1 [Homo sapiens]
fatty acid synthase [Homo sapiens]
ferritin, light polypeptide [Homo sapiens]
fibronectin 1 isoform 3 preproprotein [Homo
sapiens],fibronectin 1 isoform 2 preproprotein
[Homo sapiens],fibronectin 1 isoform 4
preproprotein [Homo sapiens],fibronectin 1 isoform
1 preproprotein [Homo sapiens]
fibulin 1 isoform C precursor [Homo sapiens]
fibulin 2 precursor, isoform a [Homo sapiens],fibulin
2 precursor, isoform b [Homo sapiens]
filamin A, alpha isoform 1 [Homo sapiens]
filamin B, beta (actin binding protein 278) [Homo
sapiens]
FK506-binding protein 1A [Homo sapiens]
FK506-binding protein 3 [Homo sapiens]
FK506-binding protein 4 [Homo sapiens]
flap structure-specific endonuclease 1 [Homo
sapiens]
follistatin-like 1 precursor [Homo sapiens]
follistatin-like 5 [Homo sapiens]
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Protein

X gi|4885063|ref|NP_005156.1|
X gi|40068512|ref|NP_114409.2|
gi|19743875|ref|NP_000134.2|
gi|47078238|ref|NP_997657.1|,
gi|47078240|ref|NP_004118.3|
gi|50355941|ref|NP_940971.1|,
gi|74048357|ref|NP_065188.4|,
X gi|74048403|ref|NP_00102756
7.1|,gi|74048422|ref|NP_00102
7566.1|

X
X
X
X
X
X

Description

P
C
C

gi|115430223|ref|NP_002297.2
|
X gi|5031863|ref|NP_005558.1|
gi|116805322|ref|NP_001449.3
|
gi|4503987|ref|NP_003869.1|
X

X
X

X
X

X

X

X

X

gi|4503971|ref|NP_001484.1|
gi|6598323|ref|NP_001485.2|
gi|4504165|ref|NP_000168.1|
gi|38044288|ref|NP_937895.1|,
gi|4504165|ref|NP_000168.1|
gi|63252913|ref|NP_001738.2|
gi|119393897|ref|NP_000149.2
|
gi|54607043|ref|NP_000148.2|,
gi|54607045|ref|NP_00100574
1.1|,gi|54607047|ref|NP_00100
5742.1|,gi|54607049|ref|NP_00
1005749.1|,gi|54607051|ref|NP
_001005750.1|
gi|13027378|ref|NP_005462.1|

X

X

X

X gi|18201905|ref|NP_000166.2|
gi|108773793|ref|NP_0010358
X 10.1|,gi|109389365|ref|NP_000
393.4|

X

X gi|4885281|ref|NP_005262.1|
gi|6912618|ref|NP_036545.1|
X

X

X gi|4826960|ref|NP_005042.1|
X gi|95113651|ref|NP_006532.2|
gi|50301238|ref|NP_000628.2|

fructose-bisphosphate aldolase C [Homo sapiens]
fucosidase, alpha-L- 2, plasma [Homo sapiens]
fumarate hydratase precursor [Homo sapiens]
G protein pathway suppressor 1 isoform 1 [Homo
sapiens],G protein pathway suppressor 1 isoform 2
[Homo sapiens]
G protein-coupled receptor 126 beta 1 [Homo
sapiens],G protein-coupled receptor 126 alpha 1
[Homo sapiens],G protein-coupled receptor 126
beta 2 [Homo sapiens],G protein-coupled receptor
126 alpha 2 [Homo sapiens]
galectin 3 [Homo sapiens]
galectin 3 binding protein [Homo sapiens]
gamma filamin [Homo sapiens]
gamma-glutamyl hydrolase precursor [Homo
sapiens]
GDP dissociation inhibitor 1 [Homo sapiens]
GDP dissociation inhibitor 2 [Homo sapiens]
gelsolin isoform a precursor [Homo sapiens]
gelsolin isoform b [Homo sapiens],gelsolin isoform
a precursor [Homo sapiens]
gelsolin-like capping protein [Homo sapiens]
glucan (1,4-alpha-), branching enzyme 1 [Homo
sapiens]
glucocerebrosidase precursor [Homo sapiens]

glucosamine-6-phosphate deaminase 1 [Homo
sapiens]
glucose phosphate isomerase [Homo sapiens]
glucose-6-phosphate dehydrogenase isoform b
[Homo sapiens],glucose-6-phosphate
dehydrogenase isoform a [Homo sapiens]
glutamate dehydrogenase 1 [Homo sapiens]
glutaminyl-peptide cyclotransferase precursor
[Homo sapiens]
glutaminyl-tRNA synthetase [Homo sapiens]
glutaredoxin 3 [Homo sapiens]
glutathione reductase [Homo sapiens]
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X
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gi|4504169|ref|NP_000169.1|
X gi|4504183|ref|NP_000843.1|
X gi|4758484|ref|NP_004823.1|
gi|7669492|ref|NP_002037.2|
X
X gi|5032009|ref|NP_005600.1|
X gi|71037379|ref|NP_002854.3|
gi|116805340|ref|NP_002038.2
X
|
X gi|34850074|ref|NP_057164.2|
gi|118402586|ref|NP_006699.2
X
|
gi|4504081|ref|NP_002072.1|
gi|39995109|ref|NP_000396.2|
X
X gi|54633312|ref|NP_036333.2|
gi|29550838|ref|NP_057632.2|,
X gi|29550850|ref|NP_808800.1|
X gi|4504151|ref|NP_002078.1|
gi|4504111|ref|NP_002077.1|,g
i|45359859|ref|NP_987102.1|
X
X

X
X

X gi|42544159|ref|NP_006635.2|
X gi|4504523|ref|NP_002148.1|
X gi|4504517|ref|NP_001531.1|
gi|19923193|ref|NP_003923.2|
X

X

X

X

X

X
X

X gi|20149594|ref|NP_031381.2|
gi|4557647|ref|NP_001528.1|

X
X

X

gi|5174447|ref|NP_006089.1|

X

X

X

gi|58761500|ref|NP_037473.3|

gi|4885431|ref|NP_005337.1|,g
X i|5123454|ref|NP_005336.2|
gi|124256496|ref|NP_005518.3
|
X gi|38327039|ref|NP_002145.3|
X gi|16507237|ref|NP_005338.1|
gi|34419635|ref|NP_002146.2|
X

X

Description

P
C
C

gi|5729877|ref|NP_006588.1|
gi|24234688|ref|NP_004125.3|

glutathione synthetase [Homo sapiens]
glutathione transferase [Homo sapiens]
glutathione-S-transferase omega 1 [Homo sapiens]
glyceraldehyde-3-phosphate dehydrogenase
[Homo sapiens]
glycogen phosphorylase [Homo sapiens]
glycogen phosphorylase, liver [Homo sapiens]
glycyl-tRNA synthetase [Homo sapiens]
glyoxalase domain containing 4 [Homo sapiens]
glyoxalase I [Homo sapiens]
glypican 1 precursor [Homo sapiens]
GM2 ganglioside activator precursor [Homo
sapiens]
golgi apparatus protein 1 [Homo sapiens]
golgi membrane protein 1 [Homo sapiens]
granulin precursor [Homo sapiens]
growth factor receptor-bound protein 2 isoform 1
[Homo sapiens],growth factor receptor-bound
protein 2 isoform 2 [Homo sapiens]
GTP-binding protein PTD004 isoform 1 [Homo
sapiens]
guanine nucleotide binding protein (G protein), beta
polypeptide 2-like 1 [Homo sapiens]
heat shock 105kD [Homo sapiens]
heat shock 10kDa protein 1 [Homo sapiens]
heat shock 27kDa protein 1 [Homo sapiens]
heat shock 70kD protein binding protein [Homo
sapiens]
heat shock 70kDa protein 1B [Homo sapiens],heat
shock 70kDa protein 1A [Homo sapiens]
heat shock 70kDa protein 1-like [Homo sapiens]
heat shock 70kDa protein 4 [Homo sapiens]
heat shock 70kDa protein 5 [Homo sapiens]
heat shock 70kDa protein 6 (HSP70B') [Homo
sapiens]
heat shock 70kDa protein 8 isoform 1 [Homo
sapiens]
heat shock 70kDa protein 9 precursor [Homo
sapiens]
heat shock 90kDa protein 1, beta [Homo sapiens]
heat shock factor binding protein 1 [Homo sapiens]

107

q
P
S
C

c
a
P
S
C
X

Protein

gi|153792590|ref|NP_0010179
63.2|,gi|154146191|ref|NP_005
X
339.3|
gi|50345292|ref|NP_00100203
3.1|,gi|50345294|ref|NP_00100
2032.1|,gi|7705877|ref|NP_057
269.1|

X

gi|21700763|ref|NP_653171.1|

X
X

X

X

X

gi|126012571|ref|NP_005520.4
|
gi|4758516|ref|NP_004485.1|
gi|14249158|ref|NP_116020.1|,
gi|48255931|ref|NP_00100152
0.1|

X

X

gi|14043070|ref|NP_112420.1|,
X gi|4504445|ref|NP_002127.1|

X

X

gi|14043072|ref|NP_112533.1|
gi|4504447|ref|NP_002128.1|

X

gi|34740329|ref|NP_919223.1|

X

X

X

gi|55956919|ref|NP_112556.2|,
X gi|55956921|ref|NP_004490.2|

X

X
X

Description

P
C
C

gi|117189975|ref|NP_112604.2
|,gi|117190174|ref|NP_004491.
2|,gi|117190192|ref|NP_00107
X
0910.1|,gi|117190254|ref|NP_0
01070911.1|
gi|14110414|ref|NP_002129.2|,
X gi|14110420|ref|NP_112738.1|
gi|14110407|ref|NP_112740.1|

heat shock protein 90kDa alpha (cytosolic), class A
member 1 isoform 1 [Homo sapiens],heat shock
protein 90kDa alpha (cytosolic), class A member 1
isoform 2 [Homo sapiens]
hematological and neurological expressed 1
isoform 3 [Homo sapiens],hematological and
neurological expressed 1 isoform 2 [Homo
sapiens],hematological and neurological expressed
1 isoform 1 [Homo sapiens]
hematological and neurological expressed 1-like
[Homo sapiens]
heparan sulfate proteoglycan 2 [Homo sapiens]
hepatoma-derived growth factor (high-mobility
group protein 1-like) [Homo sapiens]
hepatoma-derived growth factor-related protein 2
isoform 2 [Homo sapiens],hepatoma-derived
growth factor-related protein 2 isoform 1 [Homo
sapiens]
heterogeneous nuclear ribonucleoprotein A1
isoform b [Homo sapiens],heterogeneous nuclear
ribonucleoprotein A1 isoform a [Homo sapiens]
heterogeneous nuclear ribonucleoprotein A2/B1
isoform B1 [Homo sapiens]
heterogeneous nuclear ribonucleoprotein A2/B1
isoform A2 [Homo sapiens]
heterogeneous nuclear ribonucleoprotein A3
[Homo sapiens]
heterogeneous nuclear ribonucleoprotein AB
isoform a [Homo sapiens],heterogeneous nuclear
ribonucleoprotein AB isoform b [Homo sapiens]
heterogeneous nuclear ribonucleoprotein C isoform
a [Homo sapiens],heterogeneous nuclear
ribonucleoprotein C isoform b [Homo
sapiens],heterogeneous nuclear ribonucleoprotein
C isoform a [Homo sapiens],heterogeneous nuclear
ribonucleoprotein C isoform b [H
heterogeneous nuclear ribonucleoprotein D isoform
c [Homo sapiens],heterogeneous nuclear
ribonucleoprotein D isoform a [Homo sapiens]
heterogeneous nuclear ribonucleoprotein D-like
[Homo sapiens]
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Protein

X

gi|148470397|ref|NP_0010916
78.1|,gi|148470400|ref|NP_001
091677.1|,gi|148470402|ref|NP
X _001091675.1|,gi|148470404|r
ef|NP_001091674.1|,gi|148470
406|ref|NP_001091676.1|,gi|48
26760|ref|NP_004957.1|

X

X

gi|5031753|ref|NP_005511.1|

X

gi|14141157|ref|NP_036339.1|,
gi|14141159|ref|NP_067676.2|

X

gi|14165435|ref|NP_112552.1|,
gi|14165437|ref|NP_112553.1|,
X gi|14165439|ref|NP_002131.2|

X

X

X

gi|52632385|ref|NP_00100533
X 5.1|
gi|156151392|ref|NP_0010958
67.1|,gi|156151394|ref|NP_001
095868.1|,gi|156151396|ref|NP
X
_001095869.1|,gi|5031755|ref|
NP_005817.1|
gi|14141161|ref|NP_004492.2|,
gi|74136883|ref|NP_114032.2|

X

X
X
X
X
X
X

X gi|4504371|ref|NP_000511.1|
X gi|4504373|ref|NP_000512.1|
gi|22208967|ref|NP_665906.1|,
X gi|22208971|ref|NP_665908.1|,
gi|22208977|ref|NP_665911.1|
X gi|4504425|ref|NP_002119.1|
X gi|11321591|ref|NP_002120.1|
gi|71143137|ref|NP_005333.2|
gi|48255933|ref|NP_004956.5|
X

X
X
X

gi|52632383|ref|NP_001524.2|

gi|4885413|ref|NP_005331.1|

X gi|6996014|ref|NP_002100.2|
gi|4504341|ref|NP_003633.1|
gi|4885381|ref|NP_005313.1|

Description

heterogeneous nuclear ribonucleoprotein F [Homo
sapiens]

heterogeneous nuclear ribonucleoprotein H1
[Homo sapiens]
heterogeneous nuclear ribonucleoprotein H3
isoform a [Homo sapiens],heterogeneous nuclear
ribonucleoprotein H3 isoform b [Homo sapiens]
heterogeneous nuclear ribonucleoprotein K isoform
b [Homo sapiens],heterogeneous nuclear
ribonucleoprotein K isoform a [Homo
sapiens],heterogeneous nuclear ribonucleoprotein
K isoform a [Homo sapiens]
heterogeneous nuclear ribonucleoprotein L isoform
a [Homo sapiens]
heterogeneous nuclear ribonucleoprotein L isoform
b [Homo sapiens]
heterogeneous nuclear ribonucleoprotein R isoform
4 [Homo sapiens],heterogeneous nuclear
ribonucleoprotein R isoform 1 [Homo
sapiens],heterogeneous nuclear ribonucleoprotein
R isoform 3 [Homo sapiens],heterogeneous nuclear
ribonucleoprotein R isoform 2 [H
heterogeneous nuclear ribonucleoprotein U isoform
b [Homo sapiens],heterogeneous nuclear
ribonucleoprotein U isoform a [Homo sapiens]
hexosaminidase A preproprotein [Homo sapiens]
hexosaminidase B preproprotein [Homo sapiens]
high mobility group AT-hook 1 isoform a [Homo
sapiens]
high-mobility group box 1 [Homo sapiens]
high-mobility group box 2 [Homo sapiens]
high-mobility group box 3 [Homo sapiens]
high-mobility group nucleosome binding domain 1
[Homo sapiens]
histidine triad nucleotide binding protein 1 [Homo
sapiens]
histidyl-tRNA synthetase [Homo sapiens]
histone acetyltransferase 1 isoform a [Homo
sapiens]
histone cluster 1, H1b [Homo sapiens]
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Description

gi|4885375|ref|NP_005310.1|,g
i|4885377|ref|NP_005311.1|,gi|
4885379|ref|NP_005312.1|

histone cluster 1, H1c [Homo sapiens],histone
cluster 1, H1d [Homo sapiens],histone cluster 1,
H1e [Homo sapiens]

P
C
C

gi|25092737|ref|NP_734466.1|,
gi|4504253|ref|NP_002096.1|
gi|10645195|ref|NP_066390.1|,
gi|106775678|ref|NP_0010358
07.1|,gi|10800130|ref|NP_0664
09.1|,gi|10800132|ref|NP_0664
08.1|,gi|10800144|ref|NP_0665
X
44.1|,gi|15617199|ref|NP_2542
80.1|,gi|18105045|ref|NP_5421
63.1|,gi|19557656|ref|NP_0035
04.2|,gi|24638446|ref|NP_

histone cluster 1, H2aa [Homo sapiens],H2A
histone family, member X [Homo sapiens]
histone cluster 1, H2ae [Homo sapiens],histone
cluster 2, H2aa4 [Homo sapiens],histone cluster 1,
H2ad [Homo sapiens],histone cluster 1, H2ag
[Homo sapiens],histone cluster 1, H2aj [Homo
sapiens],histone cluster 3, H2a [Homo
sapiens],histone cluster 1, H2

gi|10800140|ref|NP_066406.1|,
gi|16306566|ref|NP_003518.2|,
X gi|20336754|ref|NP_066402.2|,
gi|28173554|ref|NP_778225.1|,
gi|4504277|ref|NP_003519.1|

histone cluster 1, H2bb [Homo sapiens],histone
cluster 1, H2bo [Homo sapiens],histone cluster 1,
H2bj [Homo sapiens],histone cluster 3, H2bb
[Homo sapiens],histone cluster 2, H2be [Homo
sapiens]

gi|10800138|ref|NP_066407.1|,
gi|18105048|ref|NP_542160.1|,
gi|20336752|ref|NP_619790.1|,
gi|21166389|ref|NP_003517.2|,
gi|21396484|ref|NP_003514.2|,
gi|4504257|ref|NP_003509.1|,g
i|4504259|ref|NP_003510.1|,gi|
4504261|ref|NP_003511.1|,gi|4
504263|ref|NP_003512.1

histone cluster 1, H2bd [Homo sapiens],histone
cluster 1, H2bk [Homo sapiens],histone cluster 1,
H2bd [Homo sapiens],histone cluster 1, H2bc
[Homo sapiens],histone cluster 1, H2be [Homo
sapiens],histone cluster 1, H2bg [Homo
sapiens],histone cluster 1, H2

gi|10440560|ref|NP_066298.1|,
gi|169162559|ref|XP_497711.3
|,gi|21071021|ref|NP_003521.2
|,gi|31742503|ref|NP_066403.2
|,gi|4504279|ref|NP_002098.1|,
gi|4504281|ref|NP_003520.1|,g
i|4504285|ref|NP_003522.1|,gi|
4504287|ref|NP_003523.1|,gi|4
504289|ref|NP_003524.1

histone cluster 1, H3f [Homo
sapiens],PREDICTED: hypothetical protein [Homo
sapiens],histone cluster 1, H3d [Homo
sapiens],histone cluster 2, H3c [Homo sapiens],H3
histone, family 3A [Homo sapiens],histone cluster
1, H3a [Homo sapiens],histone cluster 1,
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X
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X
X
X
X
X
X

X
X
X

X

X

Protein

Description

P
C
C
gi|11415030|ref|NP_068803.1|,
gi|28173560|ref|NP_778224.1|,
gi|4504301|ref|NP_003529.1|,g
i|4504303|ref|NP_003530.1|,gi|
4504305|ref|NP_003531.1|,gi|4
X
504307|ref|NP_003532.1|,gi|45
04309|ref|NP_003533.1|,gi|450
4311|ref|NP_003534.1|,gi|4504
313|ref|NP_003535.1|,g

histone cluster 1, H4j [Homo sapiens],histone
cluster 4, H4 [Homo sapiens],histone cluster 1, H4a
[Homo sapiens],histone cluster 1, H4d [Homo
sapiens],histone cluster 1, H4f [Homo
sapiens],histone cluster 1, H4k [Homo
sapiens],histone cluster 1, H4c [Homo

gi|18375623|ref|NP_542165.1|,
X gi|4758112|ref|NP_004631.1|

HLA-B associated transcript 1 [Homo
sapiens],HLA-B associated transcript 1 [Homo
sapiens]
HMT1 hnRNP methyltransferase-like 2 isoform 2
[Homo sapiens],HMT1 hnRNP methyltransferaselike 2 isoform 3 [Homo sapiens],HMT1 hnRNP
methyltransferase-like 2 isoform 1 [Homo sapiens]

gi|150456457|ref|NP_938075.2
|,gi|151301219|ref|NP_938074.
X 2|,gi|154759421|ref|NP_00152
7.3|
gi|7706322|ref|NP_057123.1|
gi|94538320|ref|NP_00103551
7.1|,gi|94538322|ref|NP_00531
7.2|

homeobox prox 1 [Homo sapiens]
hydroxyacyl glutathione hydrolase isoform 2 [Homo
sapiens],hydroxyacyl glutathione hydrolase isoform
1 [Homo sapiens]

gi|27734925|ref|NP_775928.1|
gi|39930541|ref|NP_899064.1|
gi|63055057|ref|NP_00101799
2.1|
gi|42734438|ref|NP_057707.3|
gi|46195792|ref|NP_060485.3|
X gi|50843837|ref|NP_060541.3|
gi|51093863|ref|NP_073744.2|,
X gi|79750824|ref|NP_00103061
1.1|

hypothetical protein LOC285315 [Homo sapiens]
hypothetical protein LOC286257 [Homo sapiens]
hypothetical protein LOC345651 [Homo sapiens]

X gi|13129018|ref|NP_076956.1|
gi|4504483|ref|NP_000185.1|
X

hypothetical protein LOC79017 [Homo sapiens]
hypoxanthine phosphoribosyltransferase 1 [Homo
sapiens]
hypoxia up-regulated 1 precursor [Homo sapiens]
inhibin beta A precursor [Homo sapiens]
insulin-like growth factor 2 receptor precursor
[Homo sapiens]
insulin-like growth factor binding protein 3 isoform b
precursor [Homo sapiens],insulin-like growth factor
binding protein 3 isoform a precursor [Homo
sapiens]
insulin-like growth factor binding protein 4
precursor [Homo sapiens]

X gi|5453832|ref|NP_006380.1|
gi|4504699|ref|NP_002183.1|
gi|119964726|ref|NP_000867.2
X
|
gi|62243068|ref|NP_000589.2|,
gi|62243248|ref|NP_00101341
6.1|
gi|62243290|ref|NP_001543.2|

hypothetical protein LOC51571 [Homo sapiens]
hypothetical protein LOC55086 [Homo sapiens]
hypothetical protein LOC55701 [Homo sapiens]
hypothetical protein LOC64855 isoform 1 [Homo
sapiens],hypothetical protein LOC64855 isoform 2
[Homo sapiens]
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X

X

gi|24234750|ref|NP_036350.2|,
gi|24234753|ref|NP_004507.2|,
X
gi|24234756|ref|NP_703194.1|
X

X

X

X

X

X

X
X
X

X

X

X
X
X
X
X

gi|4506787|ref|NP_003861.1|
gi|28178825|ref|NP_005887.2|
gi|40018633|ref|NP_004499.2|

X

X

insulin-like growth factor binding protein 6 [Homo
sapiens]
insulin-like growth factor binding protein 7 [Homo
sapiens]
integrin alpha 2b preproprotein [Homo sapiens]
integrin cytoplasmic domain-associated protein 1
isoform 1 [Homo sapiens]
interleukin 8 precursor [Homo sapiens]
interleukin enhancer binding factor 2 [Homo
sapiens]
interleukin enhancer binding factor 3 isoform a
[Homo sapiens],interleukin enhancer binding factor
3 isoform b [Homo sapiens],interleukin enhancer
binding factor 3 isoform c [Homo sapiens]
IQ motif containing GTPase activating protein 1
[Homo sapiens]
isocitrate dehydrogenase 1 (NADP+), soluble
[Homo sapiens]
isopentenyl-diphosphate delta isomerase [Homo
sapiens]
jumonji, AT rich interactive domain 1C [Homo
sapiens]
kallikrein-related peptidase 6 isoform A
preproprotein [Homo sapiens],kallikrein-related
peptidase 6 isoform A preproprotein [Homo
sapiens]
karyopherin alpha 4 [Homo sapiens]
karyopherin beta 1 [Homo sapiens]
keratin 1 [Homo sapiens]

X gi|10834978|ref|NP_000575.1|
gi|24234747|ref|NP_004506.2|
X

X

X

gi|11321593|ref|NP_002169.1|

gi|88758615|ref|NP_000410.2|
gi|4758578|ref|NP_004754.1|

X

X

Description

gi|4504619|ref|NP_001544.1|

X

X

Protein
P
C
C

gi|109255243|ref|NP_004178.2
|
gi|4506155|ref|NP_002765.1|,g
i|61744424|ref|NP_001012982.
X
1|
X gi|4504901|ref|NP_002259.1|
X gi|19923142|ref|NP_002256.2|
gi|119395750|ref|NP_006112.3
X
|
X gi|40354192|ref|NP_000412.2|
gi|4557699|ref|NP_000214.1|
gi|40354195|ref|NP_954657.1|,
X gi|4557888|ref|NP_000215.1|
gi|47132620|ref|NP_000414.2|
X gi|45597458|ref|NP_778253.1|
X gi|4504919|ref|NP_002264.1|
X gi|55956899|ref|NP_000217.2|
gi|5730027|ref|NP_006550.1|
X

gi|154355000|ref|NP_003676.2
|

keratin 10 [Homo sapiens]
keratin 12 [Homo sapiens]
keratin 18 [Homo sapiens],keratin 18 [Homo
sapiens]
keratin 2 [Homo sapiens]
keratin 77 [Homo sapiens]
keratin 8 [Homo sapiens]
keratin 9 [Homo sapiens]
KH domain containing, RNA binding, signal
transduction associated 1 [Homo sapiens]
KH-type splicing regulatory protein (FUSE binding
protein 2) [Homo sapiens]
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Protein

Description

gi|118498356|ref|NP_0010729
89.1|,gi|118498362|ref|NP_001
072990.1|,gi|118498368|ref|NP
_004977.2|,gi|33620775|ref|NP
_891556.1|

kinectin 1 isoform a [Homo sapiens],kinectin 1
isoform b [Homo sapiens],kinectin 1 isoform c
[Homo sapiens],kinectin 1 isoform a [Homo
sapiens]

P
C
C

X

gi|21361809|ref|NP_062556.2|,
X gi|56699409|ref|NP_002130.2|
gi|94557308|ref|NP_005318.2|

X
X
X

X
X
X
X
X
X
X

X

X gi|5031857|ref|NP_005557.1|
gi|4557032|ref|NP_002291.1|
X gi|27436946|ref|NP_733821.1|
gi|5031875|ref|NP_005563.1|
X gi|27436948|ref|NP_733822.1|
X gi|5031877|ref|NP_005564.1|
gi|27436951|ref|NP_116126.2|
gi|21264602|ref|NP_005551.3|
gi|145309326|ref|NP_002284.3
X
|
gi|4557733|ref|NP_000419.1|
gi|110347412|ref|NP_003564.2
|,gi|110347431|ref|NP_001036
009.1|,gi|110347437|ref|NP_00
1036010.1|

X

X

X
X
X
X
X
X

gi|21359933|ref|NP_064554.2|
X gi|5803023|ref|NP_006807.1|
gi|56682962|ref|NP_005597.3|,
X gi|56682964|ref|NP_00100853
0.1|
X
X
X
X

gi|40254924|ref|NP_060979.2|
gi|4505029|ref|NP_000886.1|
gi|5453710|ref|NP_006139.1|
gi|51317399|ref|NP_000226.2|
gi|29337281|ref|NP_076435.1|

gi|4504957|ref|NP_002285.1|,g
i|7669503|ref|NP_054701.1|
X gi|32307144|ref|NP_000293.2|
X gi|4505011|ref|NP_002309.1|
X gi|5031815|ref|NP_005539.1|

kynurenine aminotransferase III isoform 3 [Homo
sapiens],RNA binding motif protein, X-linked [Homo
sapiens]
L-3-hydroxyacyl-Coenzyme A dehydrogenase
precursor [Homo sapiens]
lactate dehydrogenase A [Homo sapiens]
lactate dehydrogenase B [Homo sapiens]
lamin A/C isoform 1 precursor [Homo sapiens]
lamin A/C isoform 2 [Homo sapiens]
lamin A/C isoform 3 [Homo sapiens]
lamin B1 [Homo sapiens]
lamin B2 [Homo sapiens]
laminin alpha 5 [Homo sapiens]
laminin, gamma 1 precursor [Homo sapiens]
latent transforming growth factor beta binding
protein 2 [Homo sapiens]
latent transforming growth factor beta binding
protein 4 isoform b [Homo sapiens],latent
transforming growth factor beta binding protein 4
isoform a [Homo sapiens],latent transforming
growth factor beta binding protein 4 isoform c
[Homo sapiens]
latexin [Homo sapiens]
lectin, mannose-binding 2 [Homo sapiens]
legumain preproprotein [Homo sapiens]

leucine rich repeat containing 59 [Homo sapiens]
leukotriene A4 hydrolase [Homo sapiens]
LIM and SH3 protein 1 [Homo sapiens]
lipase A precursor [Homo sapiens]
Ly-6 neurotoxin-like protein 1 isoform a [Homo
sapiens]
lysosomal-associated membrane protein 2
precursor [Homo sapiens]
lysyl hydroxylase precursor [Homo sapiens]
lysyl oxidase-like 2 precursor [Homo sapiens]
lysyl-tRNA synthetase [Homo sapiens]
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X

X

Protein

Description

gi|4505185|ref|NP_002406.1|

macrophage migration inhibitory factor
(glycosylation-inhibiting factor) [Homo sapiens]
mago-nashi homolog [Homo sapiens],mago-nashi
homolog B [Homo sapiens]
major histocompatibility complex, class I, A
precursor [Homo sapiens]
major histocompatibility complex, class I, C
precursor [Homo sapiens]
manganese superoxide dismutase isoform A
precursor [Homo sapiens]

gi|4505087|ref|NP_002361.1|,g
X i|8922331|ref|NP_060518.1|
gi|24797067|ref|NP_002107.3|
X
gi|52630342|ref|NP_002108.4|

X
X

X

gi|67782305|ref|NP_000627.2|,
X gi|67782307|ref|NP_00101963
6.1|

X

X

gi|24497519|ref|NP_005898.2|

X
X
X

X

gi|11342666|ref|NP_004521.1|

X
X

X
X

X

X

gi|153945728|ref|NP_005900.2
|
gi|47519639|ref|NP_002366.2|
gi|48375173|ref|NP_149052.1|

X
X

gi|30520310|ref|NP_848927.1|
gi|5174529|ref|NP_005902.1|
gi|11034825|ref|NP_037415.1|,
gi|33519455|ref|NP_877725.1|

X

X

gi|51477714|ref|NP_002363.2|

X gi|13491174|ref|NP_075385.1|
gi|11321565|ref|NP_002372.1|
gi|21626466|ref|NP_061322.2|,
X gi|62750354|ref|NP_954659.1|
gi|4505215|ref|NP_002412.1|
X

X

X

gi|20127486|ref|NP_005808.2|

X

gi|6912494|ref|NP_036457.1|
gi|4505135|ref|NP_002382.1|,g
i|59894792|ref|NP_001012334.
1|,gi|59894796|ref|NP_001012
333.1|
gi|5174557|ref|NP_005919.1|

mannose 6 phosphate receptor binding protein 1
[Homo sapiens]
mannosidase, alpha, class 1A, member 1 [Homo
sapiens]
mannosidase, alpha, class 2A, member 1 [Homo
sapiens]
MARCKS-like 1 [Homo sapiens]
matrilin 3 precursor [Homo sapiens]
matrin 3 [Homo sapiens]
matrix metalloproteinase 1 preproprotein [Homo
sapiens]
matrix metalloproteinase 2 preproprotein [Homo
sapiens]
metadherin [Homo sapiens]
methionine adenosyltransferase II, alpha [Homo
sapiens]
methionine adenosyltransferase II, beta isoform 1
[Homo sapiens],methionine adenosyltransferase II,
beta isoform 2 [Homo sapiens]
microtubule-associated protein 1B [Homo sapiens]
microtubule-associated protein 4 isoform 1 [Homo
sapiens]
microtubule-associated protein 6 isoform 1 [Homo
sapiens]
microtubule-associated protein, RP/EB family,
member 1 [Homo sapiens]
midkine [Homo sapiens]

milk fat globule-EGF factor 8 protein [Homo
sapiens]
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X
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X
X

gi|33356547|ref|NP_004517.2|

minichromosome maintenance complex component
2 [Homo sapiens]
minichromosome maintenance complex component
3 [Homo sapiens]
mitochondrial malate dehydrogenase precursor
[Homo sapiens]
Mob4B protein [Homo sapiens],MOB1, Mps One
Binder kinase activator-like 1A [Homo sapiens]

X

gi|21735621|ref|NP_005909.2|

gi|148747437|ref|NP_060691.2
|,gi|27735029|ref|NP_775739.1
|
X gi|4505257|ref|NP_002435.1|
gi|6912448|ref|NP_036418.1|
gi|156119615|ref|NP_008832.2
|
gi|29568111|ref|NP_006088.2|

X

gi|15809016|ref|NP_291024.1|,
X gi|5453740|ref|NP_006462.1|

X

X

X

X

Description

gi|6631095|ref|NP_002379.2|

X
X

Protein
P
C
C

X

gi|12667788|ref|NP_002464.1|
gi|17986258|ref|NP_066299.2|,
gi|88999583|ref|NP_524147.2|

gi|153070260|ref|NP_002347.5
|
gi|11342664|ref|NP_002454.1|
gi|12056473|ref|NP_061819.2|

X
X
X
X

gi|23510451|ref|NP_001631.3|
gi|4505415|ref|NP_000894.1|,g
i|70995396|ref|NP_001020604.
1|,gi|70995422|ref|NP_001020
X
605.1|

X

X

X

X

X

gi|5031931|ref|NP_005585.1|
gi|115527120|ref|NP_004534.2
|
gi|4502169|ref|NP_003896.1|,g
i|66363686|ref|NP_001018169.
1|,gi|66363688|ref|NP_001018
170.1|
gi|47933379|ref|NP_003818.2|

moesin [Homo sapiens]
mortality factor 4 like 2 [Homo sapiens]
myosin IXA [Homo sapiens]
myosin regulatory light chain 9 isoform a [Homo
sapiens]
myosin regulatory light chain MRCL2 [Homo
sapiens],myosin regulatory light chain MRCL3
[Homo sapiens]
myosin, heavy polypeptide 9, non-muscle [Homo
sapiens]
myosin, light chain 6, alkali, smooth muscle and
non-muscle isoform 1 [Homo sapiens],myosin, light
chain 6, alkali, smooth muscle and non-muscle
isoform 2 [Homo sapiens]
myristoylated alanine-rich protein kinase C
substrate [Homo sapiens]
myxovirus resistance protein 2 [Homo sapiens]
N-acetylneuraminic acid phosphate synthase
[Homo sapiens]
N-acylaminoacyl-peptide hydrolase [Homo sapiens]
NAD(P)H menadione oxidoreductase 1, dioxininducible isoform a [Homo sapiens],NAD(P)H
menadione oxidoreductase 1, dioxin-inducible
isoform b [Homo sapiens],NAD(P)H menadione
oxidoreductase 1, dioxin-inducible isoform c [Homo
sapiens]
nascent polypeptide-associated complex alpha
subunit isoform b [Homo sapiens]
nebulin [Homo sapiens]
NEDD8 activating enzyme E1 subunit 1 isoform a
[Homo sapiens],NEDD8 activating enzyme E1
subunit 1 isoform b [Homo sapiens],NEDD8
activating enzyme E1 subunit 1 isoform c [Homo
sapiens]
N-ethylmaleimide-sensitive factor attachment
protein, alpha [Homo sapiens]
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X

X

X
X

X

gi|4505445|ref|NP_000900.1|
gi|5453790|ref|NP_006160.1|
gi|115298674|ref|NP_002499.2
|
gi|66392203|ref|NP_00101814
X 6.1|
gi|38045913|ref|NP_937818.1|,
gi|4557797|ref|NP_000260.1|
X

X

X

X

gi|27262628|ref|NP_002473.2|,
X gi|27262634|ref|NP_751896.1|

X

X

X

X

X

gi|71361682|ref|NP_006176.2|
gi|114155142|ref|NP_003283.2
X
|
X gi|5031985|ref|NP_005787.1|
gi|34098946|ref|NP_004550.2|
X

X
X

X
X

Protein

Description

gi|5453760|ref|NP_006147.1|

neural precursor cell expressed, developmentally
down-regulated 8 [Homo sapiens]
neuropeptide Y receptor Y1 [Homo sapiens]
nicotinamide N-methyltransferase [Homo sapiens]
nidogen 1 precursor [Homo sapiens]

gi|34932414|ref|NP_031389.3|

gi|56118310|ref|NP_073568.2|
gi|5729953|ref|NP_006591.1|

X

X gi|20070228|ref|NP_006175.2|
X gi|4826870|ref|NP_005004.1|
gi|148596949|ref|NP_004732.2
X
|
X gi|55956788|ref|NP_005372.2|
gi|10835063|ref|NP_002511.1|,
X gi|40353734|ref|NP_954654.1|

X

X

X
X
X
X

X

gi|157168362|ref|NP_000261.2
|
gi|21327708|ref|NP_631946.1|,
X gi|4758756|ref|NP_004528.1|
gi|5174613|ref|NP_005960.1|
X

X

gi|37594464|ref|NP_054861.2|

X

NME1-NME2 protein [Homo sapiens]
non-metastatic cells 1, protein (NM23A) expressed
in isoform a [Homo sapiens],non-metastatic cells 1,
protein (NM23A) expressed in isoform b [Homo
sapiens]
non-POU domain containing, octamer-binding
[Homo sapiens]
nuclear autoantigenic sperm protein isoform 2
[Homo sapiens],nuclear autoantigenic sperm
protein isoform 1 [Homo sapiens]
nuclear casein kinase and cyclin-dependent kinase
substrate 1 [Homo sapiens]
nuclear distribution gene C homolog [Homo
sapiens]
nuclear mitotic apparatus protein 1 [Homo sapiens]
nuclear pore complex-associated protein TPR
[Homo sapiens]
nuclear transport factor 2 [Homo sapiens]
nuclease sensitive element binding protein 1
[Homo sapiens]
nucleobindin 1 [Homo sapiens]
nucleobindin 2 [Homo sapiens]
nucleolar and coiled-body phosphoprotein 1 [Homo
sapiens]
nucleolin [Homo sapiens]
nucleophosmin 1 isoform 1 [Homo
sapiens],nucleophosmin 1 isoform 2 [Homo
sapiens]
nucleoside phosphorylase [Homo sapiens]
nucleosome assembly protein 1-like 1 [Homo
sapiens]
nucleosome assembly protein 1-like 4 [Homo
sapiens]
nudix-type motif 5 [Homo sapiens]
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gi|18860829|ref|NP_056375.1|,
gi|18860831|ref|NP_570844.1|,
gi|18860833|ref|NP_570845.1|,
gi|18860835|ref|NP_570846.1|,
gi|18860837|ref|NP_570847.1|,
gi|18860841|ref|NP_570848.1|,
gi|18860843|ref|NP_570849.1|,
gi|18860845|ref|NP_570850.1|

optic atrophy 1 isoform 1 [Homo sapiens],optic
atrophy 1 isoform 2 [Homo sapiens],optic atrophy 1
isoform 3 [Homo sapiens],optic atrophy 1 isoform 4
[Homo sapiens],optic atrophy 1 isoform 5 [Homo
sapiens],optic atrophy 1 isoform 6 [Homo sapiens]

P
C
C

X

X

gi|109148508|ref|NP_060140.2
|
gi|24432106|ref|NP_066997.3|,
gi|40548408|ref|NP_954675.1|
gi|20149635|ref|NP_057227.2|,
gi|29568099|ref|NP_061327.2|
gi|20149635|ref|NP_057227.2|,
gi|33286434|ref|NP_872289.1|
X gi|46276863|ref|NP_002815.3|
gi|16945970|ref|NP_066967.2|,
gi|19923653|ref|NP_150091.2|

X

X gi|7657441|ref|NP_055706.1|
gi|11496885|ref|NP_005442.2|,
gi|47157328|ref|NP_998801.1|

X

X

X
X
X
X
X

X

X

X
X
X
X
X
X

gi|4506333|ref|NP_002843.1|
gi|149589008|ref|NP_000276.2
|
gi|21070974|ref|NP_620121.1|,
gi|21070980|ref|NP_620176.1|,
gi|21070982|ref|NP_620177.1|,
gi|21070984|ref|NP_000910.2|

X gi|10863927|ref|NP_066953.1|
gi|4758950|ref|NP_000933.1|
X
gi|4505991|ref|NP_000934.1|
gi|5454154|ref|NP_006338.1|
gi|7706339|ref|NP_057143.1|
gi|109150416|ref|NP_036425.1
|

otubain 1 [Homo sapiens]
p30 DBC protein [Homo sapiens]
p47 protein isoform a [Homo sapiens],p47 protein
isoform b [Homo sapiens]
p47 protein isoform a [Homo sapiens],p47 protein
isoform c [Homo sapiens]
parathymosin [Homo sapiens]
PC4 and SFRS1 interacting protein 1 isoform 1
[Homo sapiens],PC4 and SFRS1 interacting protein
1 isoform 2 [Homo sapiens]
PDGFA associated protein 1 [Homo sapiens]
PDZ and LIM domain 7 isoform 1 [Homo
sapiens],PDZ and LIM domain 7 isoform 4 [Homo
sapiens]
pentraxin-related gene, rapidly induced by IL-1 beta
[Homo sapiens]
peptidase D [Homo sapiens]
peptidylglycine alpha-amidating monooxygenase
isoform b, preproprotein [Homo
sapiens],peptidylglycine alpha-amidating
monooxygenase isoform c, preproprotein [Homo
sapiens],peptidylglycine alpha-amidating
monooxygenase isoform d, preproprotein [Homo
sapien
peptidylprolyl isomerase A [Homo sapiens]
peptidylprolyl isomerase B precursor [Homo
sapiens]
peptidylprolyl isomerase C [Homo sapiens]
peptidylprolyl isomerase H [Homo sapiens]
peptidylprolyl isomerase-like 1 [Homo sapiens]
peroxidasin homolog [Homo sapiens]
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C
peroxiredoxin 1 [Homo sapiens]

X

gi|32455264|ref|NP_859047.1|,
X gi|32455266|ref|NP_859048.1|,
gi|4505591|ref|NP_002565.1|

X

X gi|32189392|ref|NP_005800.3|
gi|32483377|ref|NP_054817.2|,
gi|5802974|ref|NP_006784.1|

X

X

peroxiredoxin 2 isoform a [Homo sapiens]
peroxiredoxin 3 isoform b [Homo
sapiens],peroxiredoxin 3 isoform a precursor
[Homo sapiens]
peroxiredoxin 5 precursor, isoform a [Homo
sapiens]
peroxiredoxin 5 precursor, isoform b [Homo
sapiens]
peroxiredoxin 6 [Homo sapiens]
peroxisomal enoyl-coenzyme A hydratase-like
protein [Homo sapiens]
phosphatidylinositol transfer protein, beta [Homo
sapiens]
phosphogluconate dehydrogenase [Homo sapiens]
phosphoglycerate kinase 1 [Homo sapiens]
phosphoglycerate mutase 1 (brain) [Homo sapiens]
phospholipid transfer protein isoform a precursor
[Homo sapiens]
phospholipid transfer protein isoform b precursor
[Homo sapiens]
phosphoprotein enriched in astrocytes 15 [Homo
sapiens]
phosphoribosylaminoimidazole carboxylase,
phosphoribosylaminoimidazole
succinocarboxamide synthetase isoform 2 [Homo
sapiens]
phosphoribosylformylglycinamidine synthase
[Homo sapiens]
phosphoserine aminotransferase isoform 1 [Homo
sapiens]
phosphoserine aminotransferase isoform 2 [Homo
sapiens]
piwi-like 3 [Homo sapiens]

X

Protein

gi|32455260|ref|NP_857634.1|

X

X

gi|6912238|ref|NP_036226.1|

X

X gi|4758638|ref|NP_004896.1|
gi|70995211|ref|NP_001389.2|
X

X

X

X
X
X
X

X gi|40068518|ref|NP_002622.2|
X gi|4505763|ref|NP_000282.1|
X gi|4505753|ref|NP_002620.1|
gi|5453914|ref|NP_006218.1|
X

X

X

gi|6912594|ref|NP_036531.1|

gi|33356541|ref|NP_872617.1|
gi|4505705|ref|NP_003759.1|

X

gi|119220557|ref|NP_0010729
92.1|,gi|5453539|ref|NP_00644
X
3.1|
gi|31657129|ref|NP_036525.1|

X
X

X
X

X
X
X
X
X

gi|17402893|ref|NP_478059.1|
gi|10863955|ref|NP_066977.1|

gi|153792298|ref|NP_0010084
X 96.2|
gi|24307907|ref|NP_006207.1|
X gi|10835159|ref|NP_000593.1|
gi|7549809|ref|NP_005023.2|
gi|4557741|ref|NP_000421.1|
gi|4505585|ref|NP_002563.1|

Description

plasminogen activator inhibitor type 1, member 2
[Homo sapiens]
plasminogen activator inhibitor-1 [Homo sapiens]
plastin 3 [Homo sapiens]
platelet-activating factor acetylhydrolase, isoform
Ib, alpha subunit [Homo sapiens]
platelet-activating factor acetylhydrolase, isoform
Ib, beta subunit 30kDa [Homo sapiens]
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X

X
X
X

X

platelet-derived growth factor C precursor [Homo
sapiens]
platelet-derived growth factor receptor-like protein
[Homo sapiens]
plectin 1 isoform 3 [Homo sapiens],plectin 1
isoform 7 [Homo sapiens],plectin 1 isoform 2
[Homo sapiens],plectin 1 isoform 10 [Homo
sapiens],plectin 1 isoform 6 [Homo sapiens],plectin
1 isoform 8 [Homo sapiens],plectin 1 isoform 11
[Homo sapiens]

gi|19923372|ref|NP_006496.2|
gi|156523968|ref|NP_001609.2
X
|
gi|46367787|ref|NP_002559.2|
X
X gi|5453854|ref|NP_006187.1|
gi|14141166|ref|NP_114366.1|,
gi|14141168|ref|NP_005007.2|,
gi|148833484|ref|NP_0010920
90.1|
X

X

X

X

gi|9994187|ref|NP_057289.1|

gi|41322908|ref|NP_958781.1|,
gi|41322910|ref|NP_958783.1|,
gi|41322912|ref|NP_958780.1|,
gi|41322914|ref|NP_958785.1|,
X gi|41322916|ref|NP_958782.1|,
gi|41322919|ref|NP_958784.1|,
gi|41322923|ref|NP_958786.1|,
gi|47607492|ref|NP_000436.2|

X

X

Description

gi|5453872|ref|NP_006198.1|

X

X

Protein
P
C
C

gi|148886654|ref|NP_699197.3
|
gi|4758412|ref|NP_004472.1|

gi|157502212|ref|NP_059119.2
|
gi|14165464|ref|NP_114367.1|,
gi|14165466|ref|NP_114368.1|,
X
gi|4506243|ref|NP_002810.1|
gi|17298690|ref|NP_055096.2|,
X gi|17978512|ref|NP_510965.1|
gi|169216498|ref|XP_0017329
09.1|,gi|169216723|ref|XP_001
X 721120.1|,gi|169217303|ref|XP
_001732908.1|,gi|4503841|ref|
NP_001460.1|

X

gi|169167572|ref|XP_0017238
34.1|,gi|169167798|ref|XP_001
720870.1|,gi|169167889|ref|XP
_001722518.1|

poliovirus receptor [Homo sapiens]
poly (ADP-ribose) polymerase family, member 1
[Homo sapiens]
poly(A) binding protein, cytoplasmic 1 [Homo
sapiens]
poly(rC) binding protein 1 [Homo sapiens]
poly(rC)-binding protein 2 isoform b [Homo
sapiens],poly(rC)-binding protein 2 isoform a
[Homo sapiens],poly(rC)-binding protein 2 isoform c
[Homo sapiens]
polydom [Homo sapiens]
polypeptide N-acetylgalactosaminyltransferase 2
[Homo sapiens]
polypeptide N-acetylgalactosaminyltransferase 7
[Homo sapiens]
polypyrimidine tract-binding protein 1 isoform b
[Homo sapiens],polypyrimidine tract-binding protein
1 isoform c [Homo sapiens],polypyrimidine tractbinding protein 1 isoform a [Homo sapiens]
poly-U binding splicing factor 60KDa isoform b
[Homo sapiens],poly-U binding splicing factor
60KDa isoform a [Homo sapiens]
PREDICTED: hypothetical LOC389901 [Homo
sapiens],ATP-dependent DNA helicase II, 70 kDa
subunit [Homo sapiens]

PREDICTED: hypothetical protein [Homo sapiens]
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X

X

X

X

Protein

Description

gi|113418707|ref|XP_0011318
59.1|,gi|113419208|ref|XP_001
126350.1|,gi|113419745|ref|XP
_001126471.1|,gi|169171467|r
ef|XP_001727085.1|,gi|503205
7|ref|NP_005611.1|

PREDICTED: hypothetical LOC729659 [Homo
sapiens],S100 calcium binding protein A11 [Homo
sapiens]

P
C
C

gi|113420837|ref|XP_0011266
59.1|,gi|113420848|ref|XP_001
127088.1|,gi|113431257|ref|XP
X _499153.3|,gi|151101404|ref|N
P_002814.3|,gi|151101407|ref|
NP_001092755.1|,gi|16921754
8|ref|XP_001722951.1|

PREDICTED: hypothetical protein [Homo
sapiens],prothymosin, alpha isoform 2 [Homo
sapiens],prothymosin, alpha isoform 1 [Homo
sapiens]

gi|169171852|ref|XP_0017138
X 92.1|,gi|17999541|ref|NP_0606
76.2|

PREDICTED: hypothetical protein [Homo
sapiens],vacuolar protein sorting 35 [Homo
sapiens]

gi|113408761|ref|XP_0011339
49.1|,gi|113408763|ref|XP_001
133950.1|,gi|113412122|ref|XP
_001134262.1|,gi|113412126|r
ef|XP_001134264.1|,gi|169160
691|ref|XP_001725753.1|,gi|16
9160693|ref|XP_001725752.1|,
gi|4507645|ref|NP_000356.1|

PREDICTED: hypothetical protein isoform 4 [Homo
sapiens],PREDICTED: hypothetical protein isoform
5 [Homo sapiens],PREDICTED: similar to rcTPI1
isoform 4 [Homo sapiens],PREDICTED: similar to
rcTPI1 isoform 6 [Homo sapiens]

gi|169218211|ref|XP_0017195
13.1|,gi|41322908|ref|NP_9587
81.1|,gi|41322910|ref|NP_9587
83.1|,gi|41322912|ref|NP_9587
80.1|,gi|41322914|ref|NP_9587
85.1|,gi|41322916|ref|NP_9587
82.1|,gi|41322919|ref|NP_9587
84.1|,gi|41322923|ref|NP_9587
86.1|,gi|47607492|ref|NP_

PREDICTED: hypothetical protein, partial [Homo
sapiens],plectin 1 isoform 3 [Homo sapiens],plectin
1 isoform 7 [Homo sapiens],plectin 1 isoform 2
[Homo sapiens],plectin 1 isoform 10 [Homo
sapiens],plectin 1 isoform 6 [Homo sapiens],plectin
1 isoform 8 [Ho

gi|169211725|ref|XP_944964.3
|,gi|169212081|ref|XP_001718
X 231.1|,gi|4506715|ref|NP_0010
22.1|

PREDICTED: similar to 40S ribosomal protein S28
[Homo sapiens]
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X

X

X

Protein

gi|169204113|ref|XP_0017265
74.1|,gi|169204115|ref|XP_001
726573.1|,gi|169204808|ref|XP
_001723478.1|,gi|169204810|r
ef|XP_001723479.1|,gi|169204
X
812|ref|XP_001723476.1|,gi|16
9205440|ref|XP_001724025.1|,
gi|169205442|ref|XP_0017240
27.1|,gi|169205444|ref|XP_001
7
gi|169211223|ref|XP_0017246
X 24.1|,gi|4503545|ref|NP_00196
1.1|
gi|113422396|ref|XP_0011280
89.1|,gi|113422908|ref|XP_001
127657.1|,gi|169202850|ref|XP
_001718427.1|,gi|4557581|ref|
NP_001435.1|
gi|113411534|ref|XP_0011343
69.1|,gi|169213804|ref|XP_001
X 721116.1|,gi|49574537|ref|NP_
004474.2|,gi|89057342|ref|XP_
950829.1|

X

X

X

Description

P
C
C

gi|169206597|ref|XP_0017168
26.1|,gi|4557617|ref|NP_00081
1.1|

PREDICTED: similar to 40S ribosomal protein SA
(p40) (34/67 kDa laminin receptor) (Colon
carcinoma laminin-binding protein) (NEM/1CHD4)
(Multidrug resistance-associated protein MGr1-Ag)
isoform 2 [Homo sapiens

PREDICTED: similar to eukaryotic initiation factor
5A [Homo sapiens],eukaryotic translation initiation
factor 5A [Homo sapiens]
PREDICTED: similar to fatty acid binding protein
homologue [Homo sapiens], PREDICTED:
hypothetical protein [Homo sapiens],fatty acid
binding protein 5 (psoriasis-associated) [Homo
sapiens]
PREDICTED: similar to Glycine cleavage system H
protein, mitochondrial [Homo sapiens],glycine
cleavage system protein H (aminomethyl carrier)
[Homo sapiens]
PREDICTED: similar to growth arrest-specific 6
[Homo sapiens],growth arrest-specific 6 [Homo
sapiens]

gi|169201876|ref|XP_0017248
91.1|,gi|4503285|ref|NP_00134
X 5.1|,gi|45446745|ref|NP_99531
7.1|,gi|5453543|ref|NP_001344
.2|
gi|17471847|ref|XP_061427.1|,
gi|29294624|ref|NP_808210.1|,
gi|4759158|ref|NP_004588.1|

PREDICTED: similar to hCG2017792 [Homo
sapiens],aldo-keto reductase family 1, member C2
[Homo sapiens],aldo-keto reductase family 1,
member C2 [Homo sapiens],aldo-keto reductase
family 1, member C1 [Homo sapiens]
PREDICTED: similar to hCG2040270 [Homo
sapiens],small nuclear ribonucleoprotein
polypeptide D2 [Homo sapiens]

gi|169206886|ref|XP_0017208
42.1|,gi|169206888|ref|XP_001
720843.1|,gi|169207175|ref|XP
X _001720508.1|,gi|169207177|r
ef|XP_001720509.1|,gi|503174
9|ref|NP_005508.1|,gi|8903758
8|ref|XP_950717.1|

PREDICTED: similar to high mobility group
nucleosomal binding domain 2 isoform 1 [Homo
sapiens],PREDICTED: similar to high mobility
group nucleosomal binding domain 2 isoform 2
[Homo sapiens],PREDICTED: similar to high
mobility group nucleosomal binding d
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Protein

gi|169215551|ref|XP_0017206
74.1|,gi|169215761|ref|XP_001
723241.1|,gi|169215763|ref|XP
X _001723240.1|,gi|169215954|r
ef|XP_001726307.1|,gi|169215
956|ref|XP_001726306.1|,gi|45
04425|ref|NP_002119.1|

X

X

X

X

PREDICTED: similar to high-mobility group
(nonhistone chromosomal) protein 1-like 10 [Homo
sapiens],PREDICTED: similar to high-mobility
group (nonhistone chromosomal) protein 1-like 10
isoform 2 [Homo sapiens]

gi|113420668|ref|XP_935058.2
|,gi|113421073|ref|XP_944970.
2|,gi|71143137|ref|NP_005333.
2|
gi|169211543|ref|XP_0017261
75.1|,gi|5031863|ref|NP_00555
8.1|

PREDICTED: similar to high-mobility group box 3
[Homo sapiens],high-mobility group box 3 [Homo
sapiens]

gi|113416734|ref|XP_0011310
22.1|,gi|113417218|ref|XP_001
130142.1|,gi|169168235|ref|XP
_001722613.1|

PREDICTED: similar to mCG13783 [Homo
sapiens]

PREDICTED: similar to lectin, galactoside-binding,
soluble, 3 binding protein [Homo sapiens],galectin
3 binding protein [Homo sapiens]

gi|169165045|ref|XP_0017261
02.1|,gi|169165350|ref|XP_001
X 722030.1|,gi|88969090|ref|XP_
946711.1|

PREDICTED: similar to peptidyl-Pro cis trans
isomerase [Homo sapiens]

gi|169215435|ref|XP_0017185
59.1|
gi|113413200|ref|XP_934799.2
X |

PREDICTED: similar to peptidylprolyl isomerase Alike [Homo sapiens]
PREDICTED: similar to protein expressed in
prostate, ovary, testis, and placenta 2 [Homo
sapiens]
PREDICTED: similar to prothymosin alpha [Homo
sapiens],PREDICTED: similar to prothymosin alpha
isoform 1 [Homo sapiens],PREDICTED: similar to
prothymosin alpha isoform 2 [Homo sapiens]

X

gi|169204588|ref|XP_0017234
53.1|,gi|89035369|ref|XP_9331
X 68.1|,gi|89036005|ref|XP_9501
71.1|

X

gi|169214627|ref|XP_0017252
25.1|,gi|169214710|ref|XP_001
725248.1|,gi|169214941|ref|XP
_001723663.1|

X

Description

P
C
C

gi|169216167|ref|XP_947703.2
|,gi|169216776|ref|XP_372200.
X
3|,gi|4506407|ref|NP_002873.1
|
gi|113417664|ref|XP_0011278
60.1|,gi|113418285|ref|XP_001
131826.1|,gi|169169852|ref|XP
_001725212.1|

PREDICTED: similar to Putative ubiquitinconjugating enzyme E2 D3-like protein [Homo
sapiens]
PREDICTED: similar to RanBP1 [Homo
sapiens],RAN binding protein 1 [Homo sapiens]

PREDICTED: similar to rCG23287 [Homo sapiens]
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Description

X

gi|169201709|ref|XP_0017201
78.1|,gi|4507217|ref|NP_00312
4.1|,gi|89031548|ref|XP_93254
4.1|,gi|89033521|ref|XP_94320
9.1|

PREDICTED: similar to signal recognition particle
subunit 9 [Homo sapiens],signal recognition particle
9kDa [Homo sapiens]

X

gi|169212783|ref|XP_0017211
75.1|,gi|169212981|ref|XP_001
714051.1|,gi|169213154|ref|XP
_001714036.1|

PREDICTED: similar to small ubiquitin-related
modifier 2 [Homo sapiens]

P
C
C

gi|169218202|ref|XP_0017244
76.1|,gi|48928058|ref|NP_0088
67.2|,gi|50400081|ref|NP_0010
X 02255.1|,gi|54792069|ref|NP_0
08868.3|,gi|54792071|ref|NP_0
01005849.1|

PREDICTED: similar to SMT3B protein [Homo
sapiens],small ubiquitin-like modifier protein 3
[Homo sapiens],SMT3 suppressor of mif two 3
homolog 4 [Homo sapiens],SMT3 suppressor of mif
two 3 homolog 2 isoform a precursor [Homo
sapiens]

X

gi|169166302|ref|XP_0017177
66.1|,gi|169166810|ref|XP_001
X 716969.1|,gi|169167074|ref|XP
_001717770.1|

PREDICTED: similar to template acyivating factor-I
alpha [Homo sapiens]

PREDICTED: similar to translatinally-controlled
tumor protein [Homo sapiens]

X

gi|169178083|ref|XP_0017173
02.1|,gi|169179309|ref|XP_001
718968.1|,gi|169181065|ref|XP
_001725799.1|,gi|4507669|ref|
NP_003286.1|,gi|46409468|ref|
NP_997305.1|
gi|169184561|ref|XP_0017233
99.1|,gi|169184563|ref|XP_001
723402.1|,gi|4506723|ref|NP_0
00997.1|,gi|51467774|ref|XP_4
X 95839.1|,gi|89031528|ref|XP_9
31621.1|,gi|89033497|ref|XP_9
48264.1|,gi|89033501|ref|XP_9
42162.1|

PREDICTED: similar to v-fos transformation
effector protein isoform 1 [Homo
sapiens],PREDICTED: similar to v-fos
transformation effector protein isoform 2 [Homo
sapiens],ribosomal protein S3a [Homo sapiens]

X
X

X

gi|169184680|ref|XP_0017143
51.1|,gi|169194808|ref|XP_001
124974.2|,gi|169194816|ref|XP
_001719067.1|
gi|12408675|ref|NP_036526.2|
X gi|4506355|ref|NP_002855.1|
gi|33636742|ref|NP_891988.1|,
gi|62739166|ref|NP_000926.2|

PREDICTED: WDFY family member 4 [Homo
sapiens],PREDICTED: similar to hCG1745555
[Homo sapiens]
prefoldin subunit 2 [Homo sapiens]
pregnancy-zone protein [Homo sapiens]
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2
isoform a precursor [Homo sapiens],procollagenlysine, 2-oxoglutarate 5-dioxygenase 2 isoform b
precursor [Homo sapiens]
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gi|4505891|ref|NP_001075.1|

procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3
precursor [Homo sapiens]
profilin 1 [Homo sapiens]
programmed cell death 5 [Homo sapiens]
programmed cell death 6 interacting protein [Homo
sapiens]
programmed cell death 8 isoform 2 [Homo
sapiens],programmed cell death 8 isoform 3 [Homo
sapiens],programmed cell death 8 isoform 1 [Homo
sapiens]
proliferating cell nuclear antigen [Homo sapiens]

P
C
C

X gi|4826898|ref|NP_005013.1|
X gi|4759224|ref|NP_004699.1|
gi|22027538|ref|NP_037506.2|
X
gi|22202629|ref|NP_665811.1|,
gi|22202631|ref|NP_665812.1|,
X
gi|4757732|ref|NP_004199.1|

X
X

gi|33239451|ref|NP_872590.1|,
X gi|4505641|ref|NP_002583.1|
gi|20070125|ref|NP_000909.2|
X
gi|117306169|ref|NP_955450.2
X |,gi|4826940|ref|NP_005031.1|
X

gi|31317307|ref|NP_777596.2|

X

X
X

X
X
X

gi|110224476|ref|NP_0010359
30.1|,gi|110224479|ref|NP_001
X 035931.1|,gi|11386147|ref|NP_
002769.1|
X gi|4505621|ref|NP_002558.1|
gi|6005882|ref|NP_009104.1|
gi|24430160|ref|NP_002797.2|
gi|25777602|ref|NP_002799.3|
X
gi|18543329|ref|NP_002804.2|

X
X
X

gi|7019519|ref|NP_037403.1|

X

gi|5453990|ref|NP_006254.1|
gi|30581141|ref|NP_788955.1|

X

X gi|30410792|ref|NP_002809.2|
gi|30410794|ref|NP_005780.2|,
gi|30410796|ref|NP_789839.1|

X

gi|23110935|ref|NP_683877.1|,
X gi|4506179|ref|NP_002777.1|

X

X gi|4506181|ref|NP_002778.1|

X

prolyl 4-hydroxylase, beta subunit precursor [Homo
sapiens]
prolylcarboxypeptidase isoform 2 preproprotein
[Homo sapiens],prolylcarboxypeptidase isoform 1
preproprotein [Homo sapiens]
proprotein convertase subtilisin/kexin type 1
inhibitor precursor [Homo sapiens]
proprotein convertase subtilisin/kexin type 9
preproprotein [Homo sapiens]
prosaposin isoform b preproprotein [Homo
sapiens],prosaposin isoform c preproprotein [Homo
sapiens],prosaposin isoform a preproprotein [Homo
sapiens]
prostatic binding protein [Homo sapiens]
protease, serine, 23 precursor [Homo sapiens]
proteasome 26S ATPase subunit 6 [Homo sapiens]
proteasome 26S non-ATPase subunit 2 [Homo
sapiens]
proteasome 26S non-ATPase subunit 9 [Homo
sapiens]
proteasome activator subunit 1 isoform 1 [Homo
sapiens]
proteasome activator subunit 1 isoform 2 [Homo
sapiens]
proteasome activator subunit 2 [Homo sapiens]
proteasome activator subunit 3 isoform 1 [Homo
sapiens],proteasome activator subunit 3 isoform 2
[Homo sapiens]
proteasome alpha 1 subunit isoform 1 [Homo
sapiens],proteasome alpha 1 subunit isoform 2
[Homo sapiens]
proteasome alpha 2 subunit [Homo sapiens]
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gi|23110939|ref|NP_687033.1|,
X gi|4506183|ref|NP_002779.1|
gi|156713442|ref|NP_0010961
X 37.1|,gi|4506185|ref|NP_00278
0.1|

proteasome alpha 3 subunit isoform 2 [Homo
sapiens],proteasome alpha 3 subunit isoform 1
[Homo sapiens]
proteasome alpha 4 subunit isoform 1 [Homo
sapiens]

X gi|23110942|ref|NP_002781.2|
X gi|23110944|ref|NP_002782.1|
X gi|4506189|ref|NP_002783.1|
gi|68303561|ref|NP_653263.2|,
gi|68303563|ref|NP_00102026
7.1|,gi|68303565|ref|NP_00102
0268.1|

proteasome alpha 5 subunit [Homo sapiens]
proteasome alpha 6 subunit [Homo sapiens]
proteasome alpha 7 subunit [Homo sapiens]
proteasome (prosome, macropain) subunit, alpha
type, 8 isoform 1 [Homo sapiens],proteasome
(prosome, macropain) subunit, alpha type, 8
isoform 2 [Homo sapiens]

X gi|4506193|ref|NP_002784.1|
gi|4506195|ref|NP_002785.1|
X gi|22538465|ref|NP_002786.2|
X gi|22538467|ref|NP_002787.2|
X gi|4506201|ref|NP_002788.1|
X gi|23110925|ref|NP_002789.1|
gi|4506203|ref|NP_002790.1|
X

proteasome beta 1 subunit [Homo sapiens]
proteasome beta 2 subunit [Homo sapiens]
proteasome beta 3 subunit [Homo sapiens]
proteasome beta 4 subunit [Homo sapiens]
proteasome beta 5 subunit [Homo sapiens]
proteasome beta 6 subunit [Homo sapiens]
proteasome beta 7 subunit proprotein [Homo
sapiens]
protein (peptidyl-prolyl cis/trans isomerase) NIMAinteracting, 4 (parvulin) [Homo sapiens]
protein disulfide isomerase-associated 3 precursor
[Homo sapiens]
protein disulfide isomerase-associated 4 [Homo
sapiens]
protein disulfide isomerase-associated 6 [Homo
sapiens]
protein kinase C substrate 80K-H isoform 1 [Homo
sapiens],protein kinase C substrate 80K-H isoform
2 [Homo sapiens]

gi|38679892|ref|NP_006214.2|

X
X

Description

P
C
C

X
X

gi|21361657|ref|NP_005304.3|
gi|4758304|ref|NP_004902.1|
gi|5031973|ref|NP_005733.1|

X

X

X

gi|48255889|ref|NP_002734.2|,
X gi|48255891|ref|NP_00100132
9.1|

X

gi|4506003|ref|NP_002699.1|,g
i|4506005|ref|NP_002700.1|,gi|
4506007|ref|NP_002701.1|,gi|4
X 5827798|ref|NP_996756.1|,gi|4
6249376|ref|NP_996759.1|,gi|5
6790945|ref|NP_001008709.1|

protein phosphatase 1, catalytic subunit, alpha
isoform 1 [Homo sapiens],protein phosphatase 1,
catalytic subunit, beta isoform 1 [Homo
sapiens],protein phosphatase 1, catalytic subunit,
gamma isoform [Homo sapiens]

gi|29826282|ref|NP_817092.1|,
gi|4505999|ref|NP_002698.1|
gi|4506017|ref|NP_002706.1|,g
i|4758952|ref|NP_004147.1|,gi|
X
57222565|ref|NP_001009552.
1|

protein phosphatase 1G [Homo sapiens]

X

protein phosphatase 2, catalytic subunit, alpha
isoform [Homo sapiens],protein phosphatase 2,
catalytic subunit, beta isoform [Homo sapiens]
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S
C

c
a
P
S
C

X
X

X

Protein

gi|29725611|ref|NP_066954.2|,
X gi|30065643|ref|NP_821067.1|,
gi|30065645|ref|NP_821068.1|

protein phosphatase 2A, regulatory subunit B'
isoform b [Homo sapiens],protein phosphatase 2A,
regulatory subunit B' isoform a [Homo sapiens]

gi|4506117|ref|NP_000304.1|
gi|109633039|ref|NP_569707.2
|,gi|109633041|ref|NP_002831.
X
2|

protein S, alpha [Homo sapiens]
protein tyrosine phosphatase, receptor type, F
isoform 2 precursor [Homo sapiens],protein
tyrosine phosphatase, receptor type, F isoform 1
precursor [Homo sapiens]
protein-L-isoaspartate (D-aspartate) Omethyltransferase [Homo sapiens]
prothymosin, alpha isoform 2 [Homo
sapiens],prothymosin, alpha isoform 1 [Homo
sapiens]

X

gi|4885539|ref|NP_005380.1|
gi|151101404|ref|NP_002814.3
|,gi|151101407|ref|NP_001092
755.1|

X

gi|9256608|ref|NP_061757.1|
gi|4557831|ref|NP_000272.1|

X
X

X

X
X
X
X
X
X
X
X
X

X

X
X

Description

P
C
C

gi|15826840|ref|NP_002812.2|,
gi|22902126|ref|NP_690619.1|,
gi|22902128|ref|NP_690620.1|,
gi|22902130|ref|NP_690621.1|

X gi|4505701|ref|NP_003672.1|
X gi|11056044|ref|NP_066952.1|
X gi|33286418|ref|NP_002645.3|
gi|33286420|ref|NP_872270.1|,
gi|33286422|ref|NP_872271.1|
gi|13325075|ref|NP_002817.2|
gi|51873067|ref|NP_00100412
X 8.1|
gi|4506467|ref|NP_002897.1|
gi|24797086|ref|NP_002262.3|
gi|45331213|ref|NP_036548.1|
gi|38327552|ref|NP_938405.1|,
X gi|5031703|ref|NP_005745.1|
gi|38505165|ref|NP_942126.1|,
gi|9845509|ref|NP_061485.1|,g
i|9845511|ref|NP_008839.2|

X gi|5453555|ref|NP_006316.1|
gi|29789090|ref|NP_061185.1|
X

protocadherin beta 14 precursor [Homo sapiens]
pterin-4 alpha-carbinolamine
dehydratase/dimerization cofactor of hepatocyte
nuclear factor 1 alpha precursor [Homo sapiens]
PTK7 protein tyrosine kinase 7 isoform a precursor
[Homo sapiens],PTK7 protein tyrosine kinase 7
isoform b precursor [Homo sapiens],PTK7 protein
tyrosine kinase 7 isoform c precursor [Homo
sapiens],PTK7 protein tyrosine kinase 7 isoform d
precursor [Homo
pyridoxal kinase [Homo sapiens]
pyrophosphatase 1 [Homo sapiens]
pyruvate kinase, muscle isoform 1 [Homo sapiens]
pyruvate kinase, muscle isoform 2 [Homo sapiens]
quiescin Q6 sulfhydryl oxidase 1 isoform a [Homo
sapiens]
quiescin Q6 sulfhydryl oxidase 1 isoform b [Homo
sapiens]
radixin [Homo sapiens]
RAN binding protein 5 [Homo sapiens]
RAN binding protein 6 [Homo sapiens]
Ras-GTPase-activating protein SH3-domainbinding protein [Homo sapiens]
ras-related C3 botulinum toxin substrate 1 isoform
Rac1c [Homo sapiens],ras-related C3 botulinum
toxin substrate 1 isoform Rac1b [Homo
sapiens],ras-related C3 botulinum toxin substrate 1
isoform Rac1 [Homo sapiens]
ras-related nuclear protein [Homo sapiens]
regulator of chromosome condensation 2 [Homo
sapiens]
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q
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S
C

c
a
P
S
C
X
X
X
X
X
X

Protein

gi|4506583|ref|NP_002936.1|
gi|4506587|ref|NP_002938.1|
X gi|4506455|ref|NP_002892.1|
gi|4506439|ref|NP_002884.1|
gi|5032027|ref|NP_005601.1|
gi|4757768|ref|NP_004300.1|
X
gi|58761492|ref|NP_060595.3|,
gi|74136547|ref|NP_00101172
2.2|

X

X

X gi|5231228|ref|NP_003721.2|
gi|21361547|ref|NP_002930.2|,
gi|42794608|ref|NP_976318.1|,
gi|42822864|ref|NP_976322.1|,
gi|42822866|ref|NP_976323.1|,
X gi|42822868|ref|NP_976321.1|,
gi|42822870|ref|NP_976320.1|,
gi|42822872|ref|NP_976317.1|,
gi|42822874|ref|NP_976319.1|
X

X
X

X

X

X

X
X

X
X
X

X
X
X

Description

P
C
C

gi|118498359|ref|NP_056474.2
|
gi|15431288|ref|NP_009035.3|
gi|4506597|ref|NP_000967.1|
gi|16933546|ref|NP_444505.1|,
gi|4506667|ref|NP_000993.1|
gi|4506671|ref|NP_000995.1|
gi|14277700|ref|NP_001007.2|
gi|5032051|ref|NP_005608.1|,g
i|68160915|ref|NP_001020241.
1|,gi|68160922|ref|NP_001020
242.1|

replication protein A1, 70kDa [Homo sapiens]
replication protein A3, 14kDa [Homo sapiens]
reticulocalbin 1 precursor [Homo sapiens]
retinoblastoma binding protein 7 [Homo sapiens]
retinoblastoma binding protein 4 [Homo sapiens]
Rho GDP dissociation inhibitor (GDI) alpha [Homo
sapiens]
Rho guanine nucleotide exchange factor (GEF) 10like isoform 1 [Homo sapiens],Rho guanine
nucleotide exchange factor (GEF) 10-like isoform 2
[Homo sapiens]
ribonuclease T2 precursor [Homo sapiens]
ribonuclease/angiogenin inhibitor [Homo sapiens]

ribosomal L1 domain containing 1 [Homo sapiens]
ribosomal protein L10a [Homo sapiens]
ribosomal protein L12 [Homo sapiens]
ribosomal protein P0 [Homo sapiens]
ribosomal protein P2 [Homo sapiens]
ribosomal protein S12 [Homo sapiens]
ribosomal protein S14 [Homo sapiens]

X gi|4506691|ref|NP_001011.1|
gi|11968182|ref|NP_072045.1|,
X gi|169168597|ref|XP_0017137
10.1|

ribosomal protein S16 [Homo sapiens]
ribosomal protein S18 [Homo sapiens]

gi|4506695|ref|NP_001013.1|
gi|4506697|ref|NP_001014.1|
gi|4506699|ref|NP_001015.1|
gi|15718687|ref|NP_000996.2|
gi|13904870|ref|NP_001000.2|
X gi|17158044|ref|NP_001001.2|
X gi|4506741|ref|NP_001002.1|

ribosomal protein S19 [Homo sapiens]
ribosomal protein S20 [Homo sapiens]
ribosomal protein S21 [Homo sapiens]
ribosomal protein S3 [Homo sapiens]
ribosomal protein S5 [Homo sapiens]
ribosomal protein S6 [Homo sapiens]
ribosomal protein S7 [Homo sapiens]

X
X
X
X
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Protein

gi|59859885|ref|NP_00101232
X 1.1|,gi|9845502|ref|NP_002286
.2|
X
X
X

X
X

X
X
X
X
X

X

X

X

X

X
X
X

X

X

X

X

gi|5803137|ref|NP_006734.1|
gi|4826972|ref|NP_005096.1|
gi|56699409|ref|NP_002130.2|
gi|4506753|ref|NP_003698.1|
gi|5730023|ref|NP_006657.1|
gi|39841073|ref|NP_060549.3|
gi|5032057|ref|NP_005611.1|
gi|4506765|ref|NP_002952.1|,g
i|9845516|ref|NP_062427.1|
gi|7657532|ref|NP_055439.1|
gi|9951915|ref|NP_000678.1|

X gi|62243484|ref|NP_996769.2|
gi|38202214|ref|NP_006355.2|
gi|56117838|ref|NP_003003.3|
gi|11545873|ref|NP_071420.1|,
gi|78190498|ref|NP_00103002
4.1|
gi|4507171|ref|NP_003109.1|

X
X

Description

P
C
C

X gi|68160947|ref|NP_003460.2|
gi|24797148|ref|NP_036379.2|
X gi|5174673|ref|NP_006071.1|
gi|8922712|ref|NP_060713.1|
gi|4758158|ref|NP_004395.1|,g
i|56549636|ref|NP_001008491.
1|,gi|56549638|ref|NP_001008
492.1|,gi|56549640|ref|NP_006
146.1|
gi|116256489|ref|NP_006631.2
|
X gi|45935371|ref|NP_002718.2|
gi|50363217|ref|NP_000286.3|,
gi|50363219|ref|NP_00100223
X 6.1|,gi|50363221|ref|NP_00100
2235.1|

X

X

X

X

gi|13489087|ref|NP_109591.1|
gi|41152086|ref|NP_004559.4|

ribosomal protein SA [Homo sapiens]

RNA binding motif protein 3 [Homo sapiens]
RNA binding motif protein 8A [Homo sapiens]
RNA binding motif protein, X-linked [Homo sapiens]
RuvB-like 1 [Homo sapiens]
RuvB-like 2 [Homo sapiens]
S1 RNA binding domain 1 [Homo sapiens]
S100 calcium binding protein A11 [Homo sapiens]
S100 calcium-binding protein A4 [Homo sapiens]
S100 calcium-binding protein A6 [Homo sapiens]
S-adenosylhomocysteine hydrolase [Homo
sapiens]
sarcoma antigen NY-SAR-41 [Homo sapiens]
SEC23-related protein A [Homo sapiens]
secreted frizzled-related protein 1 [Homo sapiens]
secreted modular calcium-binding protein 1 isoform
2 [Homo sapiens],secreted modular calciumbinding protein 1 isoform 1 [Homo sapiens]
secreted protein, acidic, cysteine-rich [Homo
sapiens]
secretogranin II precursor [Homo sapiens]
selenophosphate synthetase 1 [Homo sapiens]
semaphorin 3A precursor [Homo sapiens]
septin 11 [Homo sapiens]
septin 2 [Homo sapiens]

septin 9 isoform c [Homo sapiens]
serglycin precursor [Homo sapiens]
serine (or cysteine) proteinase inhibitor, clade A
(alpha-1 antiproteinase, antitrypsin), member 1
[Homo sapiens]
serine (or cysteine) proteinase inhibitor, clade B
(ovalbumin), member 1 [Homo sapiens]
serine (or cysteine) proteinase inhibitor, clade B
(ovalbumin), member 6 [Homo sapiens]
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Protein

Description

gi|4758906|ref|NP_004146.1|

serine (or cysteine) proteinase inhibitor, clade B
(ovalbumin), member 9 [Homo sapiens]
serine (or cysteine) proteinase inhibitor, clade F
(alpha-2 antiplasmin, pigment epithelium derived
factor), member 1 [Homo sapiens]
serine (or cysteine) proteinase inhibitor, clade H,
member 1 precursor [Homo sapiens]
serine/threonine kinase receptor associated protein
[Homo sapiens]
serpin peptidase inhibitor, clade A, member 3
precursor [Homo sapiens]
serpin peptidase inhibitor, clade I (pancpin),
member 2 [Homo sapiens]
SERPINE1 mRNA binding protein 1 isoform 1
[Homo sapiens],SERPINE1 mRNA binding protein
1 isoform 2 [Homo sapiens],SERPINE1 mRNA
binding protein 1 isoform 3 [Homo
sapiens],SERPINE1 mRNA binding protein 1
isoform 4 [Homo sapiens]
SET translocation (myeloid leukemia-associated)
[Homo sapiens]
SH3 domain binding glutamic acid-rich protein like
[Homo sapiens]
SH3 domain binding glutamic acid-rich protein like
3 [Homo sapiens]
Shwachman-Bodian-Diamond syndrome protein
[Homo sapiens]
similar to 40S ribosomal protein S17 [Homo
sapiens],ribosomal protein S17 [Homo sapiens]

P
C
C
X

gi|39725934|ref|NP_002606.3|
X
X
X
X
X

X

X

X

X

X
X

X

gi|32454741|ref|NP_001226.2|
gi|148727341|ref|NP_009109.3
|
gi|50659080|ref|NP_001076.2|
gi|5453886|ref|NP_006208.1|

gi|66346679|ref|NP_00101807
7.1|,gi|66346681|ref|NP_00101
8078.1|,gi|66346683|ref|NP_00
X
1018079.1|,gi|66346685|ref|NP
_056455.3|
X

gi|4506891|ref|NP_003002.1|
gi|4506925|ref|NP_003013.1|

X
X

gi|13775198|ref|NP_112576.1|
gi|28416940|ref|NP_057122.2|

gi|122937438|ref|NP_0010739
X 68.1|,gi|4506693|ref|NP_00101
2.1|
gi|7657234|ref|NP_055082.1|
gi|45006986|ref|NP_004748.2|

X
X
X

X

gi|4759156|ref|NP_004587.1|

X
X
X

gi|5902102|ref|NP_008869.1|

X

gi|4759160|ref|NP_004166.1|
gi|4507129|ref|NP_003085.1|

small acidic protein [Homo sapiens]
small inducible cytokine subfamily E, member 1
[Homo sapiens]
small nuclear ribonucleoprotein D1 polypeptide
16kDa [Homo sapiens]
small nuclear ribonucleoprotein polypeptide A
[Homo sapiens]
small nuclear ribonucleoprotein polypeptide D3
[Homo sapiens]
small nuclear ribonucleoprotein polypeptide E
[Homo sapiens]
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Description

small nuclear ribonucleoprotein polypeptide N
[Homo sapiens]

X

gi|13027644|ref|NP_073716.1|,
gi|13027646|ref|NP_073717.1|,
gi|13027648|ref|NP_073718.1|,
gi|13027650|ref|NP_073719.1|,
gi|38150007|ref|NP_937859.1|,
gi|4507125|ref|NP_003082.1|,g
i|4507135|ref|NP_003088.1|

X

gi|4507801|ref|NP_003343.1|,g
X i|54792065|ref|NP_001005781.
1|

SMT3 suppressor of mif two 3 homolog 1 isoform a
precursor [Homo sapiens]

gi|54792069|ref|NP_008868.3|,
gi|54792071|ref|NP_00100584
X
9.1|

SMT3 suppressor of mif two 3 homolog 2 isoform a
precursor [Homo sapiens],SMT3 suppressor of mif
two 3 homolog 2 isoform b precursor [Homo
sapiens]
solute carrier family 39 (zinc transporter), member
10 [Homo sapiens]
solute carrier family 9 (sodium/hydrogen
exchanger), isoform 3 regulator 1 [Homo sapiens]
sorbitol dehydrogenase [Homo sapiens]

P
C
C

X

gi|4759140|ref|NP_004243.1|

X
X
X
X
X
X
X
X

X
X
X
X
X

gi|55741750|ref|NP_065075.1|

gi|156627571|ref|NP_003095.2
|
gi|4759164|ref|NP_004589.1|

gi|154759259|ref|NP_003118.2
|
gi|112382250|ref|NP_003119.2
|
gi|112382252|ref|NP_842565.2
|
X gi|63253298|ref|NP_003123.2|
X gi|21264341|ref|NP_004586.2|
gi|25777711|ref|NP_008861.2|,
X gi|25777713|ref|NP_733779.1|
gi|42544123|ref|NP_973727.1|,
gi|42544125|ref|NP_973724.1|,
gi|42544130|ref|NP_004621.2|
gi|55749531|ref|NP_006833.2|
gi|54112117|ref|NP_036565.2|
X gi|54112121|ref|NP_036558.3|
gi|4826998|ref|NP_005057.1|
X

sparc/osteonectin, cwcv and kazal-like domains
proteoglycan 1 precursor [Homo sapiens]
spectrin, alpha, non-erythrocytic 1 (alpha-fodrin)
[Homo sapiens]
spectrin, beta, non-erythrocytic 1 isoform 1 [Homo
sapiens]
spectrin, beta, non-erythrocytic 1 isoform 2 [Homo
sapiens]
spermidine synthase [Homo sapiens]
spermine synthase [Homo sapiens]
S-phase kinase-associated protein 1 isoform a
[Homo sapiens],S-phase kinase-associated protein
1 isoform b [Homo sapiens]
splicing factor 1 isoform 3 [Homo sapiens],splicing
factor 1 isoform 2 [Homo sapiens],splicing factor 1
isoform 1 [Homo sapiens]
splicing factor 3B subunit 2 [Homo sapiens]
splicing factor 3b, subunit 1 isoform 1 [Homo
sapiens]
splicing factor 3b, subunit 3 [Homo sapiens]
splicing factor proline/glutamine rich
(polypyrimidine tract binding protein associated)
[Homo sapiens]
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Protein

gi|118582269|ref|NP_0010716
X 34.1|
gi|47271443|ref|NP_003007.2|

X

gi|32698750|ref|NP_067051.1|

X
X
X
X
X
X
X
X
X
X

gi|4507267|ref|NP_003705.1|
gi|77404397|ref|NP_055205.2|

gi|44890050|ref|NP_981944.1|,
X gi|44890052|ref|NP_981946.1|,
gi|5031851|ref|NP_005554.1|
gi|4506803|ref|NP_002966.1|
gi|41152074|ref|NP_955805.1|,
gi|41152076|ref|NP_955806.1|
X gi|5454052|ref|NP_006133.1|
gi|5803181|ref|NP_006810.1|
X
gi|18699732|ref|NP_057260.2|,
X gi|7706573|ref|NP_057631.1|
gi|4507241|ref|NP_003137.1|
gi|4885649|ref|NP_005490.1|

X

gi|34850061|ref|NP_008960.2|

X

X

X

X

X

X gi|4507149|ref|NP_000445.1|
gi|21237805|ref|NP_003066.2|,
gi|21237808|ref|NP_620706.1|

X

X

X

gi|23397427|ref|NP_006363.3|

gi|29568086|ref|NP_002988.3|,
X gi|55749480|ref|NP_00100694
7.1|
X
X
X

X
X

Description

P
C
C
splicing factor, arginine/serine-rich 1 isoform 2
[Homo sapiens],splicing factor, arginine/serine-rich
1 isoform 1 [Homo sapiens]
splicing factor, arginine/serine-rich 2 [Homo
sapiens]
SR-related CTD-associated factor 1 [Homo
sapiens]
stanniocalcin 2 precursor [Homo sapiens]
staphylococcal nuclease domain containing 1
[Homo sapiens]
stathmin 1 [Homo sapiens]

stem cell growth factor precursor [Homo sapiens]
steroid-sensitive protein 1 [Homo sapiens]
stratifin [Homo sapiens]
stress-induced-phosphoprotein 1 (Hsp70/Hsp90organizing protein) [Homo sapiens]
stromal cell derived factor 4 precursor [Homo
sapiens]
structure specific recognition protein 1 [Homo
sapiens]
SUMO-1 activating enzyme subunit 2 [Homo
sapiens]
superiorcervical ganglia, neural specific 10 [Homo
sapiens]
superoxide dismutase 1, soluble [Homo sapiens]
SWI/SNF-related matrix-associated actindependent regulator of chromatin c2 isoform a
[Homo sapiens],SWI/SNF-related matrixassociated actin-dependent regulator of chromatin
c2 isoform b [Homo sapiens]
synaptotagmin binding, cytoplasmic RNA
interacting protein [Homo sapiens]
syndecan 1 precursor [Homo sapiens]

X gi|38201675|ref|NP_002990.2|
gi|55749490|ref|NP_00100706
8.1|,gi|55749504|ref|NP_00100
7069.1|,gi|56243522|ref|NP_00
5616.2|

syndecan 4 precursor [Homo sapiens]
syntenin isoform 1 [Homo sapiens],syntenin
isoform 2 [Homo sapiens]

X gi|16753233|ref|NP_006280.2|
X gi|57863257|ref|NP_110379.2|

talin 1 [Homo sapiens]
T-complex protein 1 isoform a [Homo sapiens]
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X
X
X

X

X
X
X
X
X
X

X

X
X

gi|4507491|ref|NP_003240.1|
X gi|50592994|ref|NP_003320.2|
gi|52487191|ref|NP_055866.1|
X gi|5453549|ref|NP_006397.1|
gi|148277065|ref|NP_003321.3
|,gi|148277071|ref|NP_001087
240.1|,gi|33519426|ref|NP_877
X 393.1|,gi|33519428|ref|NP_877
419.1|,gi|33519430|ref|NP_877
420.1|

gi|11056061|ref|NP_066932.1|,
X gi|34013530|ref|NP_898870.1|
gi|4507511|ref|NP_003246.1|
X

thymosin, beta 4 [Homo sapiens],thymosin-like 3
[Homo sapiens]
TIMP metallopeptidase inhibitor 2 precursor [Homo
sapiens]
TIP120 protein [Homo sapiens]
tissue factor pathway inhibitor isoform a precursor
[Homo sapiens]
tissue inhibitor of metalloproteinase 1 precursor
[Homo sapiens]
TNF receptor-associated protein 1 [Homo sapiens]

X

X

X

X

X

X
X
X

thimet oligopeptidase 1 [Homo sapiens]
thioredoxin [Homo sapiens]
thioredoxin domain containing 4 (endoplasmic
reticulum) [Homo sapiens]
thioredoxin peroxidase [Homo sapiens]
thioredoxin reductase 1 isoform 1 [Homo
sapiens],thioredoxin reductase 1 isoform 3 [Homo
sapiens],thioredoxin reductase 1 isoform 2 [Homo
sapiens],thioredoxin reductase 1 isoform 2 [Homo
sapiens]
thioredoxin-like 1 [Homo sapiens]
thioredoxin-like 5 [Homo sapiens]
THO complex 4 [Homo sapiens]
threonyl-tRNA synthetase [Homo sapiens]
thrombospondin 1 precursor [Homo sapiens]
thymopoietin isoform alpha [Homo
sapiens],thymopoietin isoform gamma [Homo
sapiens],thymopoietin isoform beta [Homo sapiens]

X

X

Description

X gi|4759274|ref|NP_004777.1|
gi|14249348|ref|NP_116120.1|
gi|55770864|ref|NP_005773.2|
X gi|38202255|ref|NP_689508.3|
gi|40317626|ref|NP_003237.2|
gi|4507555|ref|NP_003267.1|,g
i|73760401|ref|NP_001027455.
1|,gi|73760405|ref|NP_001027
454.1|

X gi|21361794|ref|NP_060918.2|
gi|5454114|ref|NP_006278.1|
X

X

X

Protein
P
C
C

gi|4507509|ref|NP_003245.1|

gi|155722983|ref|NP_057376.2
|
X gi|5803187|ref|NP_006746.1|
gi|45439355|ref|NP_958845.1|,
gi|5803191|ref|NP_006747.1|
X gi|4557871|ref|NP_001054.1|
X gi|4507457|ref|NP_003225.1|
gi|63025222|ref|NP_000651.3|
gi|4507467|ref|NP_000349.1|
X
X gi|4507357|ref|NP_003555.1|
gi|39777597|ref|NP_004604.2|,
X gi|39777599|ref|NP_945189.1|

transaldolase 1 [Homo sapiens]
transcription elongation factor A 1 isoform 2 [Homo
sapiens],transcription elongation factor A 1 isoform
1 [Homo sapiens]
transferrin [Homo sapiens]
transferrin receptor [Homo sapiens]
transforming growth factor, beta 1 [Homo sapiens]
transforming growth factor, beta-induced, 68kDa
[Homo sapiens]
transgelin 2 [Homo sapiens]
transglutaminase 2 isoform a [Homo
sapiens],transglutaminase 2 isoform b [Homo
sapiens]
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q
P
S
C
X

c
a
P
S
C
X
X
X

X

Protein

gi|42518068|ref|NP_006455.2|
X gi|4507521|ref|NP_001055.1|
gi|4759270|ref|NP_004613.1|
X gi|5174731|ref|NP_005990.1|
gi|57164975|ref|NP_000347.2|,
gi|57164977|ref|NP_00100865
6.1|,gi|57164979|ref|NP_00100
8657.1|
gi|148491080|ref|NP_055903.2
|
X gi|4507645|ref|NP_000356.1|
gi|5032179|ref|NP_005753.1|
X

X

X
X

X

gi|5729770|ref|NP_000382.3|

trans-golgi network protein 2 [Homo sapiens]
transketolase [Homo sapiens]
translin [Homo sapiens]
translin-associated factor X [Homo sapiens]
Treacher Collins-Franceschetti syndrome 1 isoform
b [Homo sapiens],Treacher Collins-Franceschetti
syndrome 1 isoform a [Homo sapiens],Treacher
Collins-Franceschetti syndrome 1 isoform c [Homo
sapiens]
trinucleotide repeat containing 6B isoform 1 [Homo
sapiens]
triosephosphate isomerase 1 [Homo sapiens]
tripartite motif-containing 28 protein [Homo
sapiens]
tripeptidyl-peptidase I preproprotein [Homo
sapiens]
TRK-fused [Homo sapiens],TRK-fused [Homo
sapiens]

X

gi|21361320|ref|NP_006061.2|,
gi|56090139|ref|NP_00100756
6.1|

X

gi|63252896|ref|NP_00101800
4.1|,gi|63252900|ref|NP_00101
8006.1|

tropomyosin 1 alpha chain isoform 3 [Homo
sapiens],tropomyosin 1 alpha chain isoform 4
[Homo sapiens]

gi|42476296|ref|NP_003280.2|,
gi|47519616|ref|NP_998839.1|

tropomyosin 2 (beta) isoform 1 [Homo
sapiens],tropomyosin 2 (beta) isoform 2 [Homo
sapiens]
tropomyosin 3 isoform 4 [Homo
sapiens],tropomyosin 3 isoform 2 [Homo sapiens]

X

X
X

Description

P
C
C

X
X

X
X
X
X
X
X

gi|114155144|ref|NP_0010368
X 16.1|,gi|24119203|ref|NP_7059
35.1|
X gi|4507651|ref|NP_003281.1|
gi|47419914|ref|NP_004175.2|,
gi|47419916|ref|NP_776049.1|,
X gi|47419918|ref|NP_998810.1|,
gi|47419920|ref|NP_998811.1|

tropomyosin 4 [Homo sapiens]
tryptophanyl-tRNA synthetase isoform a [Homo
sapiens],tryptophanyl-tRNA synthetase isoform b
[Homo sapiens]

X gi|14389309|ref|NP_116093.1|
gi|17986283|ref|NP_006000.2|
X gi|57013276|ref|NP_006073.2|
X gi|29788785|ref|NP_821133.1|
X gi|14210536|ref|NP_115914.1|
X gi|5174735|ref|NP_006079.1|
X gi|4759212|ref|NP_004598.1|
gi|14790170|ref|NP_116563.1|,
X gi|4507585|ref|NP_003814.1|

tubulin alpha 6 [Homo sapiens]
tubulin, alpha 1a [Homo sapiens]
tubulin, alpha, ubiquitous [Homo sapiens]
tubulin, beta [Homo sapiens]
tubulin, beta 6 [Homo sapiens]
tubulin, beta, 2 [Homo sapiens]
tubulin-specific chaperone a [Homo sapiens]
tumor necrosis factor receptor superfamily,
member 6b [Homo sapiens]
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q
P
S
C

c
a
P
S
C

Protein

gi|40805860|ref|NP_003279.2|,
gi|40805862|ref|NP_955391.1|,
gi|40805864|ref|NP_955392.1|,
X gi|40805866|ref|NP_955393.1|,
gi|40805868|ref|NP_955394.1|,
gi|40805870|ref|NP_955395.1|
X

X

X

gi|22538444|ref|NP_004872.2|,
gi|22538446|ref|NP_671713.1|
gi|4507669|ref|NP_003286.1|

X

X

X
X
X

X gi|4507677|ref|NP_003290.1|
gi|6005846|ref|NP_009215.1|
gi|5803225|ref|NP_006752.1|
X

X

X

X

X

gi|4507951|ref|NP_003396.1|
gi|5803227|ref|NP_006817.1|

X

gi|21735625|ref|NP_663723.1|,
X gi|4507953|ref|NP_003397.1|
gi|21328448|ref|NP_647539.1|,
X gi|4507949|ref|NP_003395.1|

X

X

X

X

X

gi|6005926|ref|NP_009210.1|,g
X i|60279268|ref|NP_001012496.
1|

X

gi|21464101|ref|NP_036611.2|

X
X

X

X

X
X

Description

P
C
C

gi|29568103|ref|NP_003080.2|

gi|7706425|ref|NP_057284.1|

gi|16753203|ref|NP_038466.2|
gi|11024714|ref|NP_061828.1|,
gi|4506713|ref|NP_002945.1|,g
i|4507761|ref|NP_003324.1|,gi|
X
67191208|ref|NP_066289.2|,gi|
77539055|ref|NP_001029102.
1|
gi|21361091|ref|NP_004172.2|
gi|29501813|ref|NP_005650.2|

tumor protein D52-like 2 isoform e [Homo
sapiens],tumor protein D52-like 2 isoform f [Homo
sapiens],tumor protein D52-like 2 isoform a [Homo
sapiens],tumor protein D52-like 2 isoform b [Homo
sapiens],tumor protein D52-like 2 isoform c [Homo
sapiens]
tumor protein p53 inducible protein 3 [Homo
sapiens]
tumor protein, translationally-controlled 1 [Homo
sapiens]
tumor rejection antigen (gp96) 1 [Homo sapiens]
twinfilin-like protein [Homo sapiens]
tyrosine 3/tryptophan 5 -monooxygenase activation
protein, epsilon polypeptide [Homo sapiens]
tyrosine 3/tryptophan 5 -monooxygenase activation
protein, eta polypeptide [Homo sapiens]
tyrosine 3/tryptophan 5 -monooxygenase activation
protein, theta polypeptide [Homo sapiens]
tyrosine 3/tryptophan 5 -monooxygenase activation
protein, zeta polypeptide [Homo sapiens]
tyrosine 3-monooxygenase/tryptophan 5monooxygenase activation protein, beta
polypeptide [Homo sapiens]
tyrosine 3-monooxygenase/tryptophan 5monooxygenase activation protein, gamma
polypeptide [Homo sapiens]
U1 small nuclear ribonucleoprotein 70 kDa [Homo
sapiens]
U2 (RNU2) small nuclear RNA auxiliary factor 2
isoform a [Homo sapiens],U2 (RNU2) small nuclear
RNA auxiliary factor 2 isoform b [Homo sapiens]
U6 snRNA-associated Sm-like protein LSm8
[Homo sapiens]
ubiquilin 1 isoform 1 [Homo sapiens]
ubiquitin B precursor [Homo sapiens],ubiquitin and
ribosomal protein S27a precursor [Homo
sapiens],ubiquitin and ribosomal protein L40
precursor [Homo sapiens],ubiquitin C [Homo
sapiens]
ubiquitin carboxyl-terminal esterase L1 [Homo
sapiens]
ubiquitin fusion degradation 1-like isoform A [Homo
sapiens]
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q
P
S
C

c
a
P
S
C
X

X

X

Protein

gi|23510338|ref|NP_003325.2|,
X gi|23510340|ref|NP_695012.1|
gi|40806164|ref|NP_068823.2|,
gi|40806167|ref|NP_954595.1|,
gi|40806190|ref|NP_954673.1|,
X gi|4507795|ref|NP_003340.1|,g
i|73765546|ref|NP_001027459.
1|
X

gi|4507797|ref|NP_003341.1|
gi|4885417|ref|NP_005330.1|

X

X

gi|35493987|ref|NP_919235.1|,
gi|35493996|ref|NP_919236.1|,
X gi|35494003|ref|NP_919237.1|,
gi|4507785|ref|NP_003336.1|

X

X

X

X gi|4507793|ref|NP_003339.1|
gi|13929462|ref|NP_001488.2|

gi|4507789|ref|NP_003338.1|

X
X

X

X

X

X

X

X
X

X

X
X

Description

P
C
C

X

X

gi|5802984|ref|NP_006867.1|
gi|156627575|ref|NP_003106.3
|
gi|23308579|ref|NP_006592.3|
gi|4507835|ref|NP_000364.1|
gi|4505863|ref|NP_002649.1|
gi|71051616|ref|NP_000365.3|
gi|4506387|ref|NP_002865.1|
gi|19913428|ref|NP_001684.2|
gi|17978519|ref|NP_004887.2|

X

X

X

gi|78482614|ref|NP_00103033
X 7.1|
X gi|6005942|ref|NP_009057.1|
gi|4885653|ref|NP_005420.1|
X
X

gi|4507869|ref|NP_003361.1|

ubiquitin-activating enzyme E1 [Homo sapiens]
ubiquitin-conjugating enzyme E2 variant 1 isoform
a [Homo sapiens],ubiquitin-conjugating enzyme E2
Kua-UEV isoform 1 [Homo sapiens],ubiquitinconjugating enzyme E2 Kua-UEV isoform 2 [Homo
sapiens]
ubiquitin-conjugating enzyme E2 variant 2 [Homo
sapiens]
ubiquitin-conjugating enzyme E2-25K isoform 1
[Homo sapiens]
ubiquitin-conjugating enzyme E2I [Homo sapiens]

ubiquitin-conjugating enzyme E2L 3 isoform 1
[Homo sapiens]
ubiquitin-conjugating enzyme E2N [Homo sapiens]
UDP-Gal:betaGlcNAc beta 1,4galactosyltransferase 1, membrane-bound form
[Homo sapiens]
UDP-GlcNAc:betaGal beta-1,3-Nacetylglucosaminyltransferase 1 [Homo sapiens]
UDP-N-acteylglucosamine pyrophosphorylase 1
[Homo sapiens]
unactive progesterone receptor, 23 kD [Homo
sapiens]
uridine monophosphate synthase [Homo sapiens]
urokinase plasminogen activator preproprotein
[Homo sapiens]
uroporphyrinogen decarboxylase [Homo sapiens]
UV excision repair protein RAD23 homolog B
[Homo sapiens]
vacuolar H+ATPase B2 [Homo sapiens]
vacuolar protein sorting 26 A isoform 1 [Homo
sapiens]
vacuolar protein sorting 26 A isoform 2 [Homo
sapiens]
valosin-containing protein [Homo sapiens]
vascular endothelial growth factor C preproprotein
[Homo sapiens]
vasodilator-stimulated phosphoprotein [Homo
sapiens]
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q
P
S
C

c
a
P
S
C
X
X

X

X

X

v-crk sarcoma virus CT10 oncogene homolog
(avian)-like [Homo sapiens]
v-crk sarcoma virus CT10 oncogene homolog
isoform b [Homo sapiens],v-crk sarcoma virus
CT10 oncogene homolog isoform a [Homo sapiens]
versican [Homo sapiens]
vesicle amine transport protein 1 [Homo sapiens]
vesicle-associated membrane protein-associated
protein A isoform 1 [Homo sapiens],vesicleassociated membrane protein-associated protein A
isoform 2 [Homo sapiens]
VGF nerve growth factor inducible precursor [Homo
sapiens]
vimentin [Homo sapiens]
vinculin isoform VCL [Homo sapiens],vinculin
isoform meta-VCL [Homo sapiens]
visfatin precursor [Homo sapiens]
WD repeat-containing protein 1 isoform 1 [Homo
sapiens]
WD repeat-containing protein 1 isoform 2 [Homo
sapiens]
XTP3-transactivated protein A [Homo sapiens]
zinc finger protein 197 isoform 1 [Homo sapiens]
zyxin [Homo sapiens],zyxin [Homo sapiens]

gi|17136078|ref|NP_003369.2|

X gi|62414289|ref|NP_003371.2|
gi|4507877|ref|NP_003364.1|,g
X i|7669550|ref|NP_054706.1|
X gi|5031977|ref|NP_005737.1|
gi|9257257|ref|NP_059830.1|
X
X

X

gi|4885153|ref|NP_005198.1|

gi|21361116|ref|NP_004376.2|
gi|18379349|ref|NP_006364.2|
gi|94721250|ref|NP_003565.4|,
gi|94721252|ref|NP_919415.2|

X

X

Description

gi|41327710|ref|NP_005197.3|,
X gi|41327712|ref|NP_058431.2|

X
X

X

Protein
P
C
C

gi|53729352|ref|NP_005103.2|

X gi|13129100|ref|NP_077001.1|
gi|11386193|ref|NP_008922.1|
gi|4508047|ref|NP_003452.1|,g
X i|58530845|ref|NP_001010972.
1|
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APPENDIX 2
Wound Healing
GI No
4502101
4502107
22538433
76563933
42716297
66347875
4503123
47132557
62243290
4505029
4505185
59894792
4758804
(+3)
6912238
4505863
10835159
4507149
40317626
5454114
63025222
13929462
GI No
4502101
7662238
4757826
10834988
42716297
4502491
66347875
47132551
18201905

DAVID Gene Name
ANNEXIN A1
ANNEXIN A5
CATHEPSIN B
CHEMOKINE (C-X-C MOTIF) LIGAND 12 (STROMAL CELLDERIVED FACTOR 1)
CLUSTERIN
COMPLEMENT COMPONENT 1, R SUBCOMPONENT
CONNECTIVE TISSUE GROWTH FACTOR
FIBRONECTIN 1
INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4
LEUKOTRIENE A4 HYDROLASE
MACROPHAGE MIGRATION INHIBITORY FACTOR
(GLYCOSYLATION-INHIBITING FACTOR)
MIDKINE (NEURITE GROWTH-PROMOTING FACTOR 2)
NUCLEAR FACTOR OF ACTIVATED T-CELLS, CYTOPLASMIC,
CALCINEURIN-DEPENDENT 3
PEROXIREDOXIN 5
PLASMINOGEN ACTIVATOR, UROKINASE
SERPIN PEPTIDASE INHIBITOR, CLADE E (NEXIN,
PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1), MEMBER 1
SUPEROXIDE DISMUTASE 1, SOLUBLE (AMYOTROPHIC
LATERAL SCLEROSIS 1 (ADULT))
THROMBOSPONDIN 1
TISSUE FACTOR PATHWAY INHIBITOR (LIPOPROTEINASSOCIATED COAGULATION INHIBITOR)
TRANSFORMING GROWTH FACTOR, BETA 1 (CAMURATIENGELMANN DISEASE)
UDP-GAL:BETAGLCNAC BETA 1,4GALACTOSYLTRANSFERASE, POLYPEPTIDE 1
Inflammation
DAVID Gene Name
ANNEXIN A1
APOPTOTIC CHROMATIN CONDENSATION INDUCER 1
BETA-2-MICROGLOBULIN
CHEMOKINE (C-X-C MOTIF) LIGAND 12 (STROMAL CELLDERIVED FACTOR 1)
CLUSTERIN
COMPLEMENT COMPONENT 1, Q SUBCOMPONENT BINDING
PROTEIN
COMPLEMENT COMPONENT 1, R SUBCOMPONENT
FIBRONECTIN 1
GLUCOSE PHOSPHATE ISOMERASE
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Gene Symbol
ANXA1
ANXA5
CTSB
CXCL12
CLU
C1R
CTGF
FN1
IGFBP4
LTA4H
MIF
MDK
NFATC3
PRDX5
PLAU
SERPINE1
SOD1
THBS1
TFPI
TGFB1
B4GALT1
Gene Symbol
ANXA1
ACIN1
B2M
CXCL12
CLU
C1QBP
C1R
FN1
GPI

4504699
62243290
24234747
4505029
4505185
4505185
12667788
4758804
(+3)
46276863
32455260
30581141
30410792
6005846
4506695
4507149
40317626
4507509
45439355
63025222
29788785
5174735
4507793
13929462
41327712
GI No
41406057
4757756
4502403
4757900
21361116
87196339
4503123
4503117

Inflammation - continued
INHIBIN, BETA A (ACTIVIN A, ACTIVIN AB ALPHA
POLYPEPTIDE)
INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4
INTERLEUKIN ENHANCER BINDING FACTOR 2, 45KDA
LEUKOTRIENE A4 HYDROLASE
MACROPHAGE MIGRATION INHIBITORY FACTOR
(GLYCOSYLATION-INHIBITING FACTOR)
MACROPHAGE MIGRATION INHIBITORY FACTOR
(GLYCOSYLATION-INHIBITING FACTOR)
MYOSIN, HEAVY POLYPEPTIDE 9, NON-MUSCLE
NUCLEAR FACTOR OF ACTIVATED T-CELLS, CYTOPLASMIC,
CALCINEURIN-DEPENDENT 3
PARATHYMOSIN
PEROXIREDOXIN 5
PROTEASOME (PROSOME, MACROPAIN) ACTIVATOR
SUBUNIT 1 (PA28 ALPHA)
PROTEASOME (PROSOME, MACROPAIN) ACTIVATOR
SUBUNIT 2 (PA28 BETA)
PTK9L PROTEIN TYROSINE KINASE 9-LIKE (A6-RELATED
PROTEIN)
RIBOSOMAL PROTEIN S19
SUPEROXIDE DISMUTASE 1, SOLUBLE (AMYOTROPHIC
LATERAL SCLEROSIS 1 (ADULT))
THROMBOSPONDIN 1
TIMP METALLOPEPTIDASE INHIBITOR 1
TRANSCRIPTION ELONGATION FACTOR A (SII), 1
TRANSFORMING GROWTH FACTOR, BETA 1 (CAMURATIENGELMANN DISEASE)
TUBULIN, BETA
TUBULIN, BETA 2C
UBIQUITIN-CONJUGATING ENZYME E2N (UBC13 HOMOLOG,
YEAST)
UDP-GAL:BETAGLCNAC BETA 1,4GALACTOSYLTRANSFERASE, POLYPEPTIDE 1
V-CRK SARCOMA VIRUS CT10 ONCOGENE HOMOLOG
(AVIAN)
Fibrosis
DAVID Gene Name
AMYLOID BETA (A4) PRECURSOR PROTEIN (PEPTIDASE
NEXIN-II, ALZHEIMER DISEASE)
ANNEXIN A2
BIGLYCAN
CALRETICULIN
CHONDROITIN SULFATE PROTEOGLYCAN 2 (VERSICAN)
COLLAGEN, TYPE VI, ALPHA 1
CONNECTIVE TISSUE GROWTH FACTOR
CYSTATIN B (STEFIN B)
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INHBA
IGFBP4
ILF2
LTA4H
MIF
MIF
MYH9
NFATC3
PTMS
PRDX5
PSME1
PSME2
TWF2
RPS19
SOD1
THBS1
TIMP1
TCEA1
TGFB1
TUBB
TUBB2C
UBE2N
B4GALT1
CRK
Gene Symbol
APP
ANXA2
BGN
CALR
VCAN
COL6A1
CTGF
CSTB

4503107
4758236
16933542
34734062
5031863
11342666
4505621
4507171
41152086
10835159
24307907
5453886
4759164
4507511
5454114
4507467
GI No
12025678
66363686
4502101
21536466
4757900
5901922
38455427
42716297
4506803
4503101
31542331
4503337
4758302
19743875
47078238
4504253

Fibrosis - continued
CYSTATIN C (AMYLOID ANGIOPATHY AND CEREBRAL
HEMORRHAGE)
EXTRACELLULAR MATRIX PROTEIN 1
FIBRONECTIN 1
FIBULIN 1
LECTIN, GALACTOSIDE-BINDING, SOLUBLE, 3 BINDING
PROTEIN
MATRIX METALLOPEPTIDASE 2 (GELATINASE A, 72KDA
GELATINASE, 72KDA TYPE IV COLLAGENASE)
PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN 1
SECRETED PROTEIN, ACIDIC, CYSTEINE-RICH
(OSTEONECTIN)
SERPIN PEPTIDASE INHIBITOR, CLADE B (OVALBUMIN),
MEMBER 6
SERPIN PEPTIDASE INHIBITOR, CLADE E (NEXIN,
PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1), MEMBER 1
SERPIN PEPTIDASE INHIBITOR, CLADE E (NEXIN,
PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1), MEMBER 2
SERPIN PEPTIDASE INHIBITOR, CLADE I (PANCPIN),
MEMBER 2
SPARC/OSTEONECTIN, CWCV AND KAZAL-LIKE DOMAINS
PROTEOGLYCAN (TESTICAN) 1
TIMP METALLOPEPTIDASE INHIBITOR 2
TISSUE FACTOR PATHWAY INHIBITOR (LIPOPROTEINASSOCIATED COAGULATION INHIBITOR)
TRANSFORMING GROWTH FACTOR, BETA-INDUCED, 68KDA
Proliferation
DAVID Gene Name
ACTININ, ALPHA 4
AMYLOID BETA PRECURSOR PROTEIN BINDING PROTEIN 1
ANNEXIN A1
AXL RECEPTOR TYROSINE KINASE
CALRETICULIN
CDC37 CELL DIVISION CYCLE 37 HOMOLOG (S. CEREVISIAE)
CHAPERONIN CONTAINING TCP1, SUBUNIT 4 (DELTA)
CLUSTERIN
C-TYPE LECTIN DOMAIN FAMILY 11, MEMBER A
CYSTEINE AND GLYCINE-RICH PROTEIN 2
CYSTEINE-RICH, ANGIOGENIC INDUCER, 61
DYSKERATOSIS CONGENITA 1, DYSKERIN
ENHANCER OF RUDIMENTARY HOMOLOG (DROSOPHILA)
FUMARATE HYDRATASE
G PROTEIN PATHWAY SUPPRESSOR 1
H2A HISTONE FAMILY, MEMBER X
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CST3
ECM1
FN1
FBLN1
LGALS3BP
MMP2
PEBP1
SPARC
SERPINB6
SERPINE1
SERPINE2
SERPINI2
SPOCK1
TIMP2
TFPI
TGFBI
Gene Symbol
ACTN4
NAE1
ANXA1
AXL
CALR
CDC37
CCT4
CLU
CLEC11A
CSRP
CYR61
DKC1
ERH
FH
GPS1
H2AFX

4758516
4504699
62243290
4504619
24234750
5730027
4557733
4505185
6912494
4505135
4557797
27262628
5729953
71361682
10835063
21327708
46276863
21070974
32455264
33239451
4506003
4506005
4506007
4505999
21361399
13325075
5453555
29789090
4506583
4506439
5032057
7657532
8922712
28416940

Proliferation – continued
HEPATOMA-DERIVED GROWTH FACTOR (HIGH-MOBILITY
GROUP PROTEIN 1-LIKE)
INHIBIN, BETA A (ACTIVIN A, ACTIVIN AB ALPHA
POLYPEPTIDE)
INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4
INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 7
INTERLEUKIN ENHANCER BINDING FACTOR 3, 90KDA
KH DOMAIN CONTAINING, RNA BINDING, SIGNAL
TRANSDUCTION ASSOCIATED 1
LATENT TRANSFORMING GROWTH FACTOR BETA BINDING
PROTEIN 2
MACROPHAGE MIGRATION INHIBITORY FACTOR
(GLYCOSYLATION-INHIBITING FACTOR)
MICROTUBULE-ASSOCIATED PROTEIN, RP/EB FAMILY,
MEMBER 1
MIDKINE (NEURITE GROWTH-PROMOTING FACTOR 2)
NON-METASTATIC CELLS 1, PROTEIN (NM23A) EXPRESSED
IN
NUCLEAR AUTOANTIGENIC SPERM PROTEIN (HISTONEBINDING)
NUCLEAR DISTRIBUTION GENE C HOMOLOG (A. NIDULANS)
NUCLEAR MITOTIC APPARATUS PROTEIN 1
NUCLEOPHOSMIN (NUCLEOLAR PHOSPHOPROTEIN B23,
NUMATRIN)
NUCLEOSOME ASSEMBLY PROTEIN 1-LIKE 1
PARATHYMOSIN
PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE
PEROXIREDOXIN 1
PROLIFERATING CELL NUCLEAR ANTIGEN
PROTEIN PHOSPHATASE 1, CATALYTIC SUBUNIT, ALPHA
ISOFORM
PROTEIN PHOSPHATASE 1, CATALYTIC SUBUNIT, BETA
ISOFORM
PROTEIN PHOSPHATASE 1, CATALYTIC SUBUNIT, GAMMA
ISOFORM
PROTEIN PHOSPHATASE 1G (FORMERLY 2C), MAGNESIUMDEPENDENT, GAMMA ISOFORM
PROTEIN PHOSPHATASE 2 (FORMERLY 2A), REGULATORY
SUBUNIT A (PR 65), ALPHA ISOFORM
QUIESCIN Q6
RAN, MEMBER RAS ONCOGENE FAMILY
REGULATOR OF CHROMOSOME CONDENSATION 2
REPLICATION PROTEIN A1, 70KDA
RETINOBLASTOMA BINDING PROTEIN 7
S100 CALCIUM BINDING PROTEIN A11 (CALGIZZARIN)
S100 CALCIUM BINDING PROTEIN A6 (CALCYCLIN)
SEPTIN 11
SHWACHMAN-BODIAN-DIAMOND SYNDROME
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HDGF
INHBA
IGFBP4
IGFBP7
ILF3
KHDRBS1
LTBP2
MIF
MAPRE1
MDK
NME1
NASP
NUDC
NUMA1
NPM1
NAP1L1
PTMS
PAM
PRDX1
PCNA
PPP1CA
PPP1CB
PPP1CC
PPM1G
PPP2R1A
QSOX1
RAN
RCC2
RPA1
RBBP7
S100A11
S100A6
SEPT11
SBDS

4759164
44890050
5454052
6678271
50592994
33519426
4507509
4507511
63025222
4507467
4507951

5803227
77539055
11024714
21361091
4507797
35493987
13929462
GI No
4885049
4501891
12025678
4502027
41406055
4502169
4502101
4502107
5729730
7662238
4757900
22538431
42716297
5031635
11128019
4503545
4504183

Proliferation - continued
SPARC/OSTEONECTIN, CWCV AND KAZAL-LIKE DOMAINS
PROTEOGLYCAN (TESTICAN) 1
STATHMIN 1/ONCOPROTEIN 18
STRATIFIN
TAR DNA BINDING PROTEIN
THIOREDOXIN
THIOREDOXIN REDUCTASE 1
TIMP METALLOPEPTIDASE INHIBITOR 1
TIMP METALLOPEPTIDASE INHIBITOR 2
TRANSFORMING GROWTH FACTOR, BETA 1 (CAMURATIENGELMANN DISEASE)
TRANSFORMING GROWTH FACTOR, BETA-INDUCED, 68KDA
TYROSINE 3-MONOOXYGENASE/TRYPTOPHAN 5MONOOXYGENASE ACTIVATION PROTEIN, ETA
POLYPEPTIDE
TYROSINE 3-MONOOXYGENASE/TRYPTOPHAN 5MONOOXYGENASE ACTIVATION PROTEIN, THETA
POLYPEPTIDE
UBIQUITIN A-52 RESIDUE RIBOSOMAL PROTEIN FUSION
PRODUCT 1
UBIQUITIN B
UBIQUITIN CARBOXYL-TERMINAL ESTERASE L1 (UBIQUITIN
THIOLESTERASE)
UBIQUITIN-CONJUGATING ENZYME E2 VARIANT 2
UBIQUITIN-CONJUGATING ENZYME E2I (UBC9 HOMOLOG,
YEAST)
UDP-GAL:BETAGLCNAC BETA 1,4GALACTOSYLTRANSFERASE, POLYPEPTIDE 1
Apoptosis
DAVID Gene Name
ACTIN, ALPHA, CARDIAC MUSCLE
ACTININ, ALPHA 1
ACTININ, ALPHA 4
ALBUMIN
AMYLOID BETA (A4) PRECURSOR PROTEIN (PEPTIDASE
NEXIN-II, ALZHEIMER DISEASE)
AMYLOID BETA PRECURSOR PROTEIN BINDING PROTEIN 1
ANNEXIN A1
ANNEXIN A5
APOPTOSIS INHIBITOR 5
APOPTOTIC CHROMATIN CONDENSATION INDUCER 1
CALRETICULIN
CATHEPSIN B
CLUSTERIN
COFILIN 1 (NON-MUSCLE)
CYTOCHROME C, SOMATIC
EUKARYOTIC TRANSLATION INITIATION FACTOR 5A
GLUTATHIONE S-TRANSFERASE PI
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SPOCK1
STMN1
SFN
TARDBP
TXN
TXNRD1
TIMP1
TIMP2
TGFB1
TGFBI
YWHAH

YWHAQ
UBA52
UBB
UCHL1
UBE2V2
UBE2I
B4GALT1
Gene Symbol
ACTC1
ACTN1
ACTN4
ALB
APP
NAE1
ANXA1
ANXA5
API5
ACIN1
CALR
CTSB
CLU
CFL1
CYCS
EIF5A
GSTP1

4504523
31542947
16507237
24234688
4507677
4504425
4504699
62243068
24432106
4504981
4505185
38045913
10835063
32189392
31317307
24430160
21361657
21361399
4757768
56117838
5454052
4507149
67782305
4759274
63025222
29788785
5174735
4507669
4507951

21735625
13929462
6005942

Apoptosis - continued
HEAT SHOCK 10KDA PROTEIN 1 (CHAPERONIN 10)
HEAT SHOCK 60KDA PROTEIN 1 (CHAPERONIN)
HEAT SHOCK 70KDA PROTEIN 5 (GLUCOSE-REGULATED
PROTEIN, 78KDA)
HEAT SHOCK 70KDA PROTEIN 9B (MORTALIN-2)
HEAT SHOCK PROTEIN 90KDA BETA (GRP94), MEMBER 1
HIGH-MOBILITY GROUP BOX 1
INHIBIN, BETA A (ACTIVIN A, ACTIVIN AB ALPHA
POLYPEPTIDE)
INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3
KIAA1967
LECTIN, GALACTOSIDE-BINDING, SOLUBLE, 1 (GALECTIN 1)
MACROPHAGE MIGRATION INHIBITORY FACTOR
(GLYCOSYLATION-INHIBITING FACTOR)
NON-METASTATIC CELLS 1, PROTEIN (NM23A) EXPRESSED
IN
NUCLEOPHOSMIN (NUCLEOLAR PHOSPHOPROTEIN B23,
NUMATRIN)
PEROXIREDOXIN 2
PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9
PROTEASOME (PROSOME, MACROPAIN) 26S SUBUNIT,
ATPASE, 6
PROTEIN DISULFIDE ISOMERASE FAMILY A, MEMBER 3
PROTEIN PHOSPHATASE 2 (FORMERLY 2A), REGULATORY
SUBUNIT A (PR 65), ALPHA ISOFORM
RHO GDP DISSOCIATION INHIBITOR (GDI) ALPHA
SECRETED FRIZZLED-RELATED PROTEIN 1
STRATIFIN
SUPEROXIDE DISMUTASE 1, SOLUBLE (AMYOTROPHIC
LATERAL SCLEROSIS 1 (ADULT))
SUPEROXIDE DISMUTASE 2, MITOCHONDRIAL
THIOREDOXIN-LIKE 1
TRANSFORMING GROWTH FACTOR, BETA 1 (CAMURATIENGELMANN DISEASE)
TUBULIN, BETA
TUBULIN, BETA 2C
TUMOR PROTEIN, TRANSLATIONALLY-CONTROLLED 1
TYROSINE 3-MONOOXYGENASE/TRYPTOPHAN 5MONOOXYGENASE ACTIVATION PROTEIN, ETA
POLYPEPTIDE
TYROSINE 3-MONOOXYGENASE/TRYPTOPHAN 5MONOOXYGENASE ACTIVATION PROTEIN, ZETA
POLYPEPTIDE
UDP-GAL:BETAGLCNAC BETA 1,4GALACTOSYLTRANSFERASE, POLYPEPTIDE 1
VALOSIN-CONTAINING PROTEIN
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HSPE1
HSPD1
HSPA5
HSPA9
HSP90B1
HMGB1
INHBA
IGFBP3
KIAA1967
LGALS1
MIF
NME1
NPM1
PRDX2
PCSK9
PSMC6
PDIA3
PPP2R1A
ARHGDIA
SFRP1
SFN
SOD1
SOD2
TXNL1
TGFB1
TUBB
TUBB2C
TPT1
YWHAH

YWHAZ
B4GALT1
VCP

GI No
4501885
4501891
12025678
4502101
5031571
5031573
14589889
5453595
5453597
5453599
4826659
7330335
4503123
31542331
47132555
11342666
4505257
12667788
55956788
4757768
4506695
10835159
24307907
5453886
4759164
16753233
50592994
40317626
63025222
63252896
24119203
4507651
29788785
5174735
4507761
11024714

Invasion
DAVID Gene Name
ACTIN, BETA
ACTININ, ALPHA 1
ACTININ, ALPHA 4
ANNEXIN A1
ARP2 ACTIN-RELATED PROTEIN 2 HOMOLOG (YEAST)
ARP3 ACTIN-RELATED PROTEIN 3 HOMOLOG (YEAST)
CADHERIN 2, TYPE 1, N-CADHERIN (NEURONAL)
CAP, ADENYLATE CYCLASE-ASSOCIATED PROTEIN 1
(YEAST)
CAPPING PROTEIN (ACTIN FILAMENT) MUSCLE Z-LINE,
ALPHA 1
CAPPING PROTEIN (ACTIN FILAMENT) MUSCLE Z-LINE,
ALPHA 2
CAPPING PROTEIN (ACTIN FILAMENT) MUSCLE Z-LINE, BETA
CHLORIDE INTRACELLULAR CHANNEL 4
CONNECTIVE TISSUE GROWTH FACTOR
CYSTEINE-RICH, ANGIOGENIC INDUCER, 61
FIBRONECTIN 1
MATRIX METALLOPEPTIDASE 2 (GELATINASE A, 72KDA
GELATINASE, 72KDA TYPE IV COLLAGENASE)
MOESIN
MYOSIN, HEAVY POLYPEPTIDE 9, NON-MUSCLE
NUCLEOLIN
RHO GDP DISSOCIATION INHIBITOR (GDI) ALPHA
RIBOSOMAL PROTEIN S19
SERPIN PEPTIDASE INHIBITOR, CLADE E (NEXIN,
PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1), MEMBER 1
SERPIN PEPTIDASE INHIBITOR, CLADE E (NEXIN,
PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1), MEMBER 2
SERPIN PEPTIDASE INHIBITOR, CLADE I (PANCPIN),
MEMBER 2
SPARC/OSTEONECTIN, CWCV AND KAZAL-LIKE DOMAINS
PROTEOGLYCAN (TESTICAN) 1
TALIN 1
THIOREDOXIN
THROMBOSPONDIN 1
TRANSFORMING GROWTH FACTOR, BETA 1 (CAMURATIENGELMANN DISEASE)
TROPOMYOSIN 1 (ALPHA)
TROPOMYOSIN 3
TROPOMYOSIN 4
TUBULIN, BETA
TUBULIN, BETA 2C
UBIQUITIN A-52 RESIDUE RIBOSOMAL PROTEIN FUSION
PRODUCT 1
UBIQUITIN B
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Gene Symbol
ACTB
ACTN1
ACTN4
ANXA1
ACTR2
ACTR3
CDH2
CAP1
CAPZA1
CAPZA2
CAPZB
CLIC4
CTGF
CYR61
FN1
MMP2
MSN
MYH9
NCL
ARHGDIA
RPS19
SERPINE1
SERPINE2
SERPINI2
SPOCK1
TLN1
TXN
THBS1
TGFB1
TPM1
TPM3
TPM4
TUBB
TUBB2C
UBA52
UBB

13929462
41327710
62414289
4507877

Invasion - continued
UDP-GAL:BETAGLCNAC BETA 1,4GALACTOSYLTRANSFERASE, POLYPEPTIDE 1
V-CRK SARCOMA VIRUS CT10 ONCOGENE HOMOLOG
(AVIAN)
VIMENTIN
VINCULIN
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B4GALT1
CRK
VIM
VCL
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APPENDIX 3

Protein
6-phosphogluconolactonase
6-phosphogluconolactonase
6-phosphogluconolactonase
6-phosphogluconolactonase
6-phosphogluconolactonase
6-phosphogluconolactonase
amyloid beta A4 protein
amyloid beta A4 protein
amyloid beta A4 protein
amyloid beta A4 protein
amyloid beta A4 protein
amyloid beta A4 protein
annexin I
annexin I
annexin I
annexin I
annexin I
annexin I
anterior gradient 2 homolog
anterior gradient 2 homolog
anterior gradient 2 homolog
anterior gradient 2 homolog
anterior gradient 2 homolog
anterior gradient 2 homolog
AXL receptor tyrosine kinase
isoform 1
AXL receptor tyrosine kinase
isoform 1
AXL receptor tyrosine kinase
isoform 1
AXL receptor tyrosine kinase
isoform 1
AXL receptor tyrosine kinase
isoform 1
AXL receptor tyrosine kinase
isoform 1
cadherin 2; type 1
cadherin 2; type 1
cadherin 2; type 1
cadherin 2; type 1
cadherin 2; type 1
cadherin 2; type 1
calreticulin
calreticulin
calreticulin
calreticulin
calreticulin
calreticulin
cathepsin D
cathepsin D
cathepsin D

Peptide
ELPAAVAPAGPASLAR
ELPAAVAPAGPASLAR
ELPAAVAPAGPASLAR
ELPAAVAPAGPASLAR
ELPAAVAPAGPASLAR
ELPAAVAPAGPASLAR
VESLEQEAANER
VESLEQEAANER
VESLEQEAANER
VESLEQEAANER
VESLEQEAANER
VESLEQEAANER
GTDVNVFNTILTTR
GTDVNVFNTILTTR
GTDVNVFNTILTTR
GTDVNVFNTILTTR
GTDVNVFNTILTTR
GTDVNVFNTILTTR
IMFVDPSLTVR
IMFVDPSLTVR
IMFVDPSLTVR
IMFVDPSLTVR
IMFVDPSLTVR
IMFVDPSLTVR

Precusor
m/z
745.920
745.920
745.920
752.937
752.937
752.937
687.828
687.828
687.828
691.337
691.337
691.337
775.912
775.912
775.912
779.421
779.421
779.421
639.350
639.350
639.350
642.858
642.858
642.858

Product
m/z
1009.579
910.510
839.473
1016.596
917.528
846.491
1146.539
946.422
817.380
1153.556
946.422
817.380
1178.653
1064.610
965.541
1185.670
1071.627
972.559
1033.568
787.431
672.404
1040.585
794.448
679.421

CID
energy
25.3
25.3
25.3
25.3
25.3
25.3
23.5
23.5
23.5
23.5
23.5
23.5
26.2
26.2
26.2
26.2
26.2
26.2
22.1
22.1
22.1
22.1
22.1
22.1

Product
ion
y11
y10
y9
y11
y10
y9
y10
y8
y7
y10
y8
y7
y10
y9
y8
y10
y9
y8
y9
y7
y6
y9
y7
y6

Isotope
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy

TATITVLPQQPR

662.883

938.542

22.8

y8

light

TATITVLPQQPR

662.883

837.494

22.8

y7

light

TATITVLPQQPR

662.883

738.426

22.8

y6

light

TATITVLPQQPR

666.391

945.559

22.8

y8

heavy

TATITVLPQQPR

666.391

844.511

22.8

y7

heavy

TATITVLPQQPR
DVHEGQPLLNVK
DVHEGQPLLNVK
DVHEGQPLLNVK
DVHEGQPLLNVK
DVHEGQPLLNVK
DVHEGQPLLNVK
EQFLDGDGWTSR
EQFLDGDGWTSR
EQFLDGDGWTSR
EQFLDGDGWTSR
EQFLDGDGWTSR
EQFLDGDGWTSR
FDGILGMAYPR
FDGILGMAYPR
FDGILGMAYPR

666.391
674.865
674.865
674.865
685.889
685.889
685.889
705.818
705.818
705.818
709.326
709.326
709.326
620.313
620.313
620.313

745.443
1134.627
868.525
683.445
1156.675
890.574
705.494
1006.459
893.375
778.348
1013.476
893.375
778.348
807.418
694.334
637.313

22.8
23.2
23.2
23.2
23.2
23.2
23.2
24.1
24.1
24.1
24.1
24.1
24.1
21.5
21.5
21.5

y6
y10
y8
y6
y10
y8
y6
y9
y8
y7
y9
y8
y7
y7
y6
y5

heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light
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Protein
cathepsin D
cathepsin D
cathepsin D
cathepsin Z
cathepsin Z
cathepsin Z
cathepsin Z
cathepsin Z
cathepsin Z
coactosin-like 1
coactosin-like 1
coactosin-like 1
coactosin-like 1
coactosin-like 1
coactosin-like 1
cystatin B
cystatin B
cystatin B
cystatin B
cystatin B
cystatin B
cystatin C
cystatin C
cystatin C
cystatin C
cystatin C
cystatin C
cystatin M
cystatin M
cystatin M
cystatin M
cystatin M
cystatin M
cysteine-rich; angiogenic inducer;
61
cysteine-rich; angiogenic inducer;
61
cysteine-rich; angiogenic inducer;
61
cysteine-rich; angiogenic inducer;
61
cysteine-rich; angiogenic inducer;
61
cysteine-rich; angiogenic inducer;
61
cysteine-rich; angiogenic inducer;
61
cysteine-rich; angiogenic inducer;
61
cysteine-rich; angiogenic inducer;
61
cysteine-rich; angiogenic inducer;
61
cysteine-rich; angiogenic inducer;
61
cysteine-rich; angiogenic inducer;
61

Peptide
FDGILGMAYPR
FDGILGMAYPR
FDGILGMAYPR
VGDYGSLSGR
VGDYGSLSGR
VGDYGSLSGR
VGDYGSLSGR
VGDYGSLSGR
VGDYGSLSGR
DDGSAVIWVTFK
DDGSAVIWVTFK
DDGSAVIWVTFK
DDGSAVIWVTFK
DDGSAVIWVTFK
DDGSAVIWVTFK
VHVGDEDFVHLR
VHVGDEDFVHLR
VHVGDEDFVHLR
VHVGDEDFVHLR
VHVGDEDFVHLR
VHVGDEDFVHLR
ALDFAVGEYNK
ALDFAVGEYNK
ALDFAVGEYNK
ALDFAVGEYNK
ALDFAVGEYNK
ALDFAVGEYNK
DLSPDDPQVQK
DLSPDDPQVQK
DLSPDDPQVQK
DLSPDDPQVQK
DLSPDDPQVQK
DLSPDDPQVQK

Precusor
m/z
623.822
623.822
623.822
505.749
505.749
505.749
509.257
509.257
509.257
669.340
669.340
669.340
673.348
673.348
673.348
711.860
711.860
711.860
715.368
715.368
715.368
613.806
613.806
613.806
621.322
621.322
621.322
621.304
621.304
621.304
628.820
628.820
628.820

Product
m/z
814.435
694.334
637.313
854.400
739.373
576.310
861.417
746.390
583.327
1050.598
892.529
793.461
1058.612
900.543
801.475
1186.585
1087.517
1030.495
1193.602
1094.534
1037.512
1042.484
780.389
709.352
1050.498
788.403
717.366
1013.490
926.458
829.405
1021.504
934.472
837.419

CID
energy
21.5
21.5
21.5
18.1
18.1
18.1
18.1
18.1
18.1
23
23
23
23
23
23
24.3
24.3
24.3
24.3
24.3
24.3
21.3
21.3
21.3
21.3
21.3
21.3
21.5
21.5
21.5
21.5
21.5
21.5

Product
ion
y7
y6
y5
y8
y7
y6
y8
y7
y6
y9
y7
y6
y9
y7
y6
y10
y9
y8
y10
y9
y8
y9
y7
y6
y9
y7
y6
y9
y8
y7
y9
y8
y7

Isotope
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy

LPVFGMEPR

523.279

932.466

18.6

y8

light

LPVFGMEPR

523.279

835.413

18.6

y7

light

LPVFGMEPR

523.279

736.345

18.6

y6

light

LPVFGMEPR

526.787

932.466

18.6

y8

heavy

LPVFGMEPR

526.787

835.413

18.6

y7

heavy

LPVFGMEPR

526.787

736.345

18.6

y6

heavy

ELGFDASEVELTR

733.362

1019.500

24.9

y9

light

ELGFDASEVELTR

733.362

904.473

24.9

y8

light

ELGFDASEVELTR

733.362

833.436

24.9

y7

light

ELGFDASEVELTR

740.379

1026.518

24.9

y9

heavy

ELGFDASEVELTR

740.379

911.491

24.9

y8

heavy

ELGFDASEVELTR

740.379

840.453

24.9

y7

heavy
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Protein
desmoglein 2
desmoglein 2
desmoglein 2
desmoglein 2
desmoglein 2
desmoglein 2
enolase 1
enolase 1
enolase 1
enolase 1
enolase 1
enolase 1

Peptide
AWITAPVALR
AWITAPVALR
AWITAPVALR
AWITAPVALR
AWITAPVALR
AWITAPVALR
LAMQEFMILPVGAANFR
LAMQEFMILPVGAANFR
LAMQEFMILPVGAANFR
LAMQEFMILPVGAANFR
LAMQEFMILPVGAANFR
LAMQEFMILPVGAANFR

Precusor
m/z
549.327
549.327
549.327
552.836
552.836
552.836
954.497
954.497
954.497
961.514
961.514
961.514

Product
m/z
840.530
727.446
555.361
847.547
734.463
562.378
1057.615
944.531
831.447
1064.632
951.548
831.447

CID
energy
19.4
19.4
19.4
19.4
19.4
19.4
31.5
31.5
31.5
31.5
31.5
31.5

Product
ion
y8
y7
y5
y8
y7
y5
y10
y9
y8
y10
y9
y8

Isotope
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy

epidermal growth factor receptor
pathway substrate

APEPQLSPGSDASEVR

820.400

1342.660

27.5

y13

light

epidermal growth factor receptor
pathway substrate

APEPQLSPGSDASEVR

820.400

1004.464

27.5

y10

light

epidermal growth factor receptor
pathway substrate

APEPQLSPGSDASEVR

820.400

917.432

27.5

y9

light

epidermal growth factor receptor
pathway substrate

APEPQLSPGSDASEVR

823.908

1349.677

27.5

y13

heavy

epidermal growth factor receptor
pathway substrate

APEPQLSPGSDASEVR

823.908

1004.464

27.5

y10

heavy

APEPQLSPGSDASEVR

823.908

917.432

27.5

y9

heavy

EVGPPLPQEAVPLQK

801.449

1219.704

26.9

y11

light

EVGPPLPQEAVPLQK

801.449

1122.652

26.9

y10

light

EVGPPLPQEAVPLQK

801.449

1009.568

26.9

y9

light

EVGPPLPQEAVPLQK

812.473

1241.753

26.9

y11

heavy

EVGPPLPQEAVPLQK

812.473

1144.700

26.9

y10

heavy

epidermal growth factor receptor
pathway substrate
extracellular matrix protein 1
isoform 2
extracellular matrix protein 1
isoform 2
extracellular matrix protein 1
isoform 2
extracellular matrix protein 1
isoform 2
extracellular matrix protein 1
isoform 2
extracellular matrix protein 1
isoform 2

EVGPPLPQEAVPLQK

812.473

1024.599

26.9

y9

heavy

family with sequence similarity
3,member C

TGEVLDTK

431.729

761.404

15.9

y7

light

family with sequence similarity
3,member C

TGEVLDTK

431.729

704.382

15.9

y6

light

family with sequence similarity
3,member C

TGEVLDTK

431.729

575.340

15.9

y5

light

family with sequence similarity
3,member C

TGEVLDTK

439.245

776.435

15.9

y7

heavy

family with sequence similarity
3,member C

TGEVLDTK

439.245

719.414

15.9

y6

heavy

family with sequence similarity
3,member C

TGEVLDTK

439.245

590.371

15.9

y5

heavy

G protein coupled receptor. family
C, group 5, member

AHAWPSPYK

528.767

848.430

18.8

y7

light

G protein coupled receptor. family
C, group 5, member

AHAWPSPYK

528.767

777.393

18.8

y6

light

G protein coupled receptor. family
C, group 5, member

AHAWPSPYK

528.767

591.314

18.8

y5

light
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Protein

Peptide

Precusor
m/z

Product
m/z

CID
energy

Product
ion

Isotope

G protein coupled receptor. family
C, group 5, member

AHAWPSPYK

532.774

856.444

18.8

y7

heavy

G protein coupled receptor. family
C, group 5, member

AHAWPSPYK

532.774

785.407

18.8

y6

heavy

AHAWPSPYK
LADGGATNQGR
LADGGATNQGR
LADGGATNQGR
LADGGATNQGR
LADGGATNQGR
LADGGATNQGR
VSDATGQMNLTK
VSDATGQMNLTK
VSDATGQMNLTK
VSDATGQMNLTK
VSDATGQMNLTK
VSDATGQMNLTK
QAALQVAEGFISR
QAALQVAEGFISR
QAALQVAEGFISR
QAALQVAEGFISR
QAALQVAEGFISR
QAALQVAEGFISR
GGEIQPVSVK
GGEIQPVSVK
GGEIQPVSVK
GGEIQPVSVK
GGEIQPVSVK
GGEIQPVSVK
VLQATVVAVGSGSK
VLQATVVAVGSGSK
VLQATVVAVGSGSK
VLQATVVAVGSGSK
VLQATVVAVGSGSK
VLQATVVAVGSGSK
LATQSNEITIPVTFESR
LATQSNEITIPVTFESR
LATQSNEITIPVTFESR
LATQSNEITIPVTFESR
LATQSNEITIPVTFESR
LATQSNEITIPVTFESR
TFAPEEISAMVLTK
TFAPEEISAMVLTK
TFAPEEISAMVLTK
TFAPEEISAMVLTK
TFAPEEISAMVLTK
TFAPEEISAMVLTK

532.774
530.263
530.263
530.263
533.771
533.771
533.771
632.814
632.814
632.814
640.329
640.329
640.329
695.378
695.378
695.378
698.886
698.886
698.886
507.285
507.285
507.285
511.292
511.292
511.292
658.383
658.383
658.383
665.898
665.898
665.898
953.499
953.499
953.499
957.008
957.008
957.008
768.903
768.903
768.903
776.418
776.418
776.418

599.328
875.397
760.370
575.290
875.397
760.370
575.290
963.493
892.456
791.408
978.524
907.487
806.439
878.473
779.405
708.368
878.473
779.405
708.368
770.477
657.393
529.334
778.491
665.407
537.349
975.547
904.510
704.394
983.561
912.524
712.408
1162.647
1049.563
948.515
1162.647
1049.563
948.515
1288.682
1217.645
991.549
1303.713
1232.676
1006.581

18.8
18.8
18.8
18.8
18.8
18.8
18.8
21.9
21.9
21.9
21.9
21.9
21.9
23.8
23.8
23.8
23.8
23.8
23.8
18.1
18.1
18.1
18.1
18.1
18.1
22.7
22.7
22.7
22.7
22.7
22.7
31.5
31.5
31.5
31.5
31.5
31.5
26
26
26
26
26
26

y5
y9
y8
y5
y9
y8
y5
y9
y8
y7
y9
y8
y7
y8
y7
y6
y8
y7
y6
y7
y6
y5
y7
y6
y5
y11
y10
y8
y11
y10
y8
y10
y9
y8
y10
y9
y8
y12
y11
y9
y12
y11
y9

heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy

SFYPEEVSSMVLTK

808.897

1382.687

27.2

y12

light

SFYPEEVSSMVLTK

808.897

1219.624

27.2

y11

light

SFYPEEVSSMVLTK

808.897

1122.571

27.2

y10

light

G protein coupled receptor. family
C, group 5, member
galectin 3 binding protein
galectin 3 binding protein
galectin 3 binding protein
galectin 3 binding protein
galectin 3 binding protein
galectin 3 binding protein
gelsolin-like capping protein
gelsolin-like capping protein
gelsolin-like capping protein
gelsolin-like capping protein
gelsolin-like capping protein
gelsolin-like capping protein
gelsolin-like capping protein
gelsolin-like capping protein
gelsolin-like capping protein
gelsolin-like capping protein
gelsolin-like capping protein
gelsolin-like capping protein
heat shock 10kDa protein 1
heat shock 10kDa protein 1
heat shock 10kDa protein 1
heat shock 10kDa protein 1
heat shock 10kDa protein 1
heat shock 10kDa protein 1
heat shock 10kDa protein 1
heat shock 10kDa protein 1
heat shock 10kDa protein 1
heat shock 10kDa protein 1
heat shock 10kDa protein 1
heat shock 10kDa protein 1
heat shock 27kDa protein 1
heat shock 27kDa protein 1
heat shock 27kDa protein 1
heat shock 27kDa protein 1
heat shock 27kDa protein 1
heat shock 27kDa protein 1
heat shock 70kDa protein 5
heat shock 70kDa protein 5
heat shock 70kDa protein 5
heat shock 70kDa protein 5
heat shock 70kDa protein 5
heat shock 70kDa protein 5
heat shock 70kDa protein 8
isoform 1
heat shock 70kDa protein 8
isoform 1
heat shock 70kDa protein 8
isoform 1
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Peptide

Precusor
m/z

Product
m/z

CID
energy

Product
ion

Isotope

SFYPEEVSSMVLTK

816.413

1397.719

27.2

y12

heavy

SFYPEEVSSMVLTK

816.413

1234.655

27.2

y11

heavy

SFYPEEVSSMVLTK
GSVYIGGAPDVATLTGGR
GSVYIGGAPDVATLTGGR
GSVYIGGAPDVATLTGGR
GSVYIGGAPDVATLTGGR
GSVYIGGAPDVATLTGGR
GSVYIGGAPDVATLTGGR

816.413
845.942
845.942
845.942
849.450
849.450
849.450

1137.602
1171.607
1114.585
986.527
1178.624
1121.602
993.544

27.2
28.3
28.3
28.3
28.3
28.3
28.3

y10
y13
y12
y10
y13
y12
y10

heavy
light
light
light
heavy
heavy
heavy

hepatocyte growth factor activator
inhibitor 1 isoform 1

EGFINYLTR

556.790

926.509

19.6

y7

light

hepatocyte growth factor activator
inhibitor 1 isoform 1

EGFINYLTR

556.790

779.441

19.6

y6

light

hepatocyte growth factor activator
inhibitor 1 isoform 1

EGFINYLTR

556.790

666.357

19.6

y5

light

hepatocyte growth factor activator
inhibitor 1 isoform 1

EGFINYLTR

560.299

933.527

19.6

y7

heavy

hepatocyte growth factor activator
inhibitor 1 isoform 1

EGFINYLTR

560.299

786.458

19.6

y6

heavy

hepatocyte growth factor activator
inhibitor 1 isoform 1

EGFINYLTR

560.299

673.374

19.6

y5

heavy

heterogeneous nuclear
ribonucleoprotein D

GFGFVLFK

457.760

710.424

16.6

y6

light

heterogeneous nuclear
ribonucleoprotein D

GFGFVLFK

457.760

653.402

16.6

y5

light

heterogeneous nuclear
ribonucleoprotein D

GFGFVLFK

457.760

506.334

16.6

y4

light

heterogeneous nuclear
ribonucleoprotein D

GFGFVLFK

465.276

725.455

16.6

y6

heavy

heterogeneous nuclear
ribonucleoprotein D

GFGFVLFK

465.276

668.433

16.6

y5

heavy

heterogeneous nuclear
ribonucleoprotein D

GFGFVLFK

465.276

521.365

16.6

y4

heavy

heterogeneous nuclear
ribonucleoprotein D

IFVGGLSPDTPEEK

744.883

1129.537

25.3

y11

light

heterogeneous nuclear
ribonucleoprotein D

IFVGGLSPDTPEEK

744.883

902.410

25.3

y8

light

heterogeneous nuclear
ribonucleoprotein D

IFVGGLSPDTPEEK

744.883

815.378

25.3

y7

light

heterogeneous nuclear
ribonucleoprotein D

IFVGGLSPDTPEEK

752.398

1144.569

25.3

y11

heavy

heterogeneous nuclear
ribonucleoprotein D

IFVGGLSPDTPEEK

752.398

910.424

25.3

y8

heavy

heterogeneous nuclear
ribonucleoprotein D

IFVGGLSPDTPEEK

752.398

823.392

25.3

y7

heavy

insulin-like growth factor binding
portein 3

FLNVLSPR

473.279

685.399

17.1

y6

light

insulin-like growth factor binding
portein 3

FLNVLSPR

473.279

571.356

17.1

y5

light

insulin-like growth factor binding
portein 3

FLNVLSPR

473.279

472.288

17.1

y4

light

Protein
heat shock 70kDa protein 8
isoform 1
heat shock 70kDa protein 8
isoform 1
heat shock 70kDa protein 8
isoform 1
heparan sulfate proteoglycan 2
heparan sulfate proteoglycan 2
heparan sulfate proteoglycan 2
heparan sulfate proteoglycan 2
heparan sulfate proteoglycan 2
heparan sulfate proteoglycan 2

150

Protein

Peptide

Precusor
m/z

Product
m/z

CID
energy

Product
ion

Isotope

insulin-like growth factor binding
portein 3

FLNVLSPR

480.297

692.416

17.1

y6

heavy

insulin-like growth factor binding
portein 3

FLNVLSPR

480.297

578.373

17.1

y5

heavy

insulin-like growth factor binding
portein 3

FLNVLSPR

480.297

479.305

17.1

y4

heavy

insulin-like growth factor binding
protein 7

TELLPGDRDNLAIQTR

604.659

791.439

25.3

y14

light

insulin-like growth factor binding
protein 7

TELLPGDRDNLAIQTR

604.659

734.897

25.3

y13

light

insulin-like growth factor binding
protein 7

TELLPGDRDNLAIQTR

604.659

678.355

25.3

y12

light

insulin-like growth factor binding
protein 7

TELLPGDRDNLAIQTR

611.676

801.965

25.3

y14

heavy

insulin-like growth factor binding
protein 7

TELLPGDRDNLAIQTR

611.676

741.914

25.3

y13

heavy

TELLPGDRDNLAIQTR
YHQGSGPILPR
YHQGSGPILPR
YHQGSGPILPR
YHQGSGPILPR
YHQGSGPILPR
YHQGSGPILPR

611.676
612.828
612.828
612.828
616.336
616.336
616.336

681.864
924.526
796.468
652.414
931.543
803.485
659.431

25.3
21.3
21.3
21.3
21.3
21.3
21.3

y12
y9
y8
y6
y9
y8
y6

heavy
light
light
light
heavy
heavy
heavy

AVIHPDYDAASHDQDIMLLR

760.707

998.963

31.2

y17

light

AVIHPDYDAASHDQDIMLLR

760.707

930.433

31.2

y16

light

AVIHPDYDAASHDQDIMLLR

760.707

824.393

31.2

y14

light

AVIHPDYDAASHDQDIMLLR

765.386

1005.980

31.2

y17

heavy

AVIHPDYDAASHDQDIMLLR

765.386

937.450

31.2

y16

heavy

AVIHPDYDAASHDQDIMLLR
YEELQSLAGK
YEELQSLAGK
YEELQSLAGK
YEELQSLAGK
YEELQSLAGK
YEELQSLAGK
ASLEAAIADAEQR
ASLEAAIADAEQR
ASLEAAIADAEQR
ASLEAAIADAEQR
ASLEAAIADAEQR
ASLEAAIADAEQR
SGAQASSTPLSPTR
SGAQASSTPLSPTR
SGAQASSTPLSPTR
SGAQASSTPLSPTR
SGAQASSTPLSPTR
SGAQASSTPLSPTR
TALINSTGEEVAMR

765.386
569.293
569.293
569.293
580.317
580.317
580.317
672.841
672.841
672.841
676.350
676.350
676.350
680.347
680.347
680.347
683.855
683.855
683.855
746.377

831.411
974.515
845.473
716.430
996.564
867.521
738.479
873.442
802.405
689.321
873.442
802.405
689.321
1016.537
945.500
771.436
1023.554
952.517
778.453
1206.578

31.2
20
20
20
20
20
20
23.1
23.1
23.1
23.1
23.1
23.1
23.3
23.3
23.3
23.3
23.3
23.3
25.3

y14
y9
y8
y7
y9
y8
y7
y8
y7
y6
y8
y7
y6
y10
y9
y7
y10
y9
y7
y11

heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light

insulin-like growth factor binding
protein 7
kallikrein-related peptidase 10
kallikrein-related peptidase 10
kallikrein-related peptidase 10
kallikrein-related peptidase 10
kallikrein-related peptidase 10
kallikrein-related peptidase 10
kallikrein-related peptidase 6
isoform A
kallikrein-related peptidase 6
isoform A
kallikrein-related peptidase 6
isoform A
kallikrein-related peptidase 6
isoform A
kallikrein-related peptidase 6
isoform A
kallikrein-related peptidase 6
isoform A
keratin 8
keratin 8
keratin 8
keratin 8
keratin 8
keratin 8
keratin 8
keratin 8
keratin 8
keratin 8
keratin 8
keratin 8
lamin A/C isoform 2
lamin A/C isoform 2
lamin A/C isoform 2
lamin A/C isoform 2
lamin A/C isoform 2
lamin A/C isoform 2
lamin A/C isoform 2
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Protein
lamin A/C isoform 2
lamin A/C isoform 2
lamin A/C isoform 2
lamin A/C isoform 2
lamin A/C isoform 2
lipocalin 2
lipocalin 2
lipocalin 2
lipocalin 2
lipocalin 2
lipocalin 2
lipocalin 2
lipocalin 2
lipocalin 2
lipocalin 2
lipocalin 2
lipocalin 2
matrix metalloproteinase 2
matrix metalloproteinase 2
matrix metalloproteinase 2
matrix metalloproteinase 2
matrix metalloproteinase 2
matrix metalloproteinase 2
matrix metalloproteinase 2
matrix metalloproteinase 2
matrix metalloproteinase 2
matrix metalloproteinase 2
matrix metalloproteinase 2
matrix metalloproteinase 2
matrix metalloproteinase 7
matrix metalloproteinase 7
matrix metalloproteinase 7
matrix metalloproteinase 7
matrix metalloproteinase 7
matrix metalloproteinase 7
matrix metalloproteinase 7
matrix metalloproteinase 7
matrix metalloproteinase 7
matrix metalloproteinase 7
matrix metalloproteinase 7
matrix metalloproteinase 7
mesothelin isoform 1
mesothelin isoform 1
mesothelin isoform 1
mesothelin isoform 1
mesothelin isoform 1
mesothelin isoform 1
mesothelin isoform 1
mesothelin isoform 1
mesothelin isoform 1
mesothelin isoform 1
mesothelin isoform 1
mesothelin isoform 1

Peptide
TALINSTGEEVAMR
TALINSTGEEVAMR
TALINSTGEEVAMR
TALINSTGEEVAMR
TALINSTGEEVAMR
WYVVGLAGNAILR
WYVVGLAGNAILR
WYVVGLAGNAILR
WYVVGLAGNAILR
WYVVGLAGNAILR
WYVVGLAGNAILR
VPLQQNFQDNQFQGK
VPLQQNFQDNQFQGK
VPLQQNFQDNQFQGK
VPLQQNFQDNQFQGK
VPLQQNFQDNQFQGK
VPLQQNFQDNQFQGK
VDAAFNWSK
VDAAFNWSK
VDAAFNWSK
VDAAFNWSK
VDAAFNWSK
VDAAFNWSK
AFQVWSDVTPLR
AFQVWSDVTPLR
AFQVWSDVTPLR
AFQVWSDVTPLR
AFQVWSDVTPLR
AFQVWSDVTPLR
DLPHITVDR
DLPHITVDR
DLPHITVDR
DLPHITVDR
DLPHITVDR
DLPHITVDR
FFGLPITGMLNSR
FFGLPITGMLNSR
FFGLPITGMLNSR
FFGLPITGMLNSR
FFGLPITGMLNSR
FFGLPITGMLNSR
IQSFLGGAPTEDLK
IQSFLGGAPTEDLK
IQSFLGGAPTEDLK
IQSFLGGAPTEDLK
IQSFLGGAPTEDLK
IQSFLGGAPTEDLK
TDAVLPLTVAEVQK
TDAVLPLTVAEVQK
TDAVLPLTVAEVQK
TDAVLPLTVAEVQK
TDAVLPLTVAEVQK
TDAVLPLTVAEVQK
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Precusor
m/z
746.377
746.377
749.886
749.886
749.886
716.409
716.409
716.409
723.426
723.426
723.426
895.945
895.945
895.945
903.460
903.460
903.460
519.256
519.256
519.256
523.263
523.263
523.263
709.875
709.875
709.875
713.384
713.384
713.384
533.288
533.288
533.288
536.797
536.797
536.797
726.887
726.887
726.887
733.904
733.904
733.904
738.391
738.391
738.391
749.415
749.415
749.415
742.422
742.422
742.422
753.446
753.446
753.446

Product
m/z
1093.494
892.419
1206.578
1093.494
892.419
1082.668
983.600
884.531
1096.702
997.634
898.566
1353.618
1225.560
1111.517
1361.632
1233.574
1119.531
823.410
752.373
681.335
831.424
760.387
689.350
973.510
486.303
385.256
980.527
493.321
392.273
837.458
740.405
603.346
837.458
740.405
603.346
988.524
891.472
778.388
995.542
898.489
785.405
1234.631
887.447
830.425
1256.680
902.478
845.457
1097.656
984.572
887.520
1119.705
999.604
902.551

CID
energy
25.3
25.3
25.3
25.3
25.3
24.4
24.4
24.4
24.4
24.4
24.4
29.8
29.8
29.8
29.8
29.8
29.8
18.5
18.5
18.5
18.5
18.5
18.5
24.2
24.2
24.2
24.2
24.2
24.2
18.9
18.9
18.9
18.9
18.9
18.9
24.7
24.7
24.7
24.7
24.7
24.7
25.1
25.1
25.1
25.1
25.1
25.1
25.2
25.2
25.2
25.2
25.2
25.2

Product
ion
y10
y8
y11
y10
y8
y11
y10
y9
y11
y10
y9
y11
y10
y9
y11
y10
y9
y7
y6
y5
y7
y6
y5
y8
y4
y3
y8
y4
y3
y7
y6
y5
y7
y6
y5
y9
y8
y7
y9
y8
y7
y12
y9
y8
y12
y9
y8
y10
y9
y8
y10
y9
y8

Isotope
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy

Peptide

Precusor
m/z

Product
m/z

CID
energy

Product
ion

Isotope

AGAGSATLSMAYAGAR

727.856

1040.519

24.7

y10

light

AGAGSATLSMAYAGAR

727.856

939.472

24.7

y9

light

AGAGSATLSMAYAGAR

727.856

826.388

24.7

y8

light

AGAGSATLSMAYAGAR

731.365

1047.537

24.7

y10

heavy

AGAGSATLSMAYAGAR

731.365

946.489

24.7

y9

heavy

AGAGSATLSMAYAGAR
FVIKPIDK
FVIKPIDK
FVIKPIDK
FVIKPIDK
FVIKPIDK
FVIKPIDK

731.365
480.300
480.300
480.300
488.314
488.314
488.314

826.388
812.524
713.456
600.372
828.552
729.484
616.400

24.7
17.3
17.3
17.3
17.3
17.3
17.3

y8
y7
y6
y5
y7
y6
y5

heavy
light
light
light
heavy
heavy
heavy

myosin, heavy polypeptide 9, nonmuscle

ELEDATETADAMNR

783.341

1008.441

26.4

y9

light

myosin, heavy polypeptide 9, nonmuscle

ELEDATETADAMNR

783.341

907.394

26.4

y8

light

myosin, heavy polypeptide 9, nonmuscle

ELEDATETADAMNR

783.341

778.351

26.4

y7

light

myosin, heavy polypeptide 9, nonmuscle

ELEDATETADAMNR

786.850

1008.441

26.4

y9

heavy

myosin, heavy polypeptide 9, nonmuscle

ELEDATETADAMNR

786.850

907.394

26.4

y8

heavy

myosin, heavy polypeptide 9, nonmuscle
NME1-NME2
NME1-NME2
NME1-NME2
NME1-NME2
NME1-NME2
NME1-NME2
peptidylprolyl isomerase A
peptidylprolyl isomerase A
peptidylprolyl isomerase A
peptidylprolyl isomerase A
peptidylprolyl isomerase A
peptidylprolyl isomerase A
peptidylprolyl isomerase A
peptidylprolyl isomerase A
peptidylprolyl isomerase A
peptidylprolyl isomerase A
peptidylprolyl isomerase B
peptidylprolyl isomerase B
peptidylprolyl isomerase B
peptidylprolyl isomerase B
peptidylprolyl isomerase B
peptidylprolyl isomerase B
peptidylprolyl isomerase B
peptidylprolyl isomerase B
peptidylprolyl isomerase B

ELEDATETADAMNR
QHYIDLK
QHYIDLK
QHYIDLK
QHYIDLK
QHYIDLK
QHYIDLK
VSFELFADK
VSFELFADK
VSFELFADK
VSFELFADK
VSFELFADK
VSFELFADK
FEDENFILK
FEDENFILK
FEDENFILK
FEDENFILK
VLEGMEVVR
VLEGMEVVR
VLEGMEVVR
VLEGMEVVR
VLEGMEVVR
VLEGMEVVR
TVDNFVALATGEK
TVDNFVALATGEK
TVDNFVALATGEK

786.850
458.748
458.748
458.748
466.264
466.264
466.264
528.274
528.274
528.274
535.790
535.790
535.790
577.790
577.790
585.306
585.306
516.281
516.281
516.281
519.790
519.790
519.790
682.856
682.856
682.856

778.351
788.430
651.371
488.308
803.461
666.403
503.339
956.472
869.440
722.372
971.504
884.472
737.403
1007.504
878.462
1022.536
893.493
932.487
819.403
690.360
939.504
819.403
690.360
1164.590
788.451
689.383

26.4
16.7
16.7
16.7
16.7
16.7
16.7
18.8
18.8
18.8
18.8
18.8
18.8
20.2
20.2
20.2
20.2
18.4
18.4
18.4
18.4
18.4
18.4
23.4
23.4
23.4

y7
y6
y5
y4
y6
y5
y4
y8
y7
y6
y8
y7
y6
y8
y7
y8
y7
y8
y7
y6
y8
y7
y6
y11
y8
y7

heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light

Protein
mitochondrial malate
dehydrogenase
mitochondrial malate
dehydrogenase
mitochondrial malate
dehydrogenase
mitochondrial malate
dehydrogenase
mitochondrial malate
dehydrogenase
mitochondrial malate
dehydrogenase
moesin
moesin
moesin
moesin
moesin
moesin
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Peptide
TVDNFVALATGEK
TVDNFVALATGEK
TVDNFVALATGEK
ATFNPAQDK
ATFNPAQDK
ATFNPAQDK
ATFNPAQDK
ATFNPAQDK
ATFNPAQDK

Precusor
m/z
690.372
690.372
690.372
496.246
496.246
496.246
500.253
500.253
500.253

Product
m/z
1179.621
803.483
704.414
920.447
819.400
672.331
928.461
827.414
680.345

CID
energy
23.4
23.4
23.4
17.8
17.8
17.8
17.8
17.8
17.8

Product
ion
y11
y8
y7
y8
y7
y6
y8
y7
y6

Isotope
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy

LASVPGSQTVVVK

642.880

1100.631

22.2

y11

light

LASVPGSQTVVVK

642.880

914.531

22.2

y9

light

LASVPGSQTVVVK

642.880

817.478

22.2

y8

light

LASVPGSQTVVVK

650.395

1108.645

22.2

y11

heavy

LASVPGSQTVVVK

650.395

922.545

22.2

y9

heavy

LASVPGSQTVVVK
VQLTGEPVPMAR
VQLTGEPVPMAR
VQLTGEPVPMAR
VQLTGEPVPMAR
VQLTGEPVPMAR
VQLTGEPVPMAR
VEFLRPSFTDGTIR
VEFLRPSFTDGTIR
VEFLRPSFTDGTIR
VEFLRPSFTDGTIR
VEFLRPSFTDGTIR
VEFLRPSFTDGTIR

650.395
649.350
649.350
649.350
652.859
652.859
652.859
546.626
546.626
546.626
548.965
548.965
548.965

825.492
1070.566
957.482
670.370
1077.583
957.482
670.370
993.500
705.380
575.304
993.500
708.889
575.304

22.2
22.4
22.4
22.4
22.4
22.4
22.4
23.1
23.1
23.1
23.1
23.1
23.1

y8
y10
y9
y6
y10
y9
y6
y9
y12
y10
y9
y12
y10

heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy

PREDICTED: similar to epidermal
growth factor

SQPVSQPLTYESGPDEVR

994.982

1362.654

32.8

y12

light

PREDICTED: similar to epidermal
growth factor

SQPVSQPLTYESGPDEVR

994.982

1265.601

32.8

y11

light

PREDICTED: similar to epidermal
growth factor

SQPVSQPLTYESGPDEVR

994.982

1051.469

32.8

y9

light

PREDICTED: similar to epidermal
growth factor

SQPVSQPLTYESGPDEVR

998.490

1369.671

32.8

y12

heavy

PREDICTED: similar to epidermal
growth factor

SQPVSQPLTYESGPDEVR

998.490

1272.618

32.8

y11

heavy

PREDICTED: similar to epidermal
growth factor
SMT3A
SMT3A
SMT3A
SMT3A
SMT3A
SMT3A
profilin 1
profilin 1
profilin 1
profilin 1

SQPVSQPLTYESGPDEVR
VAGQDGSVVQFK
VAGQDGSVVQFK
VAGQDGSVVQFK
VAGQDGSVVQFK
VAGQDGSVVQFK
VAGQDGSVVQFK
DSLLQDGEFSMDLR
DSLLQDGEFSMDLR
DSLLQDGEFSMDLR
DSLLQDGEFSMDLR

998.490
617.825
617.825
617.825
621.832
621.832
621.832
813.377
813.377
813.377
823.903

1051.469
1064.537
879.457
764.430
1072.551
887.471
772.444
1197.520
1069.462
954.435
1204.538

32.8
21.4
21.4
21.4
21.4
21.4
21.4
27.3
27.3
27.3
27.3

y9
y10
y8
y7
y10
y8
y7
y10
y9
y8
y10

heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy

Protein
peptidylprolyl isomerase B
peptidylprolyl isomerase B
peptidylprolyl isomerase B
podocalyxin-like
podocalyxin-like
podocalyxin-like
podocalyxin-like
podocalyxin-like
podocalyxin-like
podocalyxin-like precursor isoform
1
podocalyxin-like precursor isoform
1
podocalyxin-like precursor isoform
1
podocalyxin-like precursor isoform
1
podocalyxin-like precursor isoform
1
podocalyxin-like precursor isoform
1
poliovirus receptor
poliovirus receptor
poliovirus receptor
poliovirus receptor
poliovirus receptor
poliovirus receptor
poliovirus receptor-related 1
poliovirus receptor-related 1
poliovirus receptor-related 1
poliovirus receptor-related 1
poliovirus receptor-related 1
poliovirus receptor-related 1
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Protein
profilin 1
profilin 1
profilin 1
profilin 1
profilin 1
profilin 1
profilin 1
profilin 1
prolyl 4-hydroxylase, beta subunit
prolyl 4-hydroxylase, beta subunit
prolyl 4-hydroxylase, beta subunit
prolyl 4-hydroxylase, beta subunit
prolyl 4-hydroxylase, beta subunit
prolyl 4-hydroxylase, beta subunit

Peptide
DSLLQDGEFSMDLR
DSLLQDGEFSMDLR
TFVNITPAEVGVLVGK
TFVNITPAEVGVLVGK
TFVNITPAEVGVLVGK
TFVNITPAEVGVLVGK
TFVNITPAEVGVLVGK
TFVNITPAEVGVLVGK
VDATEESDLAQQYGVR
VDATEESDLAQQYGVR
VDATEESDLAQQYGVR
VDATEESDLAQQYGVR
VDATEESDLAQQYGVR
VDATEESDLAQQYGVR

Precusor
m/z
823.903
823.903
822.472
822.472
822.472
829.988
829.988
829.988
890.921
890.921
890.921
894.430
894.430
894.430

Product
m/z
1076.479
961.452
1296.752
1182.709
968.578
1311.784
1197.741
983.609
1265.612
1136.569
934.510
1272.629
1143.587
941.528

CID
energy
27.3
27.3
27.6
27.6
27.6
27.6
27.6
27.6
29.6
29.6
29.6
29.6
29.6
29.6

Product
ion
y9
y8
y13
y12
y10
y13
y12
y10
y11
y10
y8
y11
y10
y8

Isotope
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy

protein disulfide isomeraseassociated 3

LAPEYEAAATR

596.304

1007.479

20.8

y9

light

protein disulfide isomeraseassociated 3

LAPEYEAAATR

596.304

910.426

20.8

y8

light

protein disulfide isomeraseassociated 3

LAPEYEAAATR

596.304

781.384

20.8

y7

light

protein disulfide isomeraseassociated 3

LAPEYEAAATR

599.812

1007.479

20.8

y9

heavy

protein disulfide isomeraseassociated 3

LAPEYEAAATR

599.812

910.426

20.8

y8

heavy

protein disulfide isomeraseassociated 3

LAPEYEAAATR

599.812

781.384

20.8

y7

heavy

retinoic acid receptor responder
(tazarotene induced)

AALHFFNFR

561.796

867.426

19.8

y6

light

retinoic acid receptor responder
(tazarotene induced)

AALHFFNFR

561.796

730.367

19.8

y5

light

retinoic acid receptor responder
(tazarotene induced)

AALHFFNFR

561.796

583.299

19.8

y4

light

retinoic acid receptor responder
(tazarotene induced)

AALHFFNFR

565.304

867.426

19.8

y6

heavy

retinoic acid receptor responder
(tazarotene induced)

AALHFFNFR

565.304

730.367

19.8

y5

heavy

AALHFFNFR

565.304

583.299

19.8

y4

heavy

AEEYEFLTPVEEAPK

876.422

1259.652

29.2

y11

light

AEEYEFLTPVEEAPK

876.422

1130.609

29.2

y10

light

AEEYEFLTPVEEAPK

876.422

983.541

29.2

y9

light

AEEYEFLTPVEEAPK

883.938

1274.683

29.2

y11

heavy

AEEYEFLTPVEEAPK

883.938

1145.641

29.2

y10

heavy

AEEYEFLTPVEEAPK
DGYNYTLSK
DGYNYTLSK
DGYNYTLSK
DGYNYTLSK
DGYNYTLSK

883.938
530.751
530.751
530.751
538.267
538.267

998.572
888.446
725.383
611.340
903.478
740.414

29.2
18.8
18.8
18.8
18.8
18.8

y9
y7
y6
y5
y7
y6

heavy
light
light
light
heavy
heavy

retinoic acid receptor responder
(tazarotene induced)
Rho GDP dissociation inhibitor
alpha
Rho GDP dissociation inhibitor
alpha
Rho GDP dissociation inhibitor
alpha
Rho GDP dissociation inhibitor
alpha
Rho GDP dissociation inhibitor
alpha
Rho GDP dissociation inhibitor
alpha
S100 calcium binding protein A11
S100 calcium binding protein A11
S100 calcium binding protein A11
S100 calcium binding protein A11
S100 calcium binding protein A11
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Protein
S100 calcium binding protein A11
S100 calcium binding protein A11
S100 calcium binding protein A11
S100 calcium binding protein A11
S100 calcium binding protein A11
S100 calcium binding protein A11
S100 calcium binding protein A11
S100 calcium binding protein A16
S100 calcium binding protein A16
S100 calcium binding protein A16
S100 calcium binding protein A16
S100 calcium binding protein A16
S100 calcium binding protein A16
S100 calcium-binding protein A6
S100 calcium-binding protein A6
S100 calcium-binding protein A6
S100 calcium-binding protein A6
S100 calcium-binding protein A6
S100 calcium-binding protein A6
secreted protein; acidic; cysteine
rich
secreted protein; acidic; cysteine
rich
secreted protein; acidic; cysteine
rich
secreted protein; acidic; cysteine
rich
secreted protein; acidic; cysteine
rich
secreted protein; acidic; cysteine
rich
solute carrier family 9
solute carrier family 9
solute carrier family 9
solute carrier family 9
solute carrier family 9
solute carrier family 9
tissue inhibitor of
metalloproteinase 1
tissue inhibitor of
metalloproteinase 1
tissue inhibitor of
metalloproteinase 1
tissue inhibitor of
metalloproteinase 1
tissue inhibitor of
metalloproteinase 1
tissue inhibitor of
metalloproteinase 1
tissue inhibitor of
metalloproteinase 1
tissue inhibitor of
metalloproteinase 1
tissue inhibitor of
metalloproteinase 1
tissue inhibitor of
metalloproteinase 1
tissue inhibitor of
metalloproteinase 1

Peptide
DGYNYTLSK
TEFLSFMNTELAAFTK
TEFLSFMNTELAAFTK
TEFLSFMNTELAAFTK
TEFLSFMNTELAAFTK
TEFLSFMNTELAAFTK
TEFLSFMNTELAAFTK
LIHEQEQQSSS
LIHEQEQQSSS
LIHEQEQQSSS
LIHEQEQQSSS
LIHEQEQQSSS
LIHEQEQQSSS
LQDAEIAR
LQDAEIAR
LQDAEIAR
LQDAEIAR
LQDAEIAR
LQDAEIAR

Precusor
m/z
538.267
925.456
925.456
925.456
936.480
936.480
936.480
643.305
643.305
643.305
646.813
646.813
646.813
458.248
458.248
458.248
461.757
461.757
461.757

Product
m/z
626.371
1359.661
1272.629
1125.561
1374.693
1287.661
1140.592
1059.434
922.375
793.332
1059.434
922.375
793.332
802.405
674.347
559.320
802.405
674.347
559.320

CID
energy
18.8
30.7
30.7
30.7
30.7
30.7
30.7
22.2
22.2
22.2
22.2
22.2
22.2
16.7
16.7
16.7
16.7
16.7
16.7

Product
ion
y5
y12
y11
y10
y12
y11
y10
y9
y8
y7
y9
y8
y7
y7
y6
y5
y7
y6
y5

Isotope
heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy

RLEAGDHPVELLAR

525.958

797.488

22.3

y7

light

RLEAGDHPVELLAR

525.958

601.367

22.3

y5

light

RLEAGDHPVELLAR

525.958

399.248

22.3

y7

light

RLEAGDHPVELLAR

532.975

811.522

22.3

y7

heavy

RLEAGDHPVELLAR

532.975

615.401

22.3

y5

heavy

RLEAGDHPVELLAR
LVEPGSPAEK
LVEPGSPAEK
LVEPGSPAEK
LVEPGSPAEK
LVEPGSPAEK
LVEPGSPAEK

532.975
513.777
513.777
513.777
521.293
521.293
521.293

406.265
814.394
685.352
588.299
822.408
693.366
596.313

22.3
18.3
18.3
18.3
18.3
18.3
18.3

y7
y8
y7
y6
y8
y7
y6

heavy
light
light
light
heavy
heavy
heavy

SEEFLIAGK

497.266

777.451

17.8

y7

light

SEEFLIAGK

497.266

648.408

17.8

y6

light

SEEFLIAGK

497.266

501.340

17.8

y5

light

SEEFLIAGK

504.782

792.482

17.8

y7

heavy

SEEFLIAGK

504.782

663.439

17.8

y6

heavy

SEEFLIAGK

504.782

516.371

17.8

y5

heavy

GFQALGDAADIR

617.315

1029.532

21.4

y10

light

GFQALGDAADIR

617.315

901.474

21.4

y9

light

GFQALGDAADIR

617.315

830.437

21.4

y8

light

GFQALGDAADIR

620.823

1036.550

21.4

y10

heavy

GFQALGDAADIR

620.823

908.491

21.4

y9

heavy
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Peptide

Precusor
m/z

Product
m/z

CID
energy

Product
ion

Isotope

GFQALGDAADIR
NGENLEVR
NGENLEVR
NGENLEVR
NGENLEVR
NGENLEVR
NGENLEVR

620.823
465.736
465.736
465.736
469.244
469.244
469.244

837.454
816.421
759.400
630.357
823.438
766.417
637.374

21.4
16.9
16.9
16.9
16.9
16.9
16.9

y8
y7
y6
y5
y7
y6
y5

heavy
light
light
light
heavy
heavy
heavy

transforming growth factor; betainduced; 68kDa

SPYQLVLQHSR

664.359

1240.680

22.8

y10

light

transforming growth factor; betainduced; 68kDa

SPYQLVLQHSR

664.359

739.421

22.8

y6

light

transforming growth factor; betainduced; 68kDa

SPYQLVLQHSR

664.359

640.353

22.8

y5

light

transforming growth factor; betainduced; 68kDa

SPYQLVLQHSR

671.377

1254.714

22.8

y10

heavy

transforming growth factor; betainduced; 68kDa

SPYQLVLQHSR

671.377

746.438

22.8

y6

heavy

transforming growth factor; betainduced; 68kDa
transgelin 2
transgelin 2
transgelin 2
transgelin 2
transgelin 2
transgelin 2
transgelin 2
transgelin 2
transgelin 2
transgelin 2
transgelin 2
transgelin 2
transketolase
transketolase
transketolase
transketolase
transketolase
transketolase
triosephosphate isomerase 1
triosephosphate isomerase 1
triosephosphate isomerase 1
triosephosphate isomerase 1
triosephosphate isomerase 1
triosephosphate isomerase 1
triosephosphate isomerase 1
triosephosphate isomerase 1
triosephosphate isomerase 1
triosephosphate isomerase 1
triosephosphate isomerase 1
triosephosphate isomerase 1
tropomyosin 3 isoform 4
tropomyosin 3 isoform 4
tropomyosin 3 isoform 4

SPYQLVLQHSR
NFSDNQLQEGK
NFSDNQLQEGK
NFSDNQLQEGK
NFSDNQLQEGK
NFSDNQLQEGK
NFSDNQLQEGK
DDGLFSGDPNWFPK
DDGLFSGDPNWFPK
DDGLFSGDPNWFPK
DDGLFSGDPNWFPK
DDGLFSGDPNWFPK
DDGLFSGDPNWFPK
HQPTAIIAK
HQPTAIIAK
HQPTAIIAK
HQPTAIIAK
HQPTAIIAK
HQPTAIIAK
HVFGESDELIGQK
HVFGESDELIGQK
HVFGESDELIGQK
HVFGESDELIGQK
HVFGESDELIGQK
HVFGESDELIGQK
TATPQQAQEVHEK
TATPQQAQEVHEK
TATPQQAQEVHEK
TATPQQAQEVHEK
TATPQQAQEVHEK
TATPQQAQEVHEK
IQLVEEELDR
IQLVEEELDR
IQLVEEELDR

671.377
640.299
640.299
640.299
647.815
647.815
647.815
797.862
797.862
797.862
805.378
805.378
805.378
489.790
489.790
489.790
493.797
493.797
493.797
729.865
729.865
729.865
737.380
737.380
737.380
733.865
733.865
733.865
737.872
737.872
737.872
622.330
622.330
622.330

647.370
1018.480
931.448
816.421
1033.511
946.479
831.452
1194.558
1047.489
788.409
1202.572
1055.504
796.423
841.514
713.456
616.403
849.528
721.470
624.417
1321.663
1222.595
1075.527
1336.695
1237.626
1090.558
840.421
647.823
597.299
848.435
651.830
601.306
1002.510
889.426
790.358

22.8
22.1
22.1
22.1
22.1
22.1
22.1
26.8
26.8
26.8
26.8
26.8
26.8
17.6
17.6
17.6
17.6
17.6
17.6
24.8
24.8
24.8
24.8
24.8
24.8
24.9
24.9
24.9
24.9
24.9
24.9
21.6
21.6
21.6

y5
y9
y8
y7
y9
y8
y7
y10
y9
y6
y10
y9
y6
y8
y7
y6
y8
y7
y6
y12
y11
y10
y12
y11
y10
y7
y11
y10
y7
y11
y10
y8
y7
y6

heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light

Protein
tissue inhibitor of
metalloproteinase 1
transcobalamin I
transcobalamin I
transcobalamin I
transcobalamin I
transcobalamin I
transcobalamin I
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Protein
tropomyosin 3 isoform 4
tropomyosin 3 isoform 4
tropomyosin 3 isoform 4
tropomyosin 3 isoform 4
tropomyosin 3 isoform 4
tropomyosin 3 isoform 4
tropomyosin 3 isoform 4
tropomyosin 3 isoform 4
tropomyosin 3 isoform 4

Peptide
IQLVEEELDR
IQLVEEELDR
IQLVEEELDR
IQVLQQQADDAEER
IQVLQQQADDAEER
IQVLQQQADDAEER
IQVLQQQADDAEER
IQVLQQQADDAEER
IQVLQQQADDAEER

Precusor
m/z
629.347
629.347
629.347
821.905
821.905
821.905
825.414
825.414
825.414

Product
m/z
1016.545
896.443
797.375
1061.449
933.391
805.332
1061.449
933.391
805.332

CID
energy
21.6
21.6
21.6
27.6
27.6
27.6
27.6
27.6
27.6

Product
ion
y8
y7
y6
y9
y8
y7
y9
y8
y7

Isotope
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy

tyrosine 3\ tryptophan 5 monooxygenase activation protein,
zeta

SVTEQGAELSNEER

774.860

1132.523

26.2

y10

light

tyrosine 3\ tryptophan 5 monooxygenase activation protein,
zeta

SVTEQGAELSNEER

774.860

1004.464

26.2

y9

light

tyrosine 3\ tryptophan 5 monooxygenase activation protein,
zeta

SVTEQGAELSNEER

774.860

876.406

26.2

y7

light

tyrosine 3\ tryptophan 5 monooxygenase activation protein,
zeta

SVTEQGAELSNEER

778.369

1139.540

26.2

y10

heavy

tyrosine 3\ tryptophan 5 monooxygenase activation protein,
zeta

SVTEQGAELSNEER

778.369

1011.481

26.2

y9

heavy

tyrosine 3\ tryptophan 5 monooxygenase activation protein,
zeta

SVTEQGAELSNEER

778.369

883.423

26.2

y7

heavy

tyrosine 3\tryptophan 5monooxygenase activation protein,
theta

LAEQAER

408.714

703.337

15.2

y6

light

tyrosine 3\tryptophan 5monooxygenase activation protein,
theta

LAEQAER

408.714

632.300

15.2

y5

light

tyrosine 3\tryptophan 5monooxygenase activation protein,
theta

LAEQAER

408.714

503.257

15.2

y4

light

tyrosine 3\tryptophan 5monooxygenase activation protein,
theta

LAEQAER

412.223

703.337

15.2

y6

heavy

tyrosine 3\tryptophan 5monooxygenase activation protein,
theta

LAEQAER

412.223

632.300

15.2

y5

heavy

tyrosine 3\tryptophan 5monooxygenase activation protein,
theta

LAEQAER

412.223

503.257

15.2

y4

heavy

tyrosine 3\tryptophan 5monooxygenase activation protein,
theta

AVTEQGAELSNEER

766.863

1132.523

25.9

y10

light

tyrosine 3\tryptophan 5monooxygenase activation protein,
theta

AVTEQGAELSNEER

766.863

1004.464

25.9

y9

light
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Protein

Peptide

Precusor
m/z

Product
m/z

CID
energy

Product
ion

Isotope

tyrosine 3\tryptophan 5monooxygenase activation protein,
theta

AVTEQGAELSNEER

766.863

876.406

25.9

y7

light

tyrosine 3\tryptophan 5monooxygenase activation protein,
theta

AVTEQGAELSNEER

770.372

1139.540

25.9

y10

heavy

tyrosine 3\tryptophan 5monooxygenase activation protein,
theta

AVTEQGAELSNEER

770.372

1011.481

25.9

y9

heavy

AVTEQGAELSNEER

770.372

883.423

25.9

y7

heavy

LGVAGQWR

443.748

716.384

16.2

y6

light

LGVAGQWR

443.748

617.315

16.2

y5

light

LGVAGQWR

443.748

546.278

16.2

y4

light

LGVAGQWR

447.257

716.384

16.2

y6

heavy

LGVAGQWR

447.257

617.315

16.2

y5

heavy

LGVAGQWR
SQEQLAAELAEYTAK
SQEQLAAELAEYTAK
SQEQLAAELAEYTAK
SQEQLAAELAEYTAK
SQEQLAAELAEYTAK
SQEQLAAELAEYTAK

447.257
826.412
826.412
826.412
837.437
837.437
837.437

546.278
1307.684
1179.626
995.504
1329.733
1201.674
1010.536

16.2
27.7
27.7
27.7
27.7
27.7
27.7

y4
y12
y11
y9
y12
y11
y9

heavy
light
light
light
heavy
heavy
heavy

tyrosine 3\tryptophan 5monooxygenase activation protein,
theta
ubiquitin carboxyl-terminal
esterase L1
ubiquitin carboxyl-terminal
esterase L1
ubiquitin carboxyl-terminal
esterase L1
ubiquitin carboxyl-terminal
esterase L1
ubiquitin carboxyl-terminal
esterase L1
ubiquitin carboxyl-terminal
esterase L1
villin 2
villin 2
villin 2
villin 2
villin 2
villin 2
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